
<html lang="en"     class="pb-page"  data-request-id="34d005ff-e9d1-4803-914b-4737cf653d7c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2018.61.issue-19;website:website:acspubs;article:article:10.1021/acs.jmedchem.8b00917;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)" /></meta><meta name="dc.Creator" content="Andrew  Fensome" /></meta><meta name="dc.Creator" content="Catherine M.  Ambler" /></meta><meta name="dc.Creator" content="Eric  Arnold" /></meta><meta name="dc.Creator" content="Mary Ellen  Banker" /></meta><meta name="dc.Creator" content="Matthew F.  Brown" /></meta><meta name="dc.Creator" content="Jill  Chrencik" /></meta><meta name="dc.Creator" content="James D.  Clark" /></meta><meta name="dc.Creator" content="Martin E.  Dowty" /></meta><meta name="dc.Creator" content="Ivan V.  Efremov" /></meta><meta name="dc.Creator" content="Andrew  Flick" /></meta><meta name="dc.Creator" content="Brian S.  Gerstenberger" /></meta><meta name="dc.Creator" content="Ariamala  Gopalsamy" /></meta><meta name="dc.Creator" content="Matthew M.  Hayward" /></meta><meta name="dc.Creator" content="Martin  Hegen" /></meta><meta name="dc.Creator" content="Brett D.  Hollingshead" /></meta><meta name="dc.Creator" content="Jason  Jussif" /></meta><meta name="dc.Creator" content="John D.  Knafels" /></meta><meta name="dc.Creator" content="David C.  Limburg" /></meta><meta name="dc.Creator" content="David  Lin" /></meta><meta name="dc.Creator" content="Tsung H.  Lin" /></meta><meta name="dc.Creator" content="Betsy S.  Pierce" /></meta><meta name="dc.Creator" content="Eddine  Saiah" /></meta><meta name="dc.Creator" content="Raman  Sharma" /></meta><meta name="dc.Creator" content="Peter T.  Symanowicz" /></meta><meta name="dc.Creator" content="Jean-Baptiste  Telliez" /></meta><meta name="dc.Creator" content="John I.  Trujillo" /></meta><meta name="dc.Creator" content="Felix F.  Vajdos" /></meta><meta name="dc.Creator" content="Fabien  Vincent" /></meta><meta name="dc.Creator" content="Zhao-Kui  Wan" /></meta><meta name="dc.Creator" content="Li  Xing" /></meta><meta name="dc.Creator" content="Xiaojing  Yang" /></meta><meta name="dc.Creator" content="Xin  Yang" /></meta><meta name="dc.Creator" content="Liying  Zhang" /></meta><meta name="dc.Description" content="Cytokine signaling is an important characteristic of autoimmune diseases. Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STA..." /></meta><meta name="Description" content="Cytokine signaling is an important characteristic of autoimmune diseases. Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STA..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 16, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00917" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00917" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00917" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00917" /></link>
        
    
    

<title>Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00917" /></meta><meta property="og:title" content="Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0016.jpeg" /></meta><meta property="og:description" content="Cytokine signaling is an important characteristic of autoimmune diseases. Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway. JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6, and type-I interferon (IFN) family, while TYK2 in addition to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling. Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease, and rheumatoid arthritis studies, leading to multiple drug approvals. We hypothesized that a dual JAK1/TYK2 inhibitor will provide additional efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes. Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compound 23), which is in Phase II clinical development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868)." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Cytokine signaling is an important characteristic of autoimmune diseases. Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway. JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6, and type-I interferon (IFN) family, while TYK2 in addition to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling. Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease, and rheumatoid arthritis studies, leading to multiple drug approvals. We hypothesized that a dual JAK1/TYK2 inhibitor will provide additional efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes. Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compound 23), which is in Phase II clinical development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868)." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0016.jpeg" /></meta><meta name="twitter:title" content="Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00917"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00917">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00917&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00917&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00917&amp;href=/doi/10.1021/acs.jmedchem.8b00917" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 8597-8612</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01397" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Featured Article</span><a href="/doi/10.1021/acs.jmedchem.8b00498" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((<i>S</i>)-2,2-Difluorocyclopropyl)((1<i>R</i>,5<i>S</i>)-3-(2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Andrew Fensome</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew Fensome</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><span class="conrtib-corresp"><strong>*</strong>A.F.: phone, 617-674-7237; e-mail, <a href="/cdn-cgi/l/email-protection#2968474d5b4c5e076f4c475a46444c69794f40534c5b074a4644"><span class="__cf_email__" data-cfemail="35745b514750421b73505b465a58507565535c4f50471b565a58">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Fensome">Andrew Fensome</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8916-1895" title="Orcid link">http://orcid.org/0000-0001-8916-1895</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Catherine M. Ambler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Catherine M. Ambler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Catherine+M.++Ambler">Catherine M. Ambler</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eric Arnold</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eric Arnold</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eric++Arnold">Eric Arnold</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mary Ellen Banker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mary Ellen Banker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mary+Ellen++Banker">Mary Ellen Banker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew F. Brown</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew F. Brown</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+F.++Brown">Matthew F. Brown</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jill Chrencik</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jill Chrencik</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jill++Chrencik">Jill Chrencik</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James D. Clark</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James D. Clark</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Inflammation and Immunology, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+D.++Clark">James D. Clark</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martin E. Dowty</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin E. Dowty</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin+E.++Dowty">Martin E. Dowty</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ivan V. Efremov</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ivan V. Efremov</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ivan+V.++Efremov">Ivan V. Efremov</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrew Flick</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew Flick</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Flick">Andrew Flick</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brian S. Gerstenberger</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian S. Gerstenberger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><span class="conrtib-corresp"><strong>*</strong>B.G.: phone, 860-686-3019; e-mail, <a href="/cdn-cgi/l/email-protection#50122239313e7e1735222324353e323522373522100036392a35227e333f3d"><span class="__cf_email__" data-cfemail="81c3f3e8e0efafc6e4f3f2f5e4efe3e4f3e6e4f3c1d1e7e8fbe4f3afe2eeec">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian+S.++Gerstenberger">Brian S. Gerstenberger</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ariamala Gopalsamy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ariamala Gopalsamy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ariamala++Gopalsamy">Ariamala Gopalsamy</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew M. Hayward</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew M. Hayward</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+M.++Hayward">Matthew M. Hayward</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martin Hegen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin Hegen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Inflammation and Immunology, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Hegen">Martin Hegen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brett D. Hollingshead</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brett D. Hollingshead</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Safety Research and Development, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brett+D.++Hollingshead">Brett D. Hollingshead</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason Jussif</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason Jussif</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Inflammation and Immunology, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Jussif">Jason Jussif</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John D. Knafels</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John D. Knafels</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+D.++Knafels">John D. Knafels</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David C. Limburg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David C. Limburg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+C.++Limburg">David C. Limburg</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Lin">David Lin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tsung H. Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tsung H. Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Inflammation and Immunology, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tsung+H.++Lin">Tsung H. Lin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Betsy S. Pierce</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Betsy S. Pierce</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Betsy+S.++Pierce">Betsy S. Pierce</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eddine Saiah</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eddine Saiah</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eddine++Saiah">Eddine Saiah</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Raman Sharma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Raman Sharma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Raman++Sharma">Raman Sharma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter T. Symanowicz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter T. Symanowicz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Inflammation and Immunology, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter+T.++Symanowicz">Peter T. Symanowicz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jean-Baptiste Telliez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jean-Baptiste Telliez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Inflammation and Immunology, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jean-Baptiste++Telliez">Jean-Baptiste Telliez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John I. Trujillo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John I. Trujillo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+I.++Trujillo">John I. Trujillo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Felix F. Vajdos</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Felix F. Vajdos</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Felix+F.++Vajdos">Felix F. Vajdos</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fabien Vincent</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fabien Vincent</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fabien++Vincent">Fabien Vincent</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhao-Kui Wan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhao-Kui Wan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhao-Kui++Wan">Zhao-Kui Wan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Li Xing</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Li Xing</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Li++Xing">Li Xing</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaojing Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaojing Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaojing++Yang">Xiaojing Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xin Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xin Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xin++Yang">Xin Yang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Liying Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liying Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liying++Zhang">Liying Zhang</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00917&amp;href=/doi/10.1021%2Facs.jmedchem.8b00917" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 8597–8612</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 16, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>8 June 2018</li><li><span class="item_label"><b>Published</b> online</span>16 August 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 October 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00917" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00917</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8597%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAndrew%2BFensome%252C%2BCatherine%2BM.%2BAmbler%252C%2BEric%2BArnold%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D19%26contentID%3Dacs.jmedchem.8b00917%26title%3DDual%2BInhibition%2Bof%2BTYK2%2Band%2BJAK1%2Bfor%2Bthe%2BTreatment%2Bof%2BAutoimmune%2BDiseases%253A%2BDiscovery%2Bof%2B%2528%2528S%2529-2%252C2-Difluorocyclopropyl%2529%2528%25281R%252C5S%2529-3-%25282-%2528%25281-methyl-1H-pyrazol-4-yl%2529amino%2529pyrimidin-4-yl%2529-3%252C8-diazabicyclo%255B3.2.1%255Doctan-8-yl%2529methanone%2B%2528PF-06700841%2529%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8612%26publicationDate%3DOctober%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00917"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6808</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">41</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00917" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Fensome&quot;},{&quot;first_name&quot;:&quot;Catherine&quot;,&quot;last_name&quot;:&quot;M. Ambler&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;Arnold&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;Ellen Banker&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;F. Brown&quot;},{&quot;first_name&quot;:&quot;Jill&quot;,&quot;last_name&quot;:&quot;Chrencik&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;D. Clark&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;E. Dowty&quot;},{&quot;first_name&quot;:&quot;Ivan&quot;,&quot;last_name&quot;:&quot;V. Efremov&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Flick&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;S. Gerstenberger&quot;},{&quot;first_name&quot;:&quot;Ariamala&quot;,&quot;last_name&quot;:&quot;Gopalsamy&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;M. Hayward&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Hegen&quot;},{&quot;first_name&quot;:&quot;Brett&quot;,&quot;last_name&quot;:&quot;D. Hollingshead&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Jussif&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;D. Knafels&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;C. Limburg&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Tsung&quot;,&quot;last_name&quot;:&quot;H. Lin&quot;},{&quot;first_name&quot;:&quot;Betsy&quot;,&quot;last_name&quot;:&quot;S. Pierce&quot;},{&quot;first_name&quot;:&quot;Eddine&quot;,&quot;last_name&quot;:&quot;Saiah&quot;},{&quot;first_name&quot;:&quot;Raman&quot;,&quot;last_name&quot;:&quot;Sharma&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;T. Symanowicz&quot;},{&quot;first_name&quot;:&quot;Jean-Baptiste&quot;,&quot;last_name&quot;:&quot;Telliez&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;I. Trujillo&quot;},{&quot;first_name&quot;:&quot;Felix&quot;,&quot;last_name&quot;:&quot;F. Vajdos&quot;},{&quot;first_name&quot;:&quot;Fabien&quot;,&quot;last_name&quot;:&quot;Vincent&quot;},{&quot;first_name&quot;:&quot;Zhao-Kui&quot;,&quot;last_name&quot;:&quot;Wan&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Xing&quot;},{&quot;first_name&quot;:&quot;Xiaojing&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Xin&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Liying&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;8597-8612&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00917&quot;},&quot;abstract&quot;:&quot;Cytokine signaling is an important characteristic of autoimmune diseases. Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway. JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6, and type-I interferon (IFN) family, while TYK2 in addition to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling. Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease, and rheumatoid arthritis studies, leading to multiple drug approvals. We hypothesized that a dual JAK1/TYK2 inhibitor will provide additional efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes. Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compound 23), which is in Phase II clinical devel&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00917&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00917" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00917&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00917" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00917&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00917" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00917&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00917&amp;href=/doi/10.1021/acs.jmedchem.8b00917" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00917" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00917" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00917%26sid%3Dliteratum%253Aachs%26pmid%3D30113844%26genre%3Darticle%26aulast%3DFensome%26date%3D2018%26atitle%3DDual%2BInhibition%2Bof%2BTYK2%2Band%2BJAK1%2Bfor%2Bthe%2BTreatment%2Bof%2BAutoimmune%2BDiseases%253A%2BDiscovery%2Bof%2B%2528%2528S%2529-2%252C2-Difluorocyclopropyl%2529%2528%25281R%252C5S%2529-3-%25282-%2528%25281-methyl-1H-pyrazol-4-yl%2529amino%2529pyrimidin-4-yl%2529-3%252C8-diazabicyclo%255B3.2.1%255Doctan-8-yl%2529methanone%2B%2528PF-06700841%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D19%26spage%3D8597%26epage%3D8612%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291297" title="Cell signaling">Cell signaling</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/19" title="Go to Volume 61, Issue 19"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/jmcmar.2018.61.issue-19/20181011/jmcmar.2018.61.issue-19.largecover.jpg" alt="Go to Volume 61, Issue 19"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Cytokine signaling is an important characteristic of autoimmune diseases. Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway. JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6, and type-I interferon (IFN) family, while TYK2 in addition to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling. Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease, and rheumatoid arthritis studies, leading to multiple drug approvals. We hypothesized that a dual JAK1/TYK2 inhibitor will provide additional efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes. Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compound <b>23</b>), which is in Phase II clinical development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48774" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48774" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Autoimmune diseases are generally characterized by a dysregulation of cytokine signaling. Targeting individual cytokines or their receptors with mAbs or other injectable biologics has shown efficacy in multiple autoimmune diseases including rheumatoid arthritis (RA), psoriasis (PSO), inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), and more recently atopic dermatitis (AD). Many of the pathogenic cytokines in these diseases signal via the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> and several oral small molecule JAK inhibitors are now approved or in late stage development.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">Across the industry, the most advanced compounds, either marketed or in Phase III clinical development, are potent JAK1 inhibitors including tofacitinib <b>1</b>, which inhibits JAK1, JAK2, JAK3, and, to a lesser extent, TYK2. Baricitinib <b>2</b> and ruxolitinib <b>3</b> both inhibit JAK1 and JAK2, while upadacitinib <b>4</b> and filgotinib <b>5</b> are reported to be JAK1 selective inhibitors (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7">(3−7)</a> Compounds <b>1</b> and <b>2</b> are currently approved for rheumatoid arthritis, while compound <b>1</b> is also approved for the treatment of psoriatic arthritis (PSA) and is in registration for ulcerative colitis (UC). The JAK1/2 inhibitor <b>3</b> is approved for myelofibrosis, and the JAK1 selective inhibitors <b>4</b> and <b>5</b> (filgotinib and upadacitinib) are in Phase III studies for RA. In addition compounds <b>2</b>, <b>4</b>, and PF-04965842 <b>6</b> (JAK1 selective) are in clinical development for the treatment of atopic dermatitis (AD). Compound <b>4</b> has also presented results for Crohn’s disease (CD).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Notably, compounds <b>1</b> and <b>2</b> are predicted to have a modest direct effect on IL-12 and IL-23 signaling via inhibition of JAK2 and weak inhibition of TYK2.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Recently, Bristol Myers-Squibb advanced a selective TYK2 inhibitor, BMS-986165 <b>7</b>, into Phase II studies for PSO and SLE.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. JAK inhibitors on the market and in late stage clinical development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The JAK kinases are intracellular protein tyrosine kinases comprised of four members: JAK1, JAK2, JAK3, and TYK2. Binding of a cytokine causes the formation of a dimer or higher order complex of receptor subunits, which allows for recruitment of a pair of JAK enzymes to the receptor (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). When in close proximity, the JAKs become phosphorylated and, in turn, phosphorylate tyrosine residues on the cytokine receptor intracellular domain. These phosphorylated receptor residues serve as binding sites for STAT proteins, which are then activated by JAK phosphorylation, enabling STAT dimerization and translocation to the nucleus where they serve as transcription factors for gene expression.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> JAK1 is the isoform most broadly found in these signaling pairs, and therefore JAK1 inhibitors will inhibit JAK1/JAK3 dependent γ-common chain cytokines, the JAK1/JAK2 dependent IFNγ and IL-6 and other gp130 cytokines, the JAK1/TYK2 dependent type I interferons, and the IL-10 family of cytokines.<a onclick="showRef(event, 'ref1 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref3">(1,3)</a> TYK2 is important for signaling associated with a subset of cytokines, with a significant role for JAK1/TYK2 dependent type I interferons and JAK2/TYK2 dependent IL-12 and IL-23.<a onclick="showRef(event, 'ref1 ref10'); return false;" href="javascript:void(0);" class="ref ref1 ref10">(1,10)</a> JAK2 uniquely forms a homodimer, which is important in hematopoiesis via signal transduction associated with erythropoietin (EPO), thrombopoietin (TPO), and IL-3.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Basic mechanism of JAK/STAT mediated cytokine signaling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although increasing dose with a JAK inhibitor generally increases clinical efficacy in multiple diseases, dose-dependent changes in clinical laboratory parameters may also occur. For example, hematological changes such as reduction in hemoglobin (Hgb) due to inhibition of JAK2 homodimer/erythropoietin signaling have been observed in Phase II studies which have informed Phase III doses which maximize efficacy, while minimizing the risk of a meaningful reduction in Hgb levels.<a onclick="showRef(event, 'ref6 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref6 ref11 ref12">(6,11,12)</a></div><div class="NLM_p">The IFNα receptor antibody Anifrolumab has recently shown efficacy in a Phase II trial in SLE.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Ustekinumab, which inhibits the shared P40 subunit of IL-12 and IL-23, is approved for PSO, PSA, and CD and has recently reported efficacy in a Phase II SLE trial.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> Anti-IL-23 antagonists have shown efficacy in CD and also in PSO.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> These results support targeting TYK2 to capitalize on the inhibition of IL-12 and IL-23 signaling. Human genetics further support targeting TYK2. A common nonsynonymous polymorphism in TYK2 P1104A (RS34536443) leads to an estimated 80% reduction in activity in homozygous carriers. Individuals with one hypomorphic allele are at reduced odds of developing PSO, RA, SLE, CD, Type I diabetes, ankylosing spondylitis, multiple sclerosis, juvenile idiopathic arthritis, and primary biliary cholangitis, while homozygous carriers are at reduced odds for UC. Bacterial, viral (including VZV), and fungal infections that have been observed in IL-12/23, type I interferon, and IL-17 deficiencies were not elevated in TYK2 hypomorphic allele carriers relative to wild type individuals.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p last">In a subset of diseases with a strong interferon and/or IL-12 or IL-23 component to the pathogenesis of disease, we may therefore be able to enhance the activity of a JAK1 inhibitor by simultaneously targeting TYK2. Such a compound would be postulated to possess the efficacy of a JAK1 inhibitor driven through γ-common chain cytokines and IL-6 signaling, with the added ability to mimic the effect of an anti-P40 inhibitor blocking IL-12 and IL-23 signaling, through TYK2 inhibition. Type I interferon signaling would be suppressed through both JAK1 and TYK2 blockade. Selectivity against JAK2 and thus JAK2 driven cytokine signaling (e.g., EPO) would in turn spare undesirable hematopoietic changes.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60717" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60717" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Program Objective</h3><div class="NLM_p">In establishing our program objectives, it was important to determine how selectivity between JAK isoforms and, more importantly, the relative level of inhibition of different cytokines at a given concentration or dose, would be defined. The relationship between pharmacokinetics and pharmacodynamics (PK:PD) are key parameters underlying these target coverage relationships. To help us with this task, we used the large body of preclinical and clinical data that we have published from the tofacitinib <b>1</b> program. Similar data have also been made available in publications for compounds <b>2</b> and <b>5</b>.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> Most importantly, we used these data to define the level of inhibition required to provide robust efficacy, defined by IFNα (JAK1/TYK2) blockade, and the level of JAK2 selectivity required to minimize inhibition of EPO signaling. Further, we related the clinical PK:PD relationships back to in vitro human whole blood cytokine inhibition using a battery of standardized assays, allowing us to develop in vitro/in vivo correlations.</div><div class="NLM_p">From infusion pump studies in the mouse collagen induced arthritis (mCIA) model, it was demonstrated that the efficacy of <b>1</b> was correlated with the in vitro whole blood IC<sub>50</sub> inhibition values for the JAK1 heterodimer signaling pathways (IL6 and IL15).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Using data from oral once daily (q.d.) and twice daily (b.i.d.) dosing paradigms, it was observed that efficacy was best explained by the 24 h average drug concentration (<i>C</i><sub>av</sub>) and not <i>C</i><sub>max</sub> or <i>C</i><sub>min</sub> values. Clinical support for <i>C</i><sub>av</sub> levels as an efficacy driver were obtained from a Phase II study of <b>1</b> in RA patients.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Furthermore, comparison of compound <b>1</b> q.d. and b.i.d. doses at the same total daily dose (20 mg) showed similar efficacy for the two regimens. Under these two dosing regimens, AUC<sub>24</sub> was similar, while <i>C</i><sub>min</sub> and <i>C</i><sub>max</sub> values were different, allowing us to conclude that average daily inhibition (<i>C</i><sub>av</sub>) can be used to derive PK:PD relationships. The 5 mg b.i.d. <i>C</i><sub>av</sub> concentration for <b>1</b> was found to be equivalent to the human whole blood potency values for IL-6 and the γ-common chain cytokine signaling pathways represented by IL-15, helping to establish a lower boundary for potency.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Further support was recently published for <b>5</b> in RA patients whereby similar efficacy was observed for b.i.d. and q.d. dosing regimens of the same total daily dose.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">Having established that drug response (at least in RA and models of RA) is driven by <i>C</i><sub>av</sub> exposure and that efficacy benefited from at least IC<sub>50</sub><i>C</i><sub>av</sub> target coverage, we next needed to determine the upper boundary for EPO signaling inhibition. In Phase II dose ranging studies in RA and PSO patients, the effect of <b>1</b> on HgB was monitored. In RA (study NCT00147498) where HgB levels are suppressed due to inflammation, HgB trended higher with 5 mg b.i.d. and decreased in a dose dependent manner at 15 and 30 mg b.i.d.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In a PSO Phase IIb study (NCT00678210), HgB levels were not statistically different from placebo at 5 mg b.i.d., but at 15 mg b.i.d. were associated with a significant reduction (−0.52 g/dL vs −0.14 g/dL for placebo) at week 4.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Across two large Phase III PSO trials (OPT1 and OPT2), which are not complicated by anemia associated with the disease, 741 patients received <b>1</b> at 10 mg b.i.d. The median HgB change from baseline was −0.3 g/dL in OPT1 and −0.4 g/dL in OPT2; neither was statistically significant. The proportion of patients with Hgb < 10 g/dL was 0.3%.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In long-term extension studies in RA patients treated over 48 months with <b>1</b> at a dose of 10 mg b.i.d. on a background of methotrexate (standard of care), less than 3% of patients had a >2 g/dL change in HgB.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p">Utilizing the global RA PK model published for <b>1</b>,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> a new model was developed to determine the relationship of plasma levels of <b>1</b> to inhibition of EPO signaling. Based upon this model, the daily <i>C</i><sub>av</sub> EPO inhibition (IC<sub><i>xx</i></sub>) for compound <b>1</b> at 5 and 10 mg b.i.d. doses was determined to be IC<sub>20</sub> and IC<sub>33</sub>, respectively.</div><div class="NLM_p last">From the data discussed above in aggregate, we established target values for the program with efficacy to be driven by <i>C</i><sub>av</sub> IC<sub>80</sub> coverage of the primary TYK2 and JAK1 pathway (IFNα) and <i>C</i><sub>av</sub> ≤ IC<sub>30</sub> for the JAK2 pathway (EPO). As an expedient for routine SAR, we calculated an IC<sub><i>xx</i></sub>* value (IC<sub><i>xx</i></sub>* = 100*((IC<sub>80</sub> IFNα)/ (IC<sub>80</sub> IFNα + IC<sub>50</sub> EPO)) to determine selectivity for EPO (CD34<sup>+</sup> cells spiked into human whole blood (HWB); see Methods) inhibition as a function of the IFNα HWB IC<sub>80</sub>. For advanced compounds, a human PK model was developed from in vitro and in vivo data, which allowed us to determine the predicted dose to cover the IFNα IC<sub>80</sub>. Target coverage IC<sub><i>xx</i></sub> values for EPO and other inhibited cytokines were derived from this model.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Assays and Data Reporting</h3><div class="NLM_p">Compounds were tested for enzymatic potency in a Caliper assay (PerkinElmer) with the ATP concentration at either the <i>K</i><sub>m</sub> for each of the JAK targets<i>,</i> or at a pseudophysiological concentration of 1 mM. At higher ATP concentrations the ability to identify weak lead matter can be compromised. During the course of our work, we have found that correlations between enzymatic potencies and cellular activities are best determined with the ATP concentration under pseudophysiological conditions at 1 mM.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Moreover, under these conditions, selectivity ratios between the JAK kinases are more appropriately determined, as opposed to using the <i>K</i><sub>m</sub> for ATP which varies for each target. For example, the ATP <i>K</i><sub>m</sub> for JAK3 has been determined in our system to be 4 μM, whereas the <i>K</i><sub>m</sub> for JAK1 is 40 μM. The <i>K</i><sub>m</sub> for TYK2 and JAK2 were determined to be 12 and 4 μM, respectively. Lipophilic efficiencies (LipE) were calculated from the TYK2 IC<sub>50</sub> measured with 1 mM ATP and the measured LogD value.</div><div class="NLM_p last">Cell potencies were determined in human whole blood assays, where blockade of STAT phosphorylation, following cytokine stimulation, was monitored by flow cytometry. As the potency is determined in whole blood, comparisons between compounds can only be made when taking into account unbound concentrations. Therefore, an estimation of the unbound potency was made from the total HWB potency, the human plasma free fraction, and red blood partitioning ratio, <a class="ref internalNav" href="#notes-1" aria-label="Table S1">Table S1</a>. Where measured data were unavailable, a calculated human plasma free fraction value was used, based upon an internal in silico model.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Lead Chemical Matter</h3><div class="NLM_p">Initial work focused upon identifying lead chemical matter which demonstrated promising potency, inhibiting both TYK2 and JAK1 kinases with evidence of selectivity over JAK2 and JAK3. A series of 2,4-diamino pyrimidines provided the interesting chiral diazabicyclo[2.2.1]octane derivative <b>8</b> and its enantiomer <b>9</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). A clear stereochemical preference is evident from the biochemical activity with <b>8</b> and <b>9</b> displaying TYK2 IC<sub>50</sub> = 23 nM and 2690 nM respectively, determined at the <i>K</i><sub>m</sub> for ATP. The role of the methylene bridge in the eutomer was apparent by comparison with the less potent piperazine analog <b>10</b>, TYK2 IC<sub>50</sub> = 368 nM.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Enzymatic Potencies for Compounds <b>8</b>–<b>10</b> Determined against TYK2, JAK1, JAK2, and JAK3 at the <i>K</i><sub>m</sub> for ATP for Each Kinase</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0015.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Compounds were assayed at least twice, and the IC<sub>50</sub> reported as the geometric mean. ATP concentration at the apparent <i>K</i><sub>m</sub> for each kinase.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Shake-flask LogD measured between octanol/water phosphate buffered to pH 7.4.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">LipE = pIC<sub>50</sub> – LogD.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">ND = Not Determined.</p></div></div><div></div></div><div class="NLM_p">The <i>S</i>,<i>S</i>-stereochemistry of the eutomer was determined from a crystal structure obtained of compound <b>8</b> bound to the TYK2 kinase domain (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure. <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Based on the crystal structure, we suggest that the bridged piperazine is serving two roles: first, to provide a conformationally rigid structure that projects the pendant cyanoacetamide toward the P-loop of TYK2, where the nitrile makes further interactions with Gly-906 and, second, to provide an additional lipophilic interaction by filling a pocket at the bottom of the binding site (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structure of compound <b>8</b> in complex with TYK2, resolved to 2.0 Å (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBK">6DBK</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>8</b> was further profiled against the JAK isoforms under the pseudophysiological conditions with [ATP] = 1 mM. At this ATP concentration, the compound demonstrated weaker inhibition of TYK2 consistent with Michaelis–Menten behavior (TYK2 IC<sub>50</sub> = 774 nM), and similarly weaker activity against JAK1, JAK2, and JAK3 (JAK1 IC<sub>50</sub> = 3714 nM, JAK2 IC<sub>50</sub> > 9972 nM and JAK3 IC<sub>50</sub> > 10 000 nM). Throughout the remainder of this manuscript, enzymatic potencies will be reported with the ATP concentration set at 1 mM.</div><div class="NLM_p">The modular nature of substituents around the pyrimidine core allowed dissection of the molecule into four R-groups: R<sup>1</sup> the bridged piperazine moiety, R<sup>2</sup> a hydrogen atom or fluorine adjacent to the gatekeeper Met-978, R<sup>3</sup> the solvent exposed aromatic substituent, and the R<sup>4</sup> functionality to interact with the P-loop of the kinase (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. R-group nomenclature for 2,4-diamino pyrimidines <b>8</b>–<b>25</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We first chose to evaluate alternate bridged diamines R<sup>1</sup> to explore the role on potency and selectivity (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). In this instance, the compounds were prepared as cyclopropyl amides. The <i>S</i>,<i>S</i>-cyclopropyl amide <b>11</b> showed similar potency to the cyanoacetamide homologue <b>8</b> (TYK2 IC<sub>50</sub> = 1738 and 774 nM, respectively) and served as a good reference point. Potency against TYK2 improved for the other compounds in the series, presumably due to improved hydrophobic interactions with the residues at the bottom of the binding site as illustrated in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. The <i>S,S</i>-diazabicyclo[2.2.2]octane <b>12</b> gained substantially in potency (TYK2 IC<sub>50</sub> = 148 nM), as did the [3.1.1] system <b>13</b> (IC<sub>50</sub> = 201 nM). The 3,8-diazabicyclo[3.2.1]octane system <b>14</b> was clearly the most potent and efficient in the series, while maintaining the desired JAK1 activity (IC<sub>50</sub> = 32 and 122 nM respectively for TYK2 and JAK1, TYK2 LipE = 5.94). Compound <b>14</b> also showed interesting selectivity against both JAK2 and JAK3 (IC<sub>50</sub> = 329 and >10 000 nM, respectively).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures for compounds <b>11</b>–<b>15</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Enzymatic Potencies for Bridged Diamines <b>11</b>–<b>15</b> Determined against TYK2, JAK1, JAK2, and JAK3</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center">TYK2<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">JAK1<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">JAK2<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">JAK3<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">sfLogD<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">LipE<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">1738</td><td class="colsep0 rowsep0" align="left">>9524</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">1.96</td><td class="colsep0 rowsep0" align="left">4.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">148</td><td class="colsep0 rowsep0" align="left">748</td><td class="colsep0 rowsep0" align="left">2782</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">2.16</td><td class="colsep0 rowsep0" align="left">4.97</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">201</td><td class="colsep0 rowsep0" align="left">3473</td><td class="colsep0 rowsep0" align="left">7851</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">2.15</td><td class="colsep0 rowsep0" align="left">4.85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">122</td><td class="colsep0 rowsep0" align="left">329</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">1.86</td><td class="colsep0 rowsep0" align="left">5.94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">63</td><td class="colsep0 rowsep0" align="left">306</td><td class="colsep0 rowsep0" align="left">3078</td><td class="colsep0 rowsep0" align="left">2.88</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Compounds were assayed at least twice, and the IC<sub>50</sub> was reported as the geometric mean. ATP concentration = 1 mM.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Shake-flask LogD measured between octanol/water phosphate buffered to pH 7.4.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">LipE = pIC50 – LogD.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">ND = not determined.</p></div></div></div><div class="NLM_p">During the course of the program, we explored the R<sup>2</sup> substituent at the 5-position of the pyrimidine. From a comparison with compound <b>15</b>, the 5-fluoro analog of compound <b>14</b> in the 3.2.1 series, it can be seen that the two compounds are within 2-fold in terms of their TYK2 potency. Furthermore, the fluorine adds approximately 1 unit of lipophilicity (shake flask LogD (sfLogD) = 1.86 and 2.88 for <b>14</b> and <b>15</b>, respectively), which consequently reduces the lipophilic efficiency of the molecule (TYK2 LipE = 5.94 and 5.13 for <b>14</b> and <b>15</b> respectively). As a result, although we studied SAR within the 5-fluoropyrimidine series, the 5-<i>H</i> analogs were generally preferred.</div><div class="NLM_p">We elected to study the 3.2.1 series further, the initial priority was given to explore the R<sup>3</sup> vector and identify replacement functionality for the embedded aniline moiety to remove the structural alert.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p">A small array of compounds, in this instance with a fluorine at position 5 of the pyrimidine ring, was prepared to assess SAR close to the solvent front of the ATP binding site of TYK2 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). It is apparent that potency can be modulated by structural modifications close to this solvent exposed vector, whereby key interactions need to be maintained with the protein. Functionalities such as the pyrazoles <b>16</b> and <b>17</b> and 3-pyridyls <b>18</b> are readily accommodated by the protein (TYK2 IC<sub>50</sub> = 55, 53, and 48 nM respectively). However, simple analogous systems such as the 2-pyridine <b>19</b> are not accommodated (TYK2 IC<sub>50</sub> = 7202 nM). This difference in activity can be explained through structural analysis (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure. <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). The planarity of the heteroaryl-2-amino pyrimidine moiety is made necessary by the presence of Leu-903 above the plane of the molecule, and Leu-1030 and Gly-984 below the plane of the molecule. This planar arrangement necessitates elimination of intramolecular stereoelectronic interactions to reduce ligand strain. This is not the case with the 2-pyridyl system <b>19</b> whereby to accommodate both requirements of planarity and internal ligand strain; the pyridyl nitrogen needs to be in close proximity with the backbone carbonyl oxygen atom of Val-981, an energetically unfavorable interaction.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of compounds <b>16</b>–<b>19</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Enzymatic and Cellular Potencies for <b>16</b>–<b>19</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">IC50 (nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">HWB IC<sub>50</sub> (nM) (free)<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center">TYK2<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">JAK1<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">JAK2<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">JAK3<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">sfLogD<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">LipE<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">IFNα<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">EPO<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">EPO IC<sub><i>xx</i></sub>*</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">55</td><td class="colsep0 rowsep0" align="left">81</td><td class="colsep0 rowsep0" align="left">260</td><td class="colsep0 rowsep0" align="left">2531</td><td class="colsep0 rowsep0" align="left">1.78</td><td class="colsep0 rowsep0" align="left">5.78</td><td class="colsep0 rowsep0" align="left">75 (70)</td><td class="colsep0 rowsep0" align="left">2,596</td><td class="colsep0 rowsep0" align="left">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">53</td><td class="colsep0 rowsep0" align="left">76</td><td class="colsep0 rowsep0" align="left">488</td><td class="colsep0 rowsep0" align="left">2878</td><td class="colsep0 rowsep0" align="left">2.13</td><td class="colsep0 rowsep0" align="left">5.45</td><td class="colsep0 rowsep0" align="left">144 (84)</td><td class="colsep0 rowsep0" align="left">6,285</td><td class="colsep0 rowsep0" align="left">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">234</td><td class="colsep0 rowsep0" align="left">692</td><td class="colsep0 rowsep0" align="left">4962</td><td class="colsep0 rowsep0" align="left">3.21</td><td class="colsep0 rowsep0" align="left">4.41</td><td class="colsep0 rowsep0" align="left">385 (91)</td><td class="colsep0 rowsep0" align="left">12,166</td><td class="colsep0 rowsep0" align="left">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">7202</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">2.71</td><td class="colsep0 rowsep0" align="left">2.73</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">ATP concentration = 1 mM.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Compounds were assayed at least twice, and the IC<sub>50</sub> reported as the geometric mean.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Shake-flask LogD measured between octanol/water phosphate buffered to pH 7.4.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">LipE = pIC<sub>50</sub> – LogD.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Free IC<sub>50</sub> = (IFNα HWB IC<sub>50</sub> * human plasma free fraction)/human red blood cell to plasma ratio.</p></div><div class="footnote" id="t3fn6"><sup><sup>f</sup></sup><p class="last">ND = not determined.</p></div></div></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compounds <b>16</b> and <b>18</b> modeled in the ATP binding site of TYK2, based upon APO protein PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBK">6DBK</a>..</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Data from compounds in this series were important to understand the translation of enzymatic to cellular potencies, and corresponding selectivity (IC<sub><i>xx</i></sub>*) over EPO inhibition. The pyrazoles <b>16</b> and <b>17</b> exhibited good potency in the IFNα HWB assay (IC<sub>50</sub> (free) = 75 (70) and 144 (84) nM respectively). The free IFNα potencies showed good concordance with the TYK2 and JAK1 enzymatic activity. In the JAK2 driven EPO HWB assay these compounds achieved good selectivity (EPO IC<sub><i>xx</i></sub>* = 10 and 8 for <b>16</b> and <b>17</b>, respectively). The pyridine <b>18</b> behaved similarly (IFNα HWB IC<sub>50</sub> (free) = 385 (91) nM, EPO IC<sub><i>xx</i></sub>* = 11).</div><div class="NLM_p">The R<sup>3</sup><i>N</i>-methyl pyrazole functionality was elected for further study due to its high lipophilic efficiency (<b>15</b> TYK2 LipE = 5.45) and reduced risk of Phase II metabolism relative to the <i>N</i>-ethanol derivative <b>14</b>.</div><div class="NLM_p">A series of acylated derivatives, amides and ureas, were prepared using the <i>N</i>-methyl pyrazole platform, in this instance with hydrogen as R<sup>2</sup> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The most active compound in this series was the cyanomethylene urea <b>20</b> PF-06730129 (TYK2 IC<sub>50</sub> = 16 nM). Similar activity was also observed for the trifluoroethyl urea <b>21</b>, both of which were more potent than the simple ethyl analog <b>22</b> (TYK2 IC<sub>50</sub> = 28 and 71 nM, for <b>21</b> and <b>22</b> respectively). The trifluoroethyl urea <b>21</b> was more potent in the IFNα HWB assay than was the cyanomethylene urea <b>20</b> (IFNα HWB IC<sub>50</sub> (free) = 51 (26) and 120 (73) nM, respectively). Compound <b>20</b> is the most polar compound in this series (LogD 0.97) and as a result suffers from relatively low permeability in the RRCK assay (A-B mean PAPP 0.6 × 10<sup>–6</sup> cm/s), which may explain its surprisingly low potency in HWB. The other compounds presented in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> have good permeability in the RRCK assay (mean PAPP 5.6–18.8 *10–6 cm/s), despite relatively high polarity (sfLogD 1.40–1.72).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures of acylated 3,8-diazabicyclo[3.2.1]octane derivatives <b>20</b>–<b>25</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Enzymatic Potencies, Efficiency, and Human Whole Blood Activity for IFNa and EPO for Compounds <b>1</b>, <b>20</b>–<b>25</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">IC50 (nM)</th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">HWB IC<sub>50</sub> (nM) (free)<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center">TYK2<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">JAK1<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">JAK2<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">JAK3<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">sfLogD<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">TYK2 LipE<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">IFNα</th><th class="colsep0 rowsep0" align="center">EPO</th><th class="colsep0 rowsep0" align="center">EPO IC<sub>xx*</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">489<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></td><td class="colsep0 rowsep0" align="left">15<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></td><td class="colsep0 rowsep0" align="left">77<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></td><td class="colsep0 rowsep0" align="left">55<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></td><td class="colsep0 rowsep0" align="left">1.13</td><td class="colsep0 rowsep0" align="left">5.17</td><td class="colsep0 rowsep0" align="left">38 (19)<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">328</td><td class="colsep0 rowsep0" align="left">33<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">67</td><td class="colsep0 rowsep0" align="left">2477</td><td class="colsep0 rowsep0" align="left">0.97</td><td class="colsep0 rowsep0" align="left">7.13</td><td class="colsep0 rowsep0" align="left">120 (73)<a class="ref internalNav" href="#t4fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">1229</td><td class="colsep0 rowsep0" align="left">28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">146</td><td class="colsep0 rowsep0" align="left">6872</td><td class="colsep0 rowsep0" align="left">1.72</td><td class="colsep0 rowsep0" align="left">6.13</td><td class="colsep0 rowsep0" align="left">51 (26)</td><td class="colsep0 rowsep0" align="left">1160</td><td class="colsep0 rowsep0" align="left">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">104</td><td class="colsep0 rowsep0" align="left">538</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">1.44</td><td class="colsep0 rowsep0" align="left">6.01</td><td class="colsep0 rowsep0" align="left">116 (60)</td><td class="colsep0 rowsep0" align="left">2866</td><td class="colsep0 rowsep0" align="left">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">77</td><td class="colsep0 rowsep0" align="left">6494</td><td class="colsep0 rowsep0" align="left">1.61</td><td class="colsep0 rowsep0" align="left">6.31</td><td class="colsep0 rowsep0" align="left">30 (13)</td><td class="colsep0 rowsep0" align="left">577</td><td class="colsep0 rowsep0" align="left">18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">76</td><td class="colsep0 rowsep0" align="left">199</td><td class="colsep0 rowsep0" align="left">684</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">1.52</td><td class="colsep0 rowsep0" align="left">5.90</td><td class="colsep0 rowsep0" align="left">119 (91)</td><td class="colsep0 rowsep0" align="left">3737</td><td class="colsep0 rowsep0" align="left">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">702</td><td class="colsep0 rowsep0" align="left">842</td><td class="colsep0 rowsep0" align="left">3148</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">1.55</td><td class="colsep0 rowsep0" align="left">4.91</td><td class="colsep0 rowsep0" align="left">823 (399)</td><td class="colsep0 rowsep0" align="left">5655</td><td class="colsep0 rowsep0" align="left">37</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Compounds were assayed at least twice, and the IC<sub>50</sub> reported as the geometric mean. ATP concentration = 1 mM.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Shake-flask LogD measured between octanol/water phosphate buffered to pH 7.4.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">LipE = pIC<sub>50</sub> – LogD.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Compounds were assayed at least twice, and the IC<sub>50</sub> reported as the geometric mean. Free IC<sub>50</sub> = (IFNα HWB IC<sub>50</sub> * human plasma free fraction)/human red blood cell to plasma ratio.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">ICxx calculated at 10 mg BID using an unbound Cav = 83 nM.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></p></div><div class="footnote" id="t4fn6"><sup><sup>f</sup></sup><p class="last">Free IC<sub>50</sub> = IFNα HWB IC<sub>50</sub> * calculated human plasma free fraction.</p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Human Whole Blood Potencies and IC<sub>xx</sub> for Compounds <b>1</b> and <b>23</b> with Different Cytokine Stimuli</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub><i>xx</i></sub></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Cytokine/pStat</th><th class="colsep0 rowsep0" align="center">JAK signaling complex</th><th class="colsep0 rowsep0" align="center" char="."><b>1</b><a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></th><th class="colsep0 rowsep0" align="center" char="."><b>23</b></th><th class="colsep0 rowsep0" align="center" char="."><b>1</b><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="."><b>23</b><a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IFNα induced pSTAT3 (lymphocytes)</td><td class="colsep0 rowsep0" align="left">TYK2/JAK1</td><td class="colsep0 rowsep0" align="char" char=".">38</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">81</td><td class="colsep0 rowsep0" align="char" char=".">80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IFNγ induced pSTAT1 (CD14<sup>+</sup> cells)</td><td class="colsep0 rowsep0" align="left">JAK1/JAK2</td><td class="colsep0 rowsep0" align="char" char=".">52</td><td class="colsep0 rowsep0" align="char" char=".">298</td><td class="colsep0 rowsep0" align="char" char=".">76</td><td class="colsep0 rowsep0" align="char" char=".">29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-6 induced pSTAT1 (CD3<sup>+</sup> cells)</td><td class="colsep0 rowsep0" align="left">JAK1/JAK2</td><td class="colsep0 rowsep0" align="char" char=".">54</td><td class="colsep0 rowsep0" align="char" char=".">81</td><td class="colsep0 rowsep0" align="char" char=".">75</td><td class="colsep0 rowsep0" align="char" char=".">60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-6 induced pSTAT3 (CD3<sup>+</sup> cells)</td><td class="colsep0 rowsep0" align="left">JAK1/JAK2</td><td class="colsep0 rowsep0" align="char" char=".">367</td><td class="colsep0 rowsep0" align="char" char=".">641</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-10 induced pSTAT3 (lymphocytes)</td><td class="colsep0 rowsep0" align="left">TYK2/JAK1</td><td class="colsep0 rowsep0" align="char" char=".">291</td><td class="colsep0 rowsep0" align="char" char=".">305</td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="char" char=".">29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-12 induced pSTAT4 (lymphocytes)</td><td class="colsep0 rowsep0" align="left">JAK2/TYK2</td><td class="colsep0 rowsep0" align="char" char=".">315</td><td class="colsep0 rowsep0" align="char" char=".">65</td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="char" char=".">65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-15 induced pSTAT5 (lymphocytes)</td><td class="colsep0 rowsep0" align="left">JAK1/JAK3</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="char" char=".">238</td><td class="colsep0 rowsep0" align="char" char=".">74</td><td class="colsep0 rowsep0" align="char" char=".">34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-21 induced pSTAT3 (lymphocytes)</td><td class="colsep0 rowsep0" align="left">JAK1/JAK3</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="char" char=".">204</td><td class="colsep0 rowsep0" align="char" char=".">76</td><td class="colsep0 rowsep0" align="char" char=".">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-23 induced pSTAT3 (lymphocytes)</td><td class="colsep0 rowsep0" align="left">JAK2/TYK2</td><td class="colsep0 rowsep0" align="char" char=".">249</td><td class="colsep0 rowsep0" align="char" char=".">120</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="char" char=".">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IL-27 induced pSTAT3 (lymphocytes)</td><td class="colsep0 rowsep0" align="left">JAK1/JAK2</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="char" char=".">86</td><td class="colsep0 rowsep0" align="char" char=".">76</td><td class="colsep0 rowsep0" align="char" char=".">59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EPO induced pSTAT5 (spiked CD34<sup>+</sup> progenitor cells)</td><td class="colsep0 rowsep0" align="left">JAK2/JAK2</td><td class="colsep0 rowsep0" align="char" char=".">328</td><td class="colsep0 rowsep0" align="char" char=".">577</td><td class="colsep0 rowsep0" align="char" char=".">33</td><td class="colsep0 rowsep0" align="char" char=".">18</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Compounds were assayed at least twice, and the IC<sub>50</sub> is reported as the geometric mean.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">IC<sub><i>xx</i></sub> calculated at 10 mg BID using an unbound C<sub>av</sub> = 83 nM.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">IC<sub><i>xx</i></sub> calculated from predicted C<sub>av</sub> exposure to cover IFNα IC<sub>80</sub>.</p></div></div></div><div class="NLM_p">In the amide series, the 1,1-difluoro-cyclopropanes proved to be particularly effective. The <i>S</i>-enantiomer <b>23</b> was found to be the eutomer, with a balanced TYK2 and JAK1 inhibition profile (TYK2 and JAK1 IC<sub>50</sub> = 23 and 17 nM, respectively). Compound <b>23</b> inhibited JAK2 and JAK3 with IC<sub>50</sub> = 77 and 6494 nM, respectively. In the IFNα human whole blood assay the compound showed good potency (IFNα HWB IC<sub>50</sub> (free) = 30 (13) nM), with EPO selectivity well within our program objective (EPO IC<sub><i>xx</i></sub>* = 18). The unsubstituted cyclopropane <b>24</b> was approximately 3-fold less potent against TYK2 and somewhat unbalanced with respect to JAK1 (TYK2 and JAK1 IC<sub>50</sub> = 76 and 199 nM, respectively), while the distomer <b>25</b>, bearing the <i>R</i>-1,1-difluorocyclopropane, was significantly less active (TYK2 and JAK1 IC<sub>50</sub> = 702 and 842 nM, respectively).</div><div class="NLM_p">To further understand the TYK2 potency of compound <b>23</b> we obtained a crystal structure with the protein (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). The compound adopts the expected binding mode, forming donor and acceptor hydrogen bonds between the amino pyrimidine moiety and Val-981. The ethylene bridge of the [3.2.1]-diazabicycle projects into the lower hydrophobic portion of the binding site as depicted in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, while the difluoromethylene of the cyclopropyl amide projects up into the P-loop of the ATP binding site. Overlaid onto the structure are simulated APO waters (Hydrosite), colored by Δ<i>H</i> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>a).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Proximal to the cyclopropyl amide in the model are three simulated waters W1, W3, and W12. W12 and W3 are considered high energy waters (Δ<i>H</i> = 5.28 and 2.09 for W12 and W3 respectively, and Δ<i>G</i> = 7.78 and 3.11 for waters W12 and W3 respectively), their displacement would be predicted to increase the binding affinity for the molecule. W1, which we considered a “neutral water” (Δ<i>H</i> = −0.54 and Δ<i>G</i> = 1.68), would also be displaced by the inhibitor. For reference the most energetically stable predicted water from the simulation (W14 not shown) has calculated Δ<i>H</i> = −3.08 and Δ<i>G</i> = −0.82. We built a model of the distomer <b>25</b>, wherein the overall binding mode of the compound is similar to that for <b>23</b>; however, in this case the difluoromethylene group projects down into a region of negative electrostatic potential formed by the side chain carbonyls of Asp-1041 and Asn-1028, an energetically unfavorable binding mode (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>c). This may account for the loss in activity for this enantiomer.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (a) Crystal structure of <b>23</b> with TYK2 (2.37 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBM">6DBM</a>); spheres represent simulated apo waters, colored by Δ<i>H</i>: blue represents negative Δ<i>H</i> stable water, red represents positive Δ<i>H</i> unstable water. (b) End view of <b>23</b> looking toward the hinge of the protein, showing proximity to key simulated water molecules (spheres) W1, W3, and W12, colored by Δ<i>H</i> as in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>a. (c) Model of <b>25</b> bound to TYK2 based upon PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBM">6DBM</a>, showing proximity of fluorine atoms to electrostatically negative (red) region of the binding pocket formed by carbonyl oxygens of Asp-1041 and Asn-1028.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A crystal structure of compound <b>23</b> was also obtained with JAK1 (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). As expected, the compound binds to the protein in approximately the same pose as in TYK2. The binding site residues that differ between JAK1 and TYK2 are rendered in stick format. Consistent with the similar enzymatic potencies of <b>23</b> against both targets (TYK2 and JAK1 IC<sub>50</sub> = 23 and 17 nM, respectively), the compound makes similar interactions with both enzymes. Examination of the simulated waters shows a similar picture as found in TYK2, with high energy waters W1 and W6 proximal to the difluorocyclopropyl amide (Δ<i>H</i> = 5.14 and 2.12, and Δ<i>G</i> = 6.21 and 3.19 for W1 and W6 respectively). In addition, a second high energy water is present proximal to the cyclopropyl moiety (W5), and an interesting unstable water (W2) is found in the hydrophobic portion of the binding site, proximal to the ethylene bridge of the ligand (Δ<i>H</i> = 2.37 and 3.38, and Δ<i>G</i> = 4.09 and 4.22 for W1 and W6 respectively). As with TYK2, a relatively stable water (W29) would also be expected to be displaced by the compound (Δ<i>H</i> = −1.03 and Δ<i>G</i> = 0.26).</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0010.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (a) <b>23</b> bound to JAK1 (2.48 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBN">6DBN</a>). Spheres represent simulated waters. colored by Δ<i>H</i>: blue represents negative Δ<i>H</i> stable water, and red represents positive Δ<i>H</i> unstable water. (b) End view showing proximity of simulated waters, and associated energy values, to the amide moiety of <b>23</b> bound to JAK1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The [3.2.1] series was found, in general, to be in good property space for oral absorption (<a class="ref internalNav" href="#notes-1" aria-label="Table S2">Table S2</a>). LogD values are aligned with the in vitro clearance values as expected. For example, human liver microsome stability was good (HLM Clint ≤12 uL/min/mg) for all compounds, except for <b>18</b>, which had the highest LogD (3.21). Kinetic solubility was also poor for compound <b>18</b> (14 μM at pH 6.5) and for compound <b>15</b> (40 μM at pH 6.5). Low LogD (sfLogD ≤ 1.52) for compounds <b>20</b>, <b>22</b>, and <b>24</b> correlated with reduced permeability in the RRCK assay (mean PAPP ≤ 6.3 × 10<sup>–6</sup> cm/s)).</div><div class="NLM_p">Compound <b>23</b> was selected for further characterization. The compound was assayed in a human whole blood panel to evaluate inhibition across the JAK/STAT cytokine signaling families (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). As previously discussed the IFNα/pSTAT3 HWB potency for the compound is 30 nM, which serves as the reference value for establishing <i>C</i><sub>eff</sub>. <b>23</b> potently inhibits TYK2/JAK2 mediated IL-12/pSTAT4 and IL-23/pSTAT3 (HWB IC<sub>50</sub> = 65 and 120 nM, respectively). The compound has good potency against IL6/pStat1 in the CD3<sup>+</sup> cellular subset (IC<sub>50</sub> = 81 nM), but lower inhibition of IL6/pSTAT3, again in the CD3<sup>+</sup> cellular subset (IC<sub>50</sub> = 641 nM). The mechanistic basis for the difference in potency in IL6 signaling between pStat1 and pStat3 is presently unknown. The compound also inhibits the JAK1/JAK3 driven γ-common chain cytokines, represented by IL-15/pStat5 and IL-21/pSTAT3 with reasonable potency (HWB IC<sub>50</sub> = 238 and 204 nM, respectively). Compound <b>23</b> inhibits EPO/pSTAT5 (JAK2 homodimer) in HWB spiked with CD34<sup>+</sup> progenitor cells (IC<sub>50</sub> = 577 nM). IL10/pSTAT3 (TYK2/JAK1) and IL27/pSTAT3 (JAK1/JAK2/TYK2) are also inhibited by the compound with IC<sub>50</sub> = 305 nM and 86 nM, respectively.</div><div class="NLM_p">Compound <b>23</b> was evaluated against a panel of 306 kinases at the apparent <i>K</i><sub>m</sub> for ATP for each kinase (Carna Biosciences). A subset of 157 kinases was additionally assayed at an ATP concentration of 1 mM. The test concentration of PF-06700841 was 1 μM, and the data were expressed as % inhibition. Under the screening conditions for ATP at the <i>K</i><sub>m</sub> for each kinase, 21 kinases out of 307 (7%) targets displayed >50%: TYK2 (101%), JAK1 (101%), JAK2 (101%), AurA/TPX2 (97%), TNK1 (94%), JAK3 (92%), QIK (91%), ACK (82%), PDGFRα (Τ674I) (78%), SIK (77%), PDGFRα (70%), MAP2K5 Cascade (70%), MNK2 (68%), PDGFRβ (66%), ERK5 (63%), AurA (62%), PDGFRa (V561D) (60%), Nuak1 (60%), FMS (59%), MARK4 (59%), and MARK3 (50%). Under the higher ATP concentration of 1 mM, 4 kinases out of 157 (4%) displayed inhibition above 50%: TYK2 (98%), JAK1 (96%), JAK2 (94%), and TNK1 (64%).</div><div class="NLM_p">Compound <b>23</b> was also profiled in vitro against a broad panel of receptors, ion channels, and transporters in the CEREP Wide Ligand Profile screen at a single concentration of 10 μM. Less than 50% inhibition of functional, binding, or enzyme activity was observed against all targets except for kinase insert domain receptor (KDR) (VEGFR2) (IC<sub>50</sub> = 1600 nM). This in vitro VEGFR2 inhibitory activity did not translate in to a functional response in a cell-based assay for VEGFR2 signaling (NovaScreen), where its IC<sub>50</sub> was determined to be >30 μM, demonstrating that the screening data from kinase assays conducted at enzymatic <i>K</i><sub>m</sub> ATP concentrations can translate poorly to functional cellular settings with higher physiologic ATP conditions.</div><div class="NLM_p">The physical properties of compound <b>23</b> were favorable for oral dosing. The conjugate acid of the compound has a measured p<i>K</i><sub>a</sub> of 6.33 and was converted into the <i>p</i>-toluenesulfonic acid salt, with a melting point of 275 °C. The salt form had good solubility in buffered water (4.84 mg/mL at pH 7.64 in phosphate buffered saline), as well as in simulated gastric fluids FASSIF and FESSIF (>7 mg/mL). Compound <b>23</b> was also shown to have high passive permeability, RRCK (mean P<sub>APP</sub> 18.8 × 10<sup>–6</sup> cm/s). The pharmacokinetics of <b>23</b> PF-06700841 were studied in Sprague–Dawley rats following intravenous and oral administration (1 and 3 mg/kg respectively) of the tosylate salt, where the compound showed a plasma clearance of 31 mL/min/kg, a volume of distribution of 2.0 L/kg, and oral bioavailability of 83%. Following the 3 mg/kg oral dose, the <i>C</i><sub>max</sub> was 774 ng/mL and the AUC<sub>∞</sub> was 1340 ng·h/mL. The high oral bioavailability indicated high absorption from the gut, consistent with its in vitro passive permeability properties and high solubility.</div><div class="NLM_p">The in vitro metabolism of <b>23</b> was studied in human liver microsomes (Cl<sub>int,u</sub> < 10 μL/min/mg protein) and hepatoctyes (Cl<sub>int,u</sub> < 0.6 μL/min/million cells), which indicated low metabolic turnover. Plasma protein binding was low in rat (fraction unbound (f<sub>u</sub>) 0.69) and human (f<sub>u</sub> 0.61), with no significant blood to plasma partitioning (human Crbc/Cp 1.2). Oxidative metabolites of compound <b>23</b> accounted for the primary routes of biotransformation in rat, monkey, and human in vitro hepatic systems, consistent with CYP450 as the primary clearance route. Metabolic pathways included oxidation of the <i>N</i>-methyl pyrazole (primary), N-demethylation, and N-dealkylation (loss of pyrazole). The clearance mechanisms of <b>23</b> were determined to be mediated primarily by CYP450 metabolism (primarily through CYP3A4), with limited renal and biliary clearance expected. Human pharmacokinetic predictions were made using human liver microsomes, hepatocytes, and recombinant CYP3A4, as well as standard single species allometric scaling techniques (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Summary of Predicted Human Blood Pharmacokinetics of <b>23</b> from in Vivo and in Vitro Systems<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">Human Prediction</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Method</th><th class="colsep0 rowsep0" align="center" char=".">Cl<sub>b</sub> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Human Liver Microsomes</td><td class="colsep0 rowsep0" align="char" char="."><3.9</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Human Hepatocytes</td><td class="colsep0 rowsep0" align="char" char="."><0.8</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rCYP3A4</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Rat Single Species Scaling</td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">CL<sub>b</sub>: blood clearance. <i>V</i><sub>ss</sub>: volume of distribution at steady state. Fraction unbound plasma protein binding in rat and human were 0.69 and 0.61 respectively. Human clearance predictions from in vitro systems were scaled based on the well-stirred model or single species scaling from allometry.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a></p></div></div></div><div class="NLM_p">The overall cytokine inhibition profile (IC<sub><i>xx</i></sub>) was calculated for <b>23</b> based upon the modeled <i>C</i><sub>av</sub> exposure to cover the IC<sub>80</sub> of IFNα (64 nM, unbound) (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). The IL-12 and IL-23 target coverage is predicted to be high, achieving IC<sub>65</sub> for IL-12 and IC<sub>50</sub> for IL-23. IL-6 inhibition of pSTAT1 signaling differentiates from that of IL6 pSTAT3 (IC<sub>60</sub> and IC<sub>16</sub>, respectively). Contribution to the profile from the γ-common chain cytokines, represented by IL-15 and IL-21, are lower at IC<sub>38</sub> and IL<sub>34</sub>, respectively. IL-27 and IL-10 target coverage is anticipated to be at IC<sub>59</sub> and IC<sub>29</sub>, respectively. Importantly, the compound is expected to spare JAK2 driven EPO signaling (IC<sub>18</sub>).</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0011.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Radial plot of cytokine inhibition IC<sub><i>xx</i></sub> relative to the IFNα IC<sub>80</sub> for compound <b>23</b>, derived from potency in human whole blood assays and predicted average daily human plasma drug concentration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>23</b> was studied in vivo under a therapeutic dosing paradigm in the rat adjuvant induced arthritis (AIA) following oral dosing of <b>23</b><i>p</i>-tosylate salt (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Female Lewis rats immunized with complete Freund’s adjuvant were dosed orally with 3, 10, or 30 mg/kg/day of <b>23</b> or vehicle for 7 consecutive days after disease onset as measured by hind paw volume using a plethysmograph. The increase in paw volume was significantly lower and dose-dependent in the compound <b>23</b> q.d. (3, 10, and 30 mg/kg) treated groups. The plasma concentrations in animals dosed with <b>23</b> at peak (30 min) and trough (24 h) time intervals post final dose respectively were as follows (mean ± SD): 3 mg/kg, 3.54 ± 0.60 μM, 0.0221 ± 0.0139 μM; 10 mg/kg, 10.95 ± 2.06 μM, 0.06 ± 0.0576 μM; and 30 mg/kg, 23.89 ± 4.12 μM, 0.06 ± 0.029 μM. Pharmacodynamics modeling of the data fit an Emax model, <a class="ref internalNav" href="#notes-1" aria-label="Figure S1">Figure S1</a>.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0012.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Activity of compound <b>23</b> in the rat AIA model following a therapeutic dosing paradigm. Immunized rats were enrolled into groups and dosed with either: 30, 10, or 3 mg/kg <b>23</b> or vehicle PO. Compared to vehicle (left panel), treatment with PF-06700841 significantly reduced disease severity as measured by plethysmograph in the 30 mg/kg (Day 1 to 7), 10 mg/kg (Day 1 to 7), and 3 mg/kg (Day 2 to 7) dose groups (<i>p</i> ≤ 0.05, <i>t</i> test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21053" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21053" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis strategy utilized key functionalized diamine cores, to which we could introduce the acetylated group (amides or ureas) or solvent exposed ring system of the diaminopyrimidine in either order to maximize synthetic efficiency. To that end, diamine intermediates <b>28</b> were obtained from the S<sub><i>N</i></sub>Ar reaction of a 2,4-dichloropyrimidine (<b>27</b>) and a Boc-protected bridged piperazine <b>26</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). At room temperature, the reaction was highly selective for displacement at the pyrimidyl 4-chloride. Pyrimidine 5-position functionality (H or F) had minimal effect on the reaction except for an increase in yield in the case of the 5-fluoro derivatives, presumably due to the higher reactivity of this dichloropyrimidine intermediate. The Boc protecting group was removed under standard acidic conditions followed by amide coupling using HATU to provide acetylated intermediates <b>29</b>. The formation of the diaryl amine hinge-binding moiety was completed to provide <b>8</b>, <b>9</b>, <b>10</b>, and <b>17</b> under acidic S<sub>N</sub>Ar conditions and <b>13</b> and <b>19</b> via Buchwald coupling conditions. Inversely the aryl group could be introduced first on the Boc-protected diamine core <b>28</b> using similar S<sub>N</sub>Ar or Buchwald conditions. The S<sub>N</sub>Ar conditions concurrently hydrolyzed the protecting group to give the amines <b>30</b>, whereas the Buchwald conditions required a subsequent acid deprotection step to afford <b>30</b>. Amide formation via standard HATU conditions provided <b>11</b>, <b>12</b>, <b>14</b>, <b>15</b>, <b>16</b>, <b>18</b>, <b>24</b>, and <b>25</b>. Using preformed imidazole-1-carboxamides under basic conditions with <b>30</b> provided ureas <b>20</b>, <b>21</b>, and <b>22</b>.</div><figure id="sch1" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0013.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of Diamine Analogs <b>8</b>–<b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TEA or DIPEA, 10–50 °C, 1–18 h, 47–96%; (b) (i) 4 N HCl, 10–20 °C, 15–16 h, (ii) cyclopropanecarboxylic acid or 2-cyanoacetic acid, HATU, DIPEA or TEA, rt, 15–60 h, 26–100%; (c) aryl amine, i-PrOH or dioxane, 1–16 h, 85–140 °C, 38–65%; (d) (i) aryl amine, Pd cat, Cs<sub>2</sub>CO<sub>3</sub> or NaOtBu, 100–145 °C, 0.5–4 h, 21–95%; (ii) 4 N HCl, 20–25 °C, 1–18 h, 86–99% (e) for amides, carboxylic acid, DIPEA or TEA, HATU, rt, 1–18 h, 18–89%; (f) for ureas, alkyl-1<i>H</i>-imidazole-1-carboxamide, EtOH, 60 °C, 3 h, 59–70%.</p></p></figure><div class="NLM_p">The synthesis of the 3,8-diazabicyclo[3.2.1]octane <b>23</b> is described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Starting from commercial racemic-<b>31</b>, esterification with (<i>S</i>)-1-phenylethan-1-ol and DCC, followed by diastereomeric separation via chiral column chromatography, provided the single diastereomer <b>32</b>. Ester hydrolysis using sodium hydroxide in methanol provided the single enantiomer-<b>33</b> in good yield. S<sub>N</sub>Ar using commercial Boc protected [3.2.1] diamine <b>34</b> with 2,4-dichloropyrimidine under basic conditions provided selective 4-position substituted product <b>35</b> in 71% yield. The pyrazole-2-amino pyrimidine moiety was constructed via a second S<sub>N</sub>Ar under acidic conditions using <b>35</b> and 1-methyl-1<i>H</i>-pyrazol-4-ylamine. The reaction conditions also resulted in loss of the Boc group on the [3.2.1] diaminobicycle to provide <b>36</b> in excellent yield. Amide formation between <b>36</b> and <b>33</b> under standard HATU conditions provided <b>31</b> in 60% yield. The material was converted to the tosylate salt in acetonitrile using 2 M <i>p</i>-toluenesulfonic acid in H<sub>2</sub>O followed by collection of salt by filtration in 76% yield.</div><figure id="sch2" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0014.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 3,8-Diazabicyclo[3.2.1]octane <b>23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (<i>S</i>)-1-phenylethan-1-ol (1.2 equiv), DCC (1.2 equiv), DMAP (0.1 equiv), rt, 18 h, 72%; (b) 1 N NaOH (3 equiv), MeOH, rt, 1.5 h, 76%; (c) 2,4-dichloropyrimidine (1.1 equiv), TEA (1.3 equiv), MeOH, rt, 18 h, 71%; (d) 1-methyl-1<i>H</i>-pyrazol-4-ylamine hydrochloride (1.1 equiv), i-PrOH, MW 140 °C, 1 h, 99%; (e) <b>33</b> (1.2 equiv) HATU (1.2 equiv), DIPEA (2 equiv), DCM, rt, 18 h, 60%; (f) 2 N TsOH in H<sub>2</sub>O, MeCN, rt, overnight, 71%.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72038" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72038" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In summary, we have described the rationale underpinning the design of a subtype selective JAK inhibitor which was designed to take advantage of inhibition of cytokines mediated by the TYK2 isoform, in particular IL-12 and IL-23, as well as those mediated by JAK1. In setting the objectives for this program, we used published clinical and preclinical data from tofacitinib <b>1</b> and other JAK inhibitors. This allowed us to establish potency and selectivity targets in human whole blood assays, which we believe predict both disease and certain safety end points (e.g., EPO modulation).</div><div class="NLM_p last">Early bicyclic leads identified from the Pfizer compound collection were developed into a series of 3,8-diazabicyclo[3.2.1]octane substituted pyrimidines, which delivered potent dual TYK2 and JAK1 potency with appropriate in-family selectivity against JAK2 and JAK3. The lead compound from this series, compound <b>23</b>, has an excellent off-target polypharmacology profile and ADME profile consistent with once daily dosing in humans. Compound <b>23</b> (PF-06700841) has completed a Phase 1 clinical study in healthy volunteers and psoriasis patients<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and is currently being studied in multiple indications in Phase II trials [NCT02969018, NCT02958865, NCT03395184, and NCT02974868].</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78706" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78706" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All activities involving laboratory animals were carried out in accordance with federal, state, local, and institutional guidelines governing the use of laboratory animals in research and were reviewed and approved by Pfizer (or other) Institutional Animal Care and Use Committee. Pfizer animal care facilities that supported this work are fully accredited by AAALAC International.</div><div class="NLM_p">The human Janus kinase (JAK) activity was determined by using a microfluidic assay to monitor phosphorylation of a synthetic peptide by the recombinant human kinase domain of each of the four members of the JAK family, JAK1, JAK2, JAK3, and TYK2. Reaction mixtures contained 1 μM of a fluorescently labeled synthetic peptide and ATP at either a level equal to the apparent <i>K</i><sub>m</sub> for ATP or at 1 mM ATP. Each assay condition was optimized to obtain a conversion rate of 20%–30% phosphorylated peptide product, and reactions were terminated by the addition of stop buffer containing EDTA. Utilizing mobility shift technology (Caliper Life Science), each assay reaction was sampled to determine the level of phosphorylation. Experimental details are as previously reported.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Human Whole Blood Assays</h3><div class="NLM_p last">In this study, the cellular potency and selectivity of compounds within the JAK/STAT signaling pathways was evaluated in human whole blood by measuring phosphorylation of signal transducer and activator of transcription (STAT) proteins, in response to specific cytokines challenges, using intracellular staining and flow cytometry. Human whole blood was collected from healthy donors via vein puncture into Vacutainer collection tubes containing sodium heparin in accordance with Pfizer protocols (Protocol No. GOHW RDP-01) approved by the Shulman Institutional Review Board. Assays were optimized to run at the approximate EC<sub>90</sub> – EC<sub>95</sub> of each cytokine evaluated. Full experimental details are available in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00917/suppl_file/jm8b00917_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Synthesis</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Chemistry Synthetic Methods and Compound Characterization</h4><div class="NLM_p last">Reactions were carried out under nitrogen at ambient temperature with reagents and solvents typically obtained from Sigma-Aldrich unless otherwise noted. Thin-layer chromatography (TLC) was visualized with ultraviolet (UV) light on 60 Å F254 glass plates precoated with a 0.25 mm thickness of silica gel purchased from EMD Chemicals Inc. Silica gel column chromatography refers to normal phase chromatography using a biotage or ISCO system using prepacked commercial columns under medium pressure. Low-resolution mass spectroscopy was carried out using liquid chromatography–mass spectrometry (LC/MS) on a Waters Acquity UPLC instrument using atmospheric pressure chemical ionization (APCI) or electrospray ionization (ESI). Proton (<sup>1</sup>H NMR) magnetic resonance spectra were obtained on a Varian or Bruker instrument in CDCl<sub>3</sub>, CD<sub>3</sub>OD, or DMSO-<i>d</i><sub>6</sub> at 400 MHz at 298 K unless otherwise noted. The following abbreviations were utilized to describe peak patterns when appropriate: br = broad, s = singlet, d = doublet, and m = multiplet. Optical rotations were measured on an Autopol Iv Automatic Polarimeter at ambient temperature and reported as an average of three runs unless otherwise noted. High-resolution mass measurements were obtained on an Agilent 6200 or 6500 series ToF or Thermo Scientific Q Exactive mass spectrometer. Compounds used in biological studies had purities that were >95%, determined by HPLC, UPLC, or LC/MS based on ultraviolet detection at 220 or 254 nm. The synthesis of compounds <b>8</b>–<b>22</b>, <b>24</b>, and <b>25</b> is provided in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Synthesis of <b>23</b> ((<i>S</i>)-2,2-Difluorocyclopropyl)((1<i>R</i>,5<i>S</i>)-3-(2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone</h4><div id="sec5_2_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i22" class="anchor-spacer"></div><h5 class="article-section__title" id="_i22"> (<i>S</i>)-1-Phenylethyl (<i>S</i>)-2,2-Difluorocyclopropane-1-carboxylate <b>32</b></h5><div class="NLM_p last">To a solution of 2,2-difluorocyclopropanecarboxylic acid (4.02 g, 33 mmol) in DCM (140 mL) was added DCC (8.16 g, 39 mmol) followed by DMAP (403 mg, 3.30 mmol), and the reaction was stirred for 10 min. (<i>S</i>)-1-Phenylethan-1-ol (4.83 g, 39 mmol) was added, and the reaction was stirred at room temperature for 72 h. The reaction was filtered, concentrated in vacuo, and purified using silica gel column chromatography eluting with 0–5% EtOAc to afford the title compounds as a mixture of diastereomers. The diastereomers were separated using chiral chromatography as described below: Kromasil Silica 10μm, 4.6 mm × 250 mm; run time 14 min; 1.0 mL/min; eluting with 3% MTBE in heptanes. The (<i>S</i>,S) enantiomer <b>32</b> was the first eluting peak. Peak 1: <i>R</i><sub>t</sub> = 5.34 min; (<i>S</i>)-1-phenylethyl (<i>S</i>)-2,2-difluorocyclopropane-1-carboxylate <b>32</b><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ ppm 1.61 (d, 3H), 1.74–1.79 (m, 1H), 2.06–2.12 (m, 1H), 2.45–2.53 (m, 1H), 5.95–6.00 (m, 1H), 7.33–7.42 (m, 5H). Peak 2: <i>R</i><sub>t</sub> = 6.22 min; (<i>S</i>)-1-phenylethyl (<i>R</i>)-2,2-difluorocyclopropane-1-carboxylate.</div></div><div id="sec5_2_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23"> (<i>S</i>)-2,2-Difluorocyclopropane-1-carboxylic Acid <b>33</b></h5><div class="NLM_p last">To a solution of (<i>S</i>)-1-phenylethyl (<i>S</i>)-2,2-difluorocyclopropane-1-carboxylate <b>32</b> (3.67 g, 16.2 mmol) in MeOH (48 mL) was added 1 N NaOH (48 mL, 48 mmol), and the reaction was stirred at room temperature for 1.5 h. The reaction was concentrated in vacuo, acidified to pH = 5.8 using 12 N HCl (aq), and extracted into <i>n</i>-BuOH. The organic layer was collected and concentrated in vacuo to afford the title compound (1.5 g, 76%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 1.90 (m, 2H), 2.65 (m, 1H).</div></div><div id="sec5_2_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> <i>tert</i>-Butyl (1<i>R</i>,5<i>S</i>)-3-(2-Chloropyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate <b>35</b></h5><div class="NLM_p last">To a solution of <i>tert</i>-butyl (1<i>R</i>,5<i>S</i>)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (11 g, 52 mmol, Combi-Blocks, CAS: 149771-44-8) in MeOH (500 mL) were added 2,4-dichloropyrimidine (8.4 g, 57 mmol) and TEA (6.7 g, 66 mmol) at 0 °C. The reaction was stirred at room temperature for 18 h before concentrating in vacuo. The residue was purified by silica gel column chromatography eluting with 20% EtOAc in petroleum ether to afford the title compound as a white solid (12 g, 71%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ ppm 1.48 (s, 9H), 1.63–1.74 (m, 2H), 1.97 (br s, 2H), 3.18 (br s, 2H), 3.38–3.74 (m, 1H), 4.36 (br s, 3H), 6.35 (d, 1H), 8.06 (d, 1H). MS <i>m</i>/<i>z</i> 325 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> 4-((1<i>R</i>,5<i>S</i>)-3,8-Diazabicyclo[3.2.1]octan-3-yl)-<i>N</i>-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine Hydrochloride <b>36</b>)</h5><div class="NLM_p last">A solution of <i>tert</i>-butyl (1<i>R</i>,5<i>S</i>)-3-(2-chloropyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate <b>35</b> (2.25 g, 6.93 mmol) and 1-methyl-1<i>H</i>-pyrazol-4-ylamine hydrochloride (1.02 g, 7.62 mmol) in <i>i</i>-PrOH (30 mL) was heated to 140 °C under microwave irradiation for 1 h. The reaction was concentrated in vacuo to afford the title compound as the hydrochloride salt (2.2 g, 99%). MS <i>m</i>/<i>z</i> 286 [M + H]<sup>+</sup>.</div></div><div id="sec5_2_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> ((<i>S</i>)-2,2-Difluorocyclopropyl)((1<i>R</i>,5<i>S</i>)-3-(2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone <b>23</b></h5><div class="NLM_p last">To a solution of (<i>S</i>)-2,2-difluorocyclopropane-1-carboxylic acid <b>33</b> (318 mg, 2.61 mmol) in DCM (20 mL) were added 4-((1<i>R</i>,5<i>S</i>)-3,8-diazabicyclo[3.2.1]octan-3-yl)-<i>N</i>-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine hydrochloride <b>36</b> (700 mg, 2.17 mmol), HATU (1.02 g, 2.61 mmol), and DIPEA (0.76 mL, 4.34 mmol), and the reaction was stirred at room temperature for 18 h. The reaction was diluted with DCM and saturated aqueous ammonium chloride solution. The organic layer was separated, washed with further ammonium chloride solution, and concentrated in vacuo. The residue was purified using silica gel column chromatography eluting with 0–12% MeOH and 1% NH<sub>4</sub>OH in DCM. The residue was dissolved in DCM and further washed with saturated aqueous ammonium chloride solution three times. The organic layer was collected, concentrated in vacuo, and dried to afford the title compound (500 mg, 60%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 1.58–2.06 (m, 6H), 2.82–2.96 (m, 1 H), 2.98–3.26 (m, 2H), 3.09–3.27 (m, 1H), 3.80 (s, 3H), 4.14 (br s, 2H), 4.55–4.74 (m, 2H), 6.07–6.19 (m, 1H), 7.44 (s, 1H), 7.74 (br s, 1H), 7.93 (d, 1H), 8.90 (br s, 1H); LCMS <i>m</i>/<i>z</i> 390 [M + H]<sup>+</sup> HPLC 98.09% at 254 nM (XBridge RP18 50 mm × 2.1 mm × 5 μm) <i>R</i><sub>t</sub> = 3.55 min; HRMS [M + H] for C<sub>18</sub>H<sub>22</sub>F<sub>2</sub>N<sub>7</sub>O, calcd, 390.1848; found, 390.1850; [α]<sub>D</sub><sup>20</sup> 50.1 (<i>c</i> 1.27, EtOH). Analytical chiral SFC EE = 98.25%, <i>R</i><sub>t</sub> = 7.695 min, 220 nM Chiralcel OJ-H 250 mm × 4.6 mm × 5 μm, 5–40% methanol (0.05% DEA) in CO<sub>2</sub> flow rate 2.35 mL/min.</div></div><div id="sec5_2_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> ((<i>S</i>)-2,2-Difluorocyclopropyl)((1<i>R</i>,5<i>S</i>)-3-(2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone 4-methylbenzenesulfonate (00110596-3088, 23-Ts)</h5><div class="NLM_p last">To a flask containing <b>23</b> (19.25 g, 49.43 mmol) was added acetonitrile (40 mL) followed by the addition of 2 M <i>p</i>-toluenesulfonic acid in H<sub>2</sub>O (28.4 mL, 56.8 mmol). The mixture was stirred at rt overnight. The resulting white solid was collected by filtration. The filter cake was washed with acetonitrile and then dried under vacuum over 2 days to provide the title compound (21.0 g, 76%). QNMR determined the parent molecule at 70.30% and <i>p</i>-toluenesulfonic acid 29.70%. Mp = 275 °C; [α]<sup>20</sup> = 29.8° (<i>c</i> = 0.885 MeOH); <sup>1</sup>H NMR (400 MHz, DMSO-d6): δ ppm 1.57–1.66 (m, 1H), 1.69–1.76 (m, 1H), 1.88–2.09 (m, 4H), 2.30 (s, 3H), 3.14–3.26 (m, 2H), 3.26–45 (br m, 1 H), 3.86 (s, 3H), 3.92–4.19 (br m, 1H), 4.40–4.60 (m, 1 H), 4.62–4.76 (m, 2H), 6.28 (s, 2H), 6.54–6.57 (m, 1 H), 7.15 (d <i>J</i> = 7.8 Hz, 2H), 7.51 (d, <i>J</i> = 8.1 Hz, 2H), 7.55 (s, 1 H), 7.85 (s, 2 H). Analytical Chiral SFC EE = 100%, <i>R</i><sub>t</sub> = 7.416 min (TsOH <i>R</i><sub>t</sub> = 9.413 min), 210 nM Lux Cellulose-1 250 mm × 4.6 mm × 5 μm, 5–60% methanol (0.2% NH<sub>4</sub><sup>+</sup>) in CO<sub>2</sub> flow rate 3.0 mL/min.</div></div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Rat Adjuvant Induced Arthritis Model</h3><div class="NLM_p last">The effect of JAK1 inhibition by <b>23</b> was evaluated in vivo using a therapeutic dosing paradigm in a rat adjuvant-induced arthritis. The efficacy of this molecule was evaluated in two separate studies using successively lower doses. Arthritis was induced by immunization of female Lewis rats (8–10 weeks old; Charles River Laboratories, Portage, MI) via intradermal injection at the base of the tail with complete Freund adjuvant with three 50 μL injections (15 mg/mL <i>Mycobacterium tuberculosis</i> (Difco) in incomplete Freund adjuvant (Sigma-Aldrich)). Seven days after the initial immunization, the baseline hind paw volume of the immunized rats was measured via plethysmograph (Buxco Inc.). The rats were monitored daily for signs of arthritis including change in body weight and hind paw volume measurement. When individual hind paw volume measurements indicated an increase of 0.2 mL (or greater) in a single hind paw, animals were randomly assigned to a treatment group. Daily treatment with compound <b>23</b> was administered via oral gavage. Treatment groups were 30, 10, and 5 mg/kg of <b>23</b><i>p</i>-tosic acid salt or vehicle (2% Tween 80/0.5% methylcellulose/deionized H<sub>2</sub>O). Dosing began once individuals were enrolled into respective groups. Treatment continued for 7 days. Animals were euthanized after 7 days of dosing. At the conclusion of the study, whole blood was taken at 15 min postdose (peak concentration in plasma) for analysis of STAT phosphorylation, and plasma was taken at peak (0.25 h) and trough (24 h) time points for exposure PK.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> X-ray Crystallography</h3><div class="NLM_p">The cloning and expression of TYK2 has been described previously.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> TYK2 cell pellets were resuspended in binding buffer (50 mM Tris HCl, 1 mM TCEP, 60 mM imidazole, 0.4 M NaCl, 10% glycerol, pH 8.2) supplemented with Roche Complete EDTA-free protease inhibitor tablets and Benzonase (EMD Millipore), lysed with a Microfluidizer (Microfluidics Corp.), and clarified by centrifuging at 30 000 × <i>G</i>. The supernatant was batch bound to Nickel Sepharose HP resin (GE Healthcare Life Sciences) overnight at 4 °C before being packed into a column. The resin was washed and eluted with binding buffer containing 250 mM imidazole. TYK2 was buffer exchanged into SEC buffer (25 mM Tris HCl, 0.25 mM TCEP, 0.25 M NaCl, 10% glycerol, pH 8.2) using a HiPrep 26/10 desalting column (GE Healthcare Life Sciences) and loaded unconcentrated onto a HiLoad 16/60 Superdex200 SEC column (GE Healthcare Life Sciences) equilibrated in SEC buffer. Monomeric TYK2 was pooled, and 10 μM tofacitinib <b>1</b> was added before concentration. TYK2 was concentrated to 5–8 mg/mL and frozen in aliquots at −80 °C. TYK2 was incubated with 1 mM CP-690550 and crystallized by sitting drop vapor-diffusion at 20 °C against well solution containing 0.1 M bis-tris pH 5.5, 0.25 M NaCl, 10 mM TCEP, and 27–33% PEG-3350. The crystallization drops consisted of 0.3 μL TYK2:<b>1</b> complex, 0.1 μL well solution, and 0.1 μL of TYK2 seed stock. Crystals appeared in 2–3 weeks and grew to full size in 2 additional weeks. TYK2 crystals were soaked for 4 days in 0.1 M bis-tris pH 5.5, 0.25 M NaCl, 10 mM TCEP, 38% PEG-3350, and 2 mM of either <b>8</b> or <b>23</b> and flash cooled in liquid nitrogen.</div><div class="NLM_p">JAK1 was cloned, expressed, and purified as described previously.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> JAK1 was further purified by buffer exchanging into 25 mM Tris, 1 mM TCEP, 10 mM MgCl<sub>2</sub>, 1 mM ATP, pH 8.0 using a HiPrep 26/10 desalting column. Desalted JAK1 was applied to a HiTrap Q Sepharose HP column (GE Healthcare Life Sciences) and eluted with a linear gradient to 250 mM NaCl. Mass spectrometry was used to pool Jak1 by phosphorylation state. JAK1 was concentrated to 10 mg/mL and frozen in aliquots at −80 °C. Doubly phosphorylated JAK1 was diluted to 6 mg/mL and incubated with freshly added 1 mM ATP and 5 mM TCEP before being crystallized by hanging drop vapor diffusion at 10 °C. Well solutions consisted of a grid of 0.1 M Tris pH 8.5, 6–9% MPD, and 24–29% PEG-1500 and streak-seeded at setup. JAK1 crystals were soaked in 0.1 M Tris pH 8.5, 4% MPD, 30% PEG-1500, 20 mM EDTA, and 5 mM <b>23</b> for 3 h and frozen in liquid nitrogen.</div><div class="NLM_p last">Data collection for all complexes was conducted at 100 K at the Industrial Macromolecular Crystallography Association Collaborative Access Team (IMCA-CAT) (Advanced Photon Source, Argonne National Laboratory, Argonne, Il, USA), beamline 17ID outfitted with a Pilatus 6 M detector (Dectris Ltd., Switzerland). Data processing was performed using AUTOPROC<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and XDS.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> All other data manipulations utilized the CCP4 suite of programs.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> A common set (5%) of test reflections was used throughout refinement for cross-validation. Structures were determined by rigid body and all-atom positional refinement using REFMAC<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> and an isomorphous model from which all waters and bound ligands had been removed. Binding of the compound of interest was confirmed visually, and the compound was fit automatically using the program RHOFIT.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Iterative rounds of automatic refinement using the program AUTOBUSTER<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> were interspersed with manual model building using COOT.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Crystallographic data and refinement statistics are reported in <a class="ref internalNav" href="#notes-1" aria-label="Table S2">Table S2</a>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00917" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57824" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57824" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00917" class="ext-link">10.1021/acs.jmedchem.8b00917</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">(1) Human whole blood assay experimental conditions; (2) Physicochemical properties for compounds <b>14</b>–<b>25</b>; (3) Exposure and activity data for compound <b>23</b> from the rat AIA model; (4) Syntheses for compounds <b>8</b>–<b>22</b>, <b>24</b>, and <b>25</b>; (5) Thermodynamic solubility determination for compound <b>23</b>; (6) Crystallographic data and refinement statistics for compounds <b>8</b> and <b>23</b> in TYK2 and compound <b>23</b> in JAK1 (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00917/suppl_file/jm8b00917_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00917/suppl_file/jm8b00917_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00917/suppl_file/jm8b00917_si_001.pdf">jm8b00917_si_001.pdf (387.62 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00917/suppl_file/jm8b00917_si_002.csv">jm8b00917_si_002.csv (1.12 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the X-ray structure of compound <b>8</b> in TYK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBK">6DBK</a>) and compound <b>23</b> in TYK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBM">6DBM</a>) and JAK1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBN">6DBN</a>) are available from the RCSB Protein Data Bank (<a href="http://www.rcsb.org" class="extLink">www.rcsb.org</a>). Authors will release the atomic coordinates upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.8b00917" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21030" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21030" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Fensome</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8916-1895" title="Orcid link">http://orcid.org/0000-0001-8916-1895</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#44052a203621336a02212a372b29210414222d3e21366a272b29"><span class="__cf_email__" data-cfemail="bafbd4dec8dfcd94fcdfd4c9d5d7dffaeadcd3c0dfc894d9d5d7">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian S. Gerstenberger</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#90d2e2f9f1febed7f5e2e3e4f5fef2f5e2f7f5e2d0c0f6f9eaf5e2bef3fffd"><span class="__cf_email__" data-cfemail="5e1c2c373f3070193b2c2d2a3b303c3b2c393b2c1e0e3837243b2c703d3133">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Catherine M. Ambler</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer
Inc., Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric Arnold</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer
Inc., Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary Ellen Banker</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer
Inc., Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew F. Brown</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer
Inc., Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jill Chrencik</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer
Inc., Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James D. Clark</span> - <span class="hlFld-Affiliation affiliation">Inflammation and Immunology,
Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin E. Dowty</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ivan V. Efremov</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Flick</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer
Inc., Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ariamala Gopalsamy</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew M. Hayward</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer
Inc., Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Hegen</span> - <span class="hlFld-Affiliation affiliation">Inflammation and Immunology,
Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brett D. Hollingshead</span> - <span class="hlFld-Affiliation affiliation">Drug Safety Research
and Development, Pfizer Inc., 1 Portland
Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Jussif</span> - <span class="hlFld-Affiliation affiliation">Inflammation and Immunology,
Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John D. Knafels</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer
Inc., Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David C. Limburg</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer
Inc., Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Lin</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer
Inc., Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tsung H. Lin</span> - <span class="hlFld-Affiliation affiliation">Inflammation and Immunology,
Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Betsy S. Pierce</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer
Inc., Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eddine Saiah</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Raman Sharma</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer
Inc., Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter T. Symanowicz</span> - <span class="hlFld-Affiliation affiliation">Inflammation and Immunology,
Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean-Baptiste Telliez</span> - <span class="hlFld-Affiliation affiliation">Inflammation and Immunology,
Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John I. Trujillo</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer
Inc., Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Felix F. Vajdos</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer
Inc., Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fabien Vincent</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer
Inc., Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhao-Kui Wan</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Xing</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaojing Yang</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xin Yang</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer
Inc., Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liying Zhang</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare the following competing financial interest(s): The authors were all employees of Pfizer while this work was completed and declare no competing interests.<br /></br></p></li></ul></div><div class="ack" id="ACK-d7e3867-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43057" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43057" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was funded by Pfizer, Inc. The authors thank Dr. David Hepworth for helpful comments during the writing of this manuscript. This research used resources at the Industrial Macromolecular Crystallography Association Collaborative Access Team (IMCA-CAT) beamline 17-ID, supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with Hauptman-Woodward Medical Research Institute. This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">TYK2</td><td class="NLM_def"><p class="first last">Tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">JAK1</td><td class="NLM_def"><p class="first last">Janus kinase 1</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">Signal Transducer and Activator of Transcription</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">Interleukin</p></td></tr><tr><td class="NLM_term">IFN</td><td class="NLM_def"><p class="first last">Interferon</p></td></tr><tr><td class="NLM_term">mAb</td><td class="NLM_def"><p class="first last">monoclonal antibody</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">SLE</td><td class="NLM_def"><p class="first last">systemic lupus erythematosus</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">atopic dermatitis</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">psoriatic arthritis</p></td></tr><tr><td class="NLM_term">UC</td><td class="NLM_def"><p class="first last">ulcerative cholitis</p></td></tr><tr><td class="NLM_term">CD</td><td class="NLM_def"><p class="first last">Crohn’s disease</p></td></tr><tr><td class="NLM_term">PSO</td><td class="NLM_def"><p class="first last">psoriasis</p></td></tr><tr><td class="NLM_term">gp130</td><td class="NLM_def"><p class="first last">glycoprotein 130</p></td></tr><tr><td class="NLM_term">EPO</td><td class="NLM_def"><p class="first last">erythropoietin</p></td></tr><tr><td class="NLM_term">TPO</td><td class="NLM_def"><p class="first last">thrombopoietin</p></td></tr><tr><td class="NLM_term">Hgb</td><td class="NLM_def"><p class="first last">hemoglobin</p></td></tr><tr><td class="NLM_term">VZV</td><td class="NLM_def"><p class="first last">varicella zoster virus</p></td></tr><tr><td class="NLM_term">mCIA</td><td class="NLM_def"><p class="first last">mouse collagen induced arthritis</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>min</sub></td><td class="NLM_def"><p class="first last">minimum concentration</p></td></tr><tr><td class="NLM_term">C<sub>av</sub></td><td class="NLM_def"><p class="first last">average concentration</p></td></tr><tr><td class="NLM_term">HgB</td><td class="NLM_def"><p class="first last">hemoglobin</p></td></tr><tr><td class="NLM_term">IC<sub><i>xx</i></sub></td><td class="NLM_def"><p class="first last">% average daily inhibition</p></td></tr><tr><td class="NLM_term">IC<sub><i>xx</i></sub>*</td><td class="NLM_def"><p class="first last">calculated % inhibition based upon human whole blood potency: IC<sub><i>xx</i></sub>* = 100*((IC<sub>80</sub> IFNα)/(IC<sub>80</sub> IFNα + IC<sub>50</sub> EPO))</p></td></tr><tr><td class="NLM_term">lipe</td><td class="NLM_def"><p class="first last">lipophilic efficiency</p></td></tr><tr><td class="NLM_term">HWB</td><td class="NLM_def"><p class="first last">human whole blood</p></td></tr><tr><td class="NLM_term">P-loop</td><td class="NLM_def"><p class="first last">fingerprint ATP binding motif Gly-X-X-Gly-X-Gly-Lys-Thr/Ser</p></td></tr><tr><td class="NLM_term">RRCK</td><td class="NLM_def"><p class="first last">Russ-Ralph canine kidney cell-line permeability assay</p></td></tr><tr><td class="NLM_term">PAPP</td><td class="NLM_def"><p class="first last">apparent permeability</p></td></tr><tr><td class="NLM_term">APO</td><td class="NLM_def"><p class="first last">unbound protein</p></td></tr><tr><td class="NLM_term">W</td><td class="NLM_def"><p class="first last">water</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">Clint</td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">CD</td><td class="NLM_def"><p class="first last">cluster of differentiation</p></td></tr><tr><td class="NLM_term">pSTAT</td><td class="NLM_def"><p class="first last">phospho STAT</p></td></tr><tr><td class="NLM_term">AURA</td><td class="NLM_def"><p class="first last">aurora A kinase</p></td></tr><tr><td class="NLM_term">TPX2</td><td class="NLM_def"><p class="first last">microtubule nucleation factor</p></td></tr><tr><td class="NLM_term">TNK1</td><td class="NLM_def"><p class="first last">tyrosine kinase, nonreceptor 1</p></td></tr><tr><td class="NLM_term">QIK</td><td class="NLM_def"><p class="first last">salt inducible kinase 2</p></td></tr><tr><td class="NLM_term">ACK</td><td class="NLM_def"><p class="first last">activated CDC42 kinase</p></td></tr><tr><td class="NLM_term">PDGFRα</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor alpha</p></td></tr><tr><td class="NLM_term">SIK</td><td class="NLM_def"><p class="first last">serine threonine protein kinase</p></td></tr><tr><td class="NLM_term">MAP2K2</td><td class="NLM_def"><p class="first last">dual specificity mitogen activated protein kinase kinase 2</p></td></tr><tr><td class="NLM_term">MNK2</td><td class="NLM_def"><p class="first last">MAP kinase-interacting serine/threonine-protein kinase 2</p></td></tr><tr><td class="NLM_term">FMS</td><td class="NLM_def"><p class="first last">feline McDonough sarcoma kinase</p></td></tr><tr><td class="NLM_term">NUAK1</td><td class="NLM_def"><p class="first last">NUAK family SNF1-like kinase 1</p></td></tr><tr><td class="NLM_term">MARK</td><td class="NLM_def"><p class="first last">microtubule affinity-regulating kinase</p></td></tr><tr><td class="NLM_term">KDR</td><td class="NLM_def"><p class="first last">kinase insert domain receptor; vascular endothelial growth factor receptor kinase</p></td></tr><tr><td class="NLM_term">FASSIF</td><td class="NLM_def"><p class="first last">fasted state simulated intestinal fluid</p></td></tr><tr><td class="NLM_term">FESSIF</td><td class="NLM_def"><p class="first last">fed state simulated intestinal fluid</p></td></tr><tr><td class="NLM_term">Clint,u</td><td class="NLM_def"><p class="first last">intrinsic unbound clearance</p></td></tr><tr><td class="NLM_term">Crbc/Cp</td><td class="NLM_def"><p class="first last">red blood cell concentration/plasma concentration</p></td></tr><tr><td class="NLM_term">AIA</td><td class="NLM_def"><p class="first last">adjuvant induced arthritis</p></td></tr><tr><td class="NLM_term">Emax</td><td class="NLM_def"><p class="first last">sigmoidal Emax</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">hexafluorophosphate azabenzotriazole tetramethyl uronium.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78143" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78143" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 43 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liongue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, A. C.</span></span> <span> </span><span class="NLM_article-title">Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease</span>. <i>Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">2506</span>, <span class="refDoi"> DOI: 10.1016/j.molimm.2006.11.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1016%2Fj.molimm.2006.11.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=17208301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVSmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2007&pages=2497-2506&author=L.+A.+O%E2%80%99Sullivanauthor=C.+Liongueauthor=R.+S.+Lewisauthor=S.+E.+Stephensonauthor=A.+C.+Ward&title=Cytokine+receptor+signaling+through+the+Jak-Stat-Socs+pathway+in+disease&doi=10.1016%2Fj.molimm.2006.11.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease</span></div><div class="casAuthors">O'Sullivan, Lynda A.; Liongue, Clifford; Lewis, Rowena S.; Stephenson, Sarah E. M.; Ward, Alister C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2497-2506</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The complexity of multicellular organisms is dependent on systems enabling cells to respond to specific stimuli.  Cytokines and their receptors are one such system, whose perturbation can lead to a variety of disease states.  This review represents an overview of our current understanding of the cytokine receptors, Janus kinases (Jaks), Signal transducers and activators of transcription (Stats) and Suppressors of cytokine signaling (Socs), focusing on their contribution to diseases of an immune or hematol. nature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRJCsJ5di3XbVg90H21EOLACvtfcHk0lhEJuI_RALM6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVSmur8%253D&md5=0011026cc2b9be7e0d7cdb854aab300a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.molimm.2006.11.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molimm.2006.11.025%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DL.%2BA.%26aulast%3DLiongue%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DR.%2BS.%26aulast%3DStephenson%26aufirst%3DS.%2BE.%26aulast%3DWard%26aufirst%3DA.%2BC.%26atitle%3DCytokine%2520receptor%2520signaling%2520through%2520the%2520Jak-Stat-Socs%2520pathway%2520in%2520disease%26jtitle%3DMol.%2520Immunol.%26date%3D2007%26volume%3D44%26spage%3D2497%26epage%3D2506%26doi%3D10.1016%2Fj.molimm.2006.11.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1038%2Fnrd.2017.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=29104284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=843-862&author=D.+M.+Schwartzauthor=Y.+Kannoauthor=A.+Villarinoauthor=M.+Wardauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=JAK+inhibition+as+a+therapeutic+strategy+for+immune+and+inflammatory+diseases&doi=10.1038%2Fnrd.2017.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Kanno, Yuka; Villarino, Alejandro; Ward, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-862</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts to target their assocd. signalling pathways.  Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-mol. inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.  Building on the clin. success of first-generation jakinibs, second-generation compds. that claim to be more selective are currently undergoing development and proceeding to clin. trials.  However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs.  This Review discusses the biol. of jakinibs from a translational perspective, focusing on recent insights from clin. trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TNpGT01l8rVg90H21EOLACvtfcHk0liKz-UBQl4zMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO&md5=4607422f83f94c0c7194935d6d460c31</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.201%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DVillarino%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJAK%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520immune%2520and%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D843%26epage%3D862%26doi%3D10.1038%2Fnrd.2017.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.+B.+Telliez&title=Discovery+and+development+of+Janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0liKz-UBQl4zMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520and%2520development%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covington, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favata, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeleswaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">5298</span>– <span class="NLM_lpage">5307</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0902819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.4049%2Fjimmunol.0902819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=20363976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=5298-5307&author=J.+S.+Fridmanauthor=P.+A.+Scherleauthor=R.+Collinsauthor=T.+C.+Burnauthor=Y.+Liauthor=J.+Liauthor=M.+B.+Covingtonauthor=B.+Thomasauthor=P.+Collierauthor=M.+F.+Favataauthor=X.+Wenauthor=J.+Shiauthor=R.+McGeeauthor=P.+J.+Haleyauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=S.+Yeleswaramauthor=G.+Hollisauthor=R.+C.+Newtonauthor=B.+Metcalfauthor=S.+M.+Friedmanauthor=K.+Vaddi&title=Selective+inhibition+of+JAK1+and+JAK2+is+efficacious+in+rodent+models+of+arthritis%3A+preclinical+characterization+of+INCB028050&doi=10.4049%2Fjimmunol.0902819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050</span></div><div class="casAuthors">Fridman, Jordan S.; Scherle, Peggy A.; Collins, Robert; Burn, Timothy C.; Li, Yanlong; Li, Jun; Covington, Maryanne B.; Thomas, Beth; Collier, Paul; Favata, Margaret F.; Wen, Xiaoming; Shi, Jack; McGee, Ryan; Haley, Patrick J.; Shepard, Stacey; Rodgers, James D.; Yeleswaram, Swamy; Hollis, Greg; Newton, Robert C.; Metcalf, Brian; Friedman, Steven M.; Vaddi, Kris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5298-5307</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases such as rheumatoid arthritis.  Kinase inhibitors have shown promising oral disease-modifying antirheumatic drug potential with efficacy similar to anti-TNF biologics.  Direct and indirect inhibition of the JAKs, with small mol. inhibitors like CP-690,550 and INCB018424 or neutralizing Abs, such as the anti-IL6 receptor Ab tocilizumab, have demonstrated rapid and sustained improvement in clin. measures of disease, consistent with their resp. preclin. expts.  Therefore, it is of interest to identify optimized JAK inhibitors with unique profiles to maximize therapeutic opportunities.  INCB028050 is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).  INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concns. <50 nM.  Significant efficacy, as assessed by improvements in clin., histol. and radiog. signs of disease, was achieved in the rat adjuvant arthritis model with doses of INCB028050 providing partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3.  Diminution of inflammatory Th1 and Th17 assocd. cytokine mRNA levels was obsd. in the draining lymph nodes of treated rats.  INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematol. effects.  These data suggest that fractional inhibition of JAK1 and JAK2 is sufficient for significant activity in autoimmune disease models.  Clin. evaluation of INCB028050 in RA is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4QiklQbX72bVg90H21EOLACvtfcHk0lj2BuzFvKt86w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D&md5=30b22f275eb2ba2dbca7fb7bec768bb9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902819%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%2BB.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DFavata%26aufirst%3DM.%2BF.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DR.%26aulast%3DHaley%26aufirst%3DP.%2BJ.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DFriedman%26aufirst%3DS.%2BM.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DSelective%2520inhibition%2520of%2520JAK1%2520and%2520JAK2%2520is%2520efficacious%2520in%2520rodent%2520models%2520of%2520arthritis%253A%2520preclinical%2520characterization%2520of%2520INCB028050%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D5298%26epage%3D5307%26doi%3D10.4049%2Fjimmunol.0902819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Rompaey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Aar, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement-Lacroix, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smets, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepescheux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christophe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrath, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandeghinste, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vayssiere, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brys, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van ’t Klooster, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">3568</span>– <span class="NLM_lpage">3577</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1201348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.4049%2Fjimmunol.1201348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=24006460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2nsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=3568-3577&author=L.+Van+Rompaeyauthor=R.+Galienauthor=E.+M.+van+der%0AAarauthor=P.+Clement-Lacroixauthor=L.+Nellesauthor=B.+Smetsauthor=L.+Lepescheuxauthor=T.+Christopheauthor=K.+Conrathauthor=N.+Vandeghinsteauthor=B.+Vayssiereauthor=S.+De+Vosauthor=S.+Fletcherauthor=R.+Brysauthor=G.+van+%E2%80%99t+Kloosterauthor=J.+H.+Feyenauthor=C.+Menet&title=Preclinical+characterization+of+GLPG0634%2C+a+selective+inhibitor+of+JAK1%2C+for+the+treatment+of+inflammatory+diseases&doi=10.4049%2Fjimmunol.1201348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases</span></div><div class="casAuthors">Van Rompaey, Luc; Galien, Rene; van der Aar, Ellen M.; Clement-Lacroix, Philippe; Nelles, Luc; Smets, Bart; Lepescheux, Lien; Christophe, Thierry; Conrath, Katja; Vandeghinste, Nick; Vayssiere, Beatrice; De Vos, Steve; Fletcher, Stephen; Brys, Reginald; van 't Klooster, Gerben; Feyen, Jean H. M.; Menet, Christel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3568-3577</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The JAKs receive continued interest as therapeutic targets for autoimmune, inflammatory, and oncol. diseases.  JAKs play crit. roles in the development and biol. of the hematopoietic system, as evidenced by mouse and human genetics.  JAK1 is crit. for the signal transduction of many type I and type II inflammatory cytokine receptors.  In a search for JAK small mol. inhibitors, GLPG0634 was identified as a lead compd. belonging to a novel class of JAK inhibitors.  It displayed a JAK1/JAK2 inhibitor profile in biochem. assays, but subsequent studies in cellular and whole blood assays revealed a selectivity of ∼30-fold for JAK1- over JAK2-dependent signaling.  GLPG0634 dose-dependently inhibited Th1 and Th2 differentiation and to a lesser extent the differentiation of Th17 cells in vitro.  GLPG0634 was well exposed in rodents upon oral dosing, and exposure levels correlated with repression of Mx2 expression in leukocytes.  Oral dosing of GLPG0634 in a therapeutic set-up in a collagen-induced arthritis model in rodents resulted in a significant dose-dependent redn. of the disease progression.  Paw swelling, bone and cartilage degrdn., and levels of inflammatory cytokines were reduced by GLPG0634 treatment.  Efficacy of GLPG0634 in the collagen-induced arthritis models was comparable to the results obtained with etanercept.  In conclusion, the JAK1 selective inhibitor GLPG0634 is a promising novel therapeutic with potential for oral treatment of rheumatoid arthritis and possibly other immune-inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOIeLPk4kdvbVg90H21EOLACvtfcHk0lioQ1B-QCkvMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2nsLzI&md5=01042ebac904fecbcdffe494e456c199</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1201348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1201348%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3Dvan%2Bder%2BAar%26aufirst%3DE.%2BM.%26aulast%3DClement-Lacroix%26aufirst%3DP.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DSmets%26aufirst%3DB.%26aulast%3DLepescheux%26aufirst%3DL.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DConrath%26aufirst%3DK.%26aulast%3DVandeghinste%26aufirst%3DN.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DDe%2BVos%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DBrys%26aufirst%3DR.%26aulast%3Dvan%2B%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26aulast%3DFeyen%26aufirst%3DJ.%2BH.%26aulast%3DMenet%26aufirst%3DC.%26atitle%3DPreclinical%2520characterization%2520of%2520GLPG0634%252C%2520a%2520selective%2520inhibitor%2520of%2520JAK1%252C%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D3568%26epage%3D3577%26doi%3D10.4049%2Fjimmunol.1201348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinblatt, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burmester, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meerwein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Othman, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pangan, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jungerwirth, S.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2857</span>– <span class="NLM_lpage">2866</span>, <span class="refDoi"> DOI: 10.1002/art.39808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1002%2Fart.39808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=27390150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGgsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=2857-2866&author=M.+C.+Genoveseauthor=J.+S.+Smolenauthor=M.+E.+Weinblattauthor=G.+R.+Burmesterauthor=S.+Meerweinauthor=H.+S.+Campauthor=L.+Wangauthor=A.+A.+Othmanauthor=N.+Khanauthor=A.+L.+Panganauthor=S.+Jungerwirth&title=Efficacy+and+Safety+of+ABT-494%2C+a+Selective+JAK-1+Inhibitor%2C+in+a+Phase+IIb+Study+in+Patients+With+Rheumatoid+Arthritis+and+an+Inadequate+Response+to+Methotrexate&doi=10.1002%2Fart.39808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate</span></div><div class="casAuthors">Genovese, Mark C.; Smolen, Josef S.; Weinblatt, Michael E.; Burmester, Gerd R.; Meerwein, Sebastian; Camp, Heidi S.; Wang, Li; Othman, Ahmed A.; Khan, Nasser; Pangan, Aileen L.; Jungerwirth, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2857-2866</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To evaluate the efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in patients with moderate-to-severe rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX).  Methods : Three hundred RA patients receiving stable doses of MTX were randomly assigned equally to receive immediate-release ABT-494 at 3, 6, 12, or 18 mg twice daily, 24 mg once daily, or placebo for 12 wk.  The primary efficacy end point was the proportion of patients meeting the American College of Rheumatol. 20% improvement criteria (achieving an ACR20 response) at week 12, as detd. using the last observation carried forward method.  Results : At week 12, the proportion of ACR20 responses was higher with ABT-494 (62%, 68%, 80%, 64%, and 76% for the 3, 6, 12, 18, and 24 mg doses, resp.) than with placebo (46%) (using nonresponder imputation) (P < 0.05 for the 6, 12, and 24 mg doses).  There was a significant dose-response relationship among all ABT-494 doses (P < 0.001).  The proportions of patients achieving ACR50 and ACR70 responses were significantly higher for all ABT-494 doses (except the 12 mg dose for the ACR70 response) than for placebo, as were changes in the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP).  Rapid improvement was demonstrated by significant differences in ACR20 response rates and changes in the DAS28-CRP for all doses compared with placebo at week 2 (the first postbaseline visit).  The incidence of adverse events was similar across groups; most were mild, and infections were the most frequent.  One serious infection (community-acquired pneumonia) occurred with ABT-494 at 12 mg.  There were dose-dependent increases in high-d. lipoprotein (HDL) and low-d. lipoprotein (LDL) cholesterol, but the LDL cholesterol:HDL cholesterol ratios were unchanged through week 12.  Mean Hb levels remained stable at lower doses, but decreases were obsd. at higher doses.  Conclusion : This study evaluated a broad range of doses of ABT-494 in RA patients with an inadequate response to MTX.  ABT-494 demonstrated efficacy, with a safety and tolerability profile similar to that of other JAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc0MsK02mgIbVg90H21EOLACvtfcHk0li4PLy4V0dL5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGgsL3I&md5=5d4bf383496b2153fede781caf6ba0c7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fart.39808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.39808%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DWeinblatt%26aufirst%3DM.%2BE.%26aulast%3DBurmester%26aufirst%3DG.%2BR.%26aulast%3DMeerwein%26aufirst%3DS.%26aulast%3DCamp%26aufirst%3DH.%2BS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DOthman%26aufirst%3DA.%2BA.%26aulast%3DKhan%26aufirst%3DN.%26aulast%3DPangan%26aufirst%3DA.%2BL.%26aulast%3DJungerwirth%26aufirst%3DS.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520ABT-494%252C%2520a%2520Selective%2520JAK-1%2520Inhibitor%252C%2520in%2520a%2520Phase%2520IIb%2520Study%2520in%2520Patients%2520With%2520Rheumatoid%2520Arthritis%2520and%2520an%2520Inadequate%2520Response%2520to%2520Methotrexate%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2016%26volume%3D68%26spage%3D2857%26epage%3D2866%26doi%3D10.1002%2Fart.39808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintas-Cardama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manshouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caulder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waeltz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3109</span>– <span class="NLM_lpage">3117</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-04-214957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1182%2Fblood-2009-04-214957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=20130243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=3109-3117&author=A.+Quintas-Cardamaauthor=K.+Vaddiauthor=P.+Liuauthor=T.+Manshouriauthor=J.+Liauthor=P.+A.+Scherleauthor=E.+Caulderauthor=X.+Wenauthor=Y.+Liauthor=P.+Waeltzauthor=M.+Ruparauthor=T.+Burnauthor=Y.+Loauthor=J.+Kelleyauthor=M.+Covingtonauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=P.+Haleyauthor=H.+Kantarjianauthor=J.+S.+Fridmanauthor=S.+Verstovsek&title=Preclinical+characterization+of+the+selective+JAK1%2F2+inhibitor+INCB018424%3A+therapeutic+implications+for+the+treatment+of+myeloproliferative+neoplasms&doi=10.1182%2Fblood-2009-04-214957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Vaddi, Kris; Liu, Phillip; Manshouri, Taghi; Li, Jun; Scherle, Peggy A.; Caulder, Eian; Wen, Xiaoming; Li, Yanlong; Waeltz, Paul; Rupar, Mark; Burn, Timothy; Lo, Yvonne; Kelley, Jennifer; Covington, Maryanne; Shepard, Stacey; Rodgers, James D.; Haley, Patrick; Kantarjian, Hagop; Fridman, Jordan S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3109-3117</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates myeloproliferative neoplasm (MPN) phenotypes in mice, establishing JAK2 inhibition as a potential therapeutic strategy.  Although most polycythemia vera patients carry the JAK2V617F mutation, half of those with essential thrombocythemia or primary myelofibrosis do not, suggesting alternative mechanisms for constitutive JAK-STAT signaling in MPNs.  Most patients with primary myelofibrosis have elevated levels of JAK-dependent proinflammatory cytokines (eg, interleukin-6) consistent with our observation of JAK1 hyperactivation.  Accordingly, we evaluated the effectiveness of selective JAK1/2 inhibition in exptl. models relevant to MPNs and report on the effects of INCB018424, the first potent, selective, oral JAK1/JAK2 inhibitor to enter the clinic.  INCB018424 inhibited interleukin-6 signaling (50% inhibitory concn. [IC50] = 281nM), and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127nM).  In primary cultures, INCB018424 preferentially suppressed erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67nM) vs. healthy donors (IC50 > 400nM).  In a mouse model of JAK2V617F+ MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects.  Preliminary clin. results support these preclin. data and establish INCB018424 as a promising oral agent for the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvKGz1l6Y-CbVg90H21EOLACvtfcHk0li4PLy4V0dL5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D&md5=cd52b7013d76ed00ca2df22444c45160</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-04-214957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-04-214957%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCaulder%26aufirst%3DE.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWaeltz%26aufirst%3DP.%26aulast%3DRupar%26aufirst%3DM.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DLo%26aufirst%3DY.%26aulast%3DKelley%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DHaley%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPreclinical%2520characterization%2520of%2520the%2520selective%2520JAK1%252F2%2520inhibitor%2520INCB018424%253A%2520therapeutic%2520implications%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D3109%26epage%3D3117%26doi%3D10.1182%2Fblood-2009-04-214957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Argollo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindryckx, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyrin-Biroulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danese, S.</span></span> <span> </span><span class="NLM_article-title">Novel therapeutic targets for inflammatory bowel disease</span>. <i>J. Autoimmun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1016/j.jaut.2017.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1016%2Fj.jaut.2017.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=28711286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFKhtL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2017&pages=103-116&author=M.+Argolloauthor=G.+Fiorinoauthor=P.+Hindryckxauthor=L.+Peyrin-Birouletauthor=S.+Danese&title=Novel+therapeutic+targets+for+inflammatory+bowel+disease&doi=10.1016%2Fj.jaut.2017.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Novel therapeutic targets for inflammatory bowel disease</span></div><div class="casAuthors">Argollo, Marjorie; Fiorino, Gionata; Hindryck, Pieter; Peyrin-Biroulet, Laurent; Danese, Silvio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Autoimmunity</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103-116</span>CODEN:
                <span class="NLM_cas:coden">JOAUEP</span>;
        ISSN:<span class="NLM_cas:issn">0896-8411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Inflammatory bowel disease (IBD), including Crohn's disease (CD) and Ulcerative Colitis (UC), are immune mediated conditions assocd. with progressive damage of the inflamed gut tissue, and have a considerable impact on the patient's quality of life.  The pathogenesis remains uncertain, but it is clear that complex mechanisms assocd. with host and luminal factors are involved, generating an unbalance between pro- and anti-inflammatory signaling.  It is well established that the purpose of an adequate and complete control of the intestinal inflammation measured not only by clin. symptoms, but also with more objective data such as fecal biomarkers (calprotectin) and endoscopy.  The treat to target approach possibly correlates with minor risk for complications assocd. with IBD, specially surgery and cancer.  The most studied inflammatory pathway in IBD, is described to be dependent of the pro-inflammatory cytokine tumor necrosis factor-alfa (TNF-α), and compose the first line studies for development of biol. drugs, in this case, targeting specifically the action of TNF-α.  Even though, the use of anti-TNFs drugs are assocd. with improvement of the inflammation in some patients, a great portion do not respond at first or lose response over time.  These findings made clear about the possibility of other mechanisms involved in perpetuating the chronic inflammatory state.  Many years of intensive research have led to the identification of different inflammatory pathways that form the basis of the intensive drug development that we are experiencing today.  These novel drugs include agents that target leukocyte trafficking, Interleukin (IL) 23, Janus kinases (JAK), Sphingosine 1 phosphate (S1P) and Smad7, an inhibitor of the immunosuppressive cytokine transforming growth factor β1 (TGF-β1).  In this manuscript, we aim to review the most promising late-stage drug candidates for the treatment of IBD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrd3OxavnOtbVg90H21EOLACvtfcHk0liswmHymBxvfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFKhtL3K&md5=d9c71c3f750bd592d1318db0b9b09a50</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.jaut.2017.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaut.2017.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DArgollo%26aufirst%3DM.%26aulast%3DFiorino%26aufirst%3DG.%26aulast%3DHindryckx%26aufirst%3DP.%26aulast%3DPeyrin-Biroulet%26aufirst%3DL.%26aulast%3DDanese%26aufirst%3DS.%26atitle%3DNovel%2520therapeutic%2520targets%2520for%2520inflammatory%2520bowel%2520disease%26jtitle%3DJ.%2520Autoimmun.%26date%3D2017%26volume%3D85%26spage%3D103%26epage%3D116%26doi%3D10.1016%2Fj.jaut.2017.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D.</span>; <span class="NLM_string-name">Wrobleski, S.</span>; <span class="NLM_string-name">Moslin, R.</span>; <span class="NLM_string-name">Lin, S.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Spergel, S.</span>; <span class="NLM_string-name">Mertzman, M.</span>; <span class="NLM_string-name">Tokarski, J.</span>; <span class="NLM_string-name">Sun, H.</span>; <span class="NLM_string-name">Chiney, M.</span>; <span class="NLM_string-name">Elzinga, P.</span>; <span class="NLM_string-name">Aranibar, N.</span>; <span class="NLM_string-name">Chimalakonda, A.</span>; <span class="NLM_string-name">Strnad, J.</span>; <span class="NLM_string-name">Zupa-Fernandez, A.</span>; <span class="NLM_string-name">Cheng, L.</span>; <span class="NLM_string-name">Gillooly, K.</span>; <span class="NLM_string-name">McIntyre, K.</span>; <span class="NLM_string-name">Carter, P.</span>; <span class="NLM_string-name">Lombardo, L.</span>; <span class="NLM_string-name">Burke, J.</span>; <span class="NLM_string-name">Macor, J.</span></span> <i>Tilte</i>; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=D.+Weinstein&author=S.+Wrobleski&author=R.+Moslin&author=S.+Lin&author=Y.+Zhang&author=S.+Spergel&author=M.+Mertzman&author=J.+Tokarski&author=H.+Sun&author=M.+Chiney&author=P.+Elzinga&author=N.+Aranibar&author=A.+Chimalakonda&author=J.+Strnad&author=A.+Zupa-Fernandez&author=L.+Cheng&author=K.+Gillooly&author=K.+McIntyre&author=P.+Carter&author=L.+Lombardo&author=J.+Burke&author=J.+Macor&title=Tilte"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstein%26aufirst%3DD.%26btitle%3DTilte%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dendrou, C.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attfield, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jostins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuttikkatte, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faergeman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheeseman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neville, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawcer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVean, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fugger, L.</span></span> <span> </span><span class="NLM_article-title">Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">363ra149</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aag1974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1126%2Fscitranslmed.aag1974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=27807284" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=363ra149&author=C.%0AA.+Dendrouauthor=A.+Cortesauthor=L.+Shipmanauthor=H.+G.+Evansauthor=K.+E.+Attfieldauthor=L.+Jostinsauthor=T.+Barberauthor=G.+Kaurauthor=S.+B.+Kuttikkatteauthor=O.+A.+Leachauthor=C.+Deselauthor=S.+L.+Faergemanauthor=J.+Cheesemanauthor=M.+J.+Nevilleauthor=S.+Sawcerauthor=A.+Compstonauthor=A.+R.+Johnsonauthor=C.+Everettauthor=J.+I.+Bellauthor=F.+Karpeauthor=M.+Ultschauthor=C.+Eigenbrotauthor=G.+McVeanauthor=L.+Fugger&title=Resolving+TYK2+locus+genotype-to-phenotype+differences+in+autoimmunity&doi=10.1126%2Fscitranslmed.aag1974"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aag1974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aag1974%26sid%3Dliteratum%253Aachs%26aulast%3DDendrou%26aufirst%3DC.%2BA.%26aulast%3DCortes%26aufirst%3DA.%26aulast%3DShipman%26aufirst%3DL.%26aulast%3DEvans%26aufirst%3DH.%2BG.%26aulast%3DAttfield%26aufirst%3DK.%2BE.%26aulast%3DJostins%26aufirst%3DL.%26aulast%3DBarber%26aufirst%3DT.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DKuttikkatte%26aufirst%3DS.%2BB.%26aulast%3DLeach%26aufirst%3DO.%2BA.%26aulast%3DDesel%26aufirst%3DC.%26aulast%3DFaergeman%26aufirst%3DS.%2BL.%26aulast%3DCheeseman%26aufirst%3DJ.%26aulast%3DNeville%26aufirst%3DM.%2BJ.%26aulast%3DSawcer%26aufirst%3DS.%26aulast%3DCompston%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DBell%26aufirst%3DJ.%2BI.%26aulast%3DKarpe%26aufirst%3DF.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DMcVean%26aufirst%3DG.%26aulast%3DFugger%26aufirst%3DL.%26atitle%3DResolving%2520TYK2%2520locus%2520genotype-to-phenotype%2520differences%2520in%2520autoimmunity%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26spage%3D363ra149%26doi%3D10.1126%2Fscitranslmed.aag1974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Graaf, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandema, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anziano, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalonde, R. L.</span></span> <span> </span><span class="NLM_article-title">Model-based drug development: a rational approach to efficiently accelerate drug development</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">502</span>– <span class="NLM_lpage">514</span>, <span class="refDoi"> DOI: 10.1038/clpt.2013.54</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1038%2Fclpt.2013.54" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=23588322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1arsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2013&pages=502-514&author=P.+A.+Milliganauthor=M.+J.+Brownauthor=B.+Marchantauthor=S.+W.+Martinauthor=P.+H.+van+der+Graafauthor=N.+Bensonauthor=G.+Nucciauthor=D.+J.+Nicholsauthor=R.+A.+Boydauthor=J.+W.+Mandemaauthor=S.+Krishnaswamiauthor=S.+Zwillichauthor=D.+Grubenauthor=R.+J.+Anzianoauthor=T.+C.+Stockauthor=R.+L.+Lalonde&title=Model-based+drug+development%3A+a+rational+approach+to+efficiently+accelerate+drug+development&doi=10.1038%2Fclpt.2013.54"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development</span></div><div class="casAuthors">Milligan, P. A.; Brown, M. J.; Marchant, B.; Martin, S. W.; van der Graaf, P. H.; Benson, N.; Nucci, G.; Nichols, D. J.; Boyd, R. A.; Mandema, J. W.; Krishnaswami, S.; Zwillich, S.; Gruben, D.; Anziano, R. J.; Stock, T. C.; Lalonde, R. L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">502-514</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The pharmaceutical industry continues to face significant challenges.  Very few compds. that enter development reach the marketplace, and the investment required for each success can surpass 1.8 billion.  Despite attempts to improve efficiency and increase productivity, total investment continues to rise whereas the output of new medicines declines.  With costs increasing exponentially through each development phase, it is failure in phase II and phase III that is most wasteful.  In today's development paradigm, late-stage failure is principally a result of insufficient efficacy.  This is manifested as either a failure to differentiate sufficiently from placebo (shown for both novel and precedented mechanisms) or a failure to demonstrate sufficient differentiation from existing compds.  Set in this context, this article will discuss the role model-based drug development (MBDD) approaches can and do play in accelerating and optimizing compd. development strategies through a series of illustrative examples.  Clin. Pharmacol. & Therapeutics (2013); 93 6, 502-514. doi:10.1038/clpt.2013.54.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcq-yl0EkXMLVg90H21EOLACvtfcHk0lg7kHOt8FKVvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1arsbs%253D&md5=89db09d5e3ea787abd2a7a610b496ea8</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2013.54&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2013.54%26sid%3Dliteratum%253Aachs%26aulast%3DMilligan%26aufirst%3DP.%2BA.%26aulast%3DBrown%26aufirst%3DM.%2BJ.%26aulast%3DMarchant%26aufirst%3DB.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3Dvan%2Bder%2BGraaf%26aufirst%3DP.%2BH.%26aulast%3DBenson%26aufirst%3DN.%26aulast%3DNucci%26aufirst%3DG.%26aulast%3DNichols%26aufirst%3DD.%2BJ.%26aulast%3DBoyd%26aufirst%3DR.%2BA.%26aulast%3DMandema%26aufirst%3DJ.%2BW.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DZwillich%26aufirst%3DS.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DAnziano%26aufirst%3DR.%2BJ.%26aulast%3DStock%26aufirst%3DT.%2BC.%26aulast%3DLalonde%26aufirst%3DR.%2BL.%26atitle%3DModel-based%2520drug%2520development%253A%2520a%2520rational%2520approach%2520to%2520efficiently%2520accelerate%2520drug%2520development%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D93%26spage%3D502%26epage%3D514%26doi%3D10.1038%2Fclpt.2013.54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keystone, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drescher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berclaz, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidelus-Gort, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luchi, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2014-206478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1136%2Fannrheumdis-2014-206478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=25431052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVSltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2015&pages=333-340&author=E.+C.+Keystoneauthor=P.+C.+Taylorauthor=E.+Drescherauthor=D.+E.+Schlichtingauthor=S.+D.+Beattieauthor=P.+Y.+Berclazauthor=C.+H.+Leeauthor=R.+K.+Fidelus-Gortauthor=M.+E.+Luchiauthor=T.+P.+Rooneyauthor=W.+L.+Maciasauthor=M.+C.+Genovese&title=Safety+and+efficacy+of+baricitinib+at+24+weeks+in+patients+with+rheumatoid+arthritis+who+have+had+an+inadequate+response+to+methotrexate&doi=10.1136%2Fannrheumdis-2014-206478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate</span></div><div class="casAuthors">Keystone, Edward C.; Taylor, Peter C.; Drescher, Edit; Schlichting, Douglas E.; Beattie, Scott D.; Berclaz, Pierre-Yves; Lee, Chin H.; Fidelus-Gort, Rosanne K.; Luchi, Monica E.; Rooney, Terence P.; Macias, William L.; Genovese, Mark C.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">333-340</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite treatment with methotrexate.  Methods In this phase IIb study, 301 patients were randomized 2:1:1:1:1 to receive once daily doses of placebo or 1, 2, 4 or 8 mg baricitinib for 12 wk.  Patients assigned to 2, 4 and 8 mg baricitinib continued blinded treatment for an addnl. 12 wk.  Patients assigned to placebo or 1 mg baricitinib were reassigned to 2 mg twice daily or 4 mg once daily baricitinib between weeks 12-24.  The primary endpoint was the proportion of patients in the combined 4 and 8 mg groups achieving an American College of Rheumatol. 20% (ACR20) response vs. placebo at week 12.  Results Significantly more patients in the combined baricitinib 4 and 8 mg groups compared with placebo achieved an ACR20 response at week 12 (76% vs 41%, p<0.001).  At week 12, significant differences vs. placebo were also obsd. in patients achieving ACR50, ACR70 and remission as measured by Disease Activity Score for 28-joint counts, Clin. Disease Activity Index and Simplified Disease Activity Index.  Patients receiving 2, 4, or 8 mg baricitinib maintained or improved in all measures through 24 wk.  Similar proportions of patients experienced at least one adverse event in the placebo and baricitinib groups.  Serious infections developed in three patients receiving baricitinib.  No cases of tuberculosis, herpes zoster, opportunistic infections or deaths were reported.  Dose-dependent decreases in Hb were obsd. with baricitinib.  Conclusions Baricitinib improved the signs and symptoms of RA in methotrexate inadequate responders with active disease.  Baricitinib was well tolerated with no unexpected safety findings through week 24.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz3lYB7HU_KbVg90H21EOLACvtfcHk0liEFehBVI9c8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVSltbc%253D&md5=2f13c96c1c1dc5f68e69cd3e6da457b7</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2014-206478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2014-206478%26sid%3Dliteratum%253Aachs%26aulast%3DKeystone%26aufirst%3DE.%2BC.%26aulast%3DTaylor%26aufirst%3DP.%2BC.%26aulast%3DDrescher%26aufirst%3DE.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DBeattie%26aufirst%3DS.%2BD.%26aulast%3DBerclaz%26aufirst%3DP.%2BY.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DFidelus-Gort%26aufirst%3DR.%2BK.%26aulast%3DLuchi%26aufirst%3DM.%2BE.%26aulast%3DRooney%26aufirst%3DT.%2BP.%26aulast%3DMacias%26aufirst%3DW.%2BL.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520baricitinib%2520at%252024%2520weeks%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%2520who%2520have%2520had%2520an%2520inadequate%2520response%2520to%2520methotrexate%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2015%26volume%3D74%26spage%3D333%26epage%3D340%26doi%3D10.1136%2Fannrheumdis-2014-206478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamashta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrill, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werth, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalunian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brohawn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illei, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drappa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Investigators, C. D. S.</span></span> <span> </span><span class="NLM_article-title">Anifrolumab, an Anti-Interferon-alpha Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1002/art.39962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1002%2Fart.39962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=28130918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslWrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=376-386&author=R.+Furieauthor=M.+Khamashtaauthor=J.+T.+Merrillauthor=V.+P.+Werthauthor=K.+Kalunianauthor=P.+Brohawnauthor=G.+G.+Illeiauthor=J.+Drappaauthor=L.+Wangauthor=S.+Yooauthor=C.+D.+S.+Investigators&title=Anifrolumab%2C+an+Anti-Interferon-alpha+Receptor+Monoclonal+Antibody%2C+in+Moderate-to-Severe+Systemic+Lupus+Erythematosus&doi=10.1002%2Fart.39962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus</span></div><div class="casAuthors">Furie, Richard; Khamashta, Munther; Merrill, Joan T.; Werth, Victoria P.; Kalunian, Kenneth; Brohawn, Philip; Illei, Gabor G.; Drappa, Jorn; Wang, Liangwei; Yoo, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">376-386</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (SLE).  Methods: Patients (n = 305) were randomized to receive i.v. anifrolumab (300 mg or 1,000 mg) or placebo, in addn. to std. therapy, every 4 wk for 48 wk.  Randomization was stratified by SLE Disease Activity Index 2000 score (<10 or ≥10), oral corticosteroid dosage (<10 or ≥10 mg/day), and type I IFN gene signature test status (high or low) based on a 4-gene expression assay.  The primary end point was the percentage of patients achieving an SLE Responder Index (SRI[4]) response at week 24 with sustained redn. of oral corticosteroids (<10 mg/day and less than or equal to the dose at week 1 from week 12 through 24).  Other end points (including SRI[4], British Isles Lupus Assessment Group [BILAG]-based Composite Lupus Assessment [BICLA], modified SRI[6], and major clin. response) were assessed at week 52.  The primary end point was analyzed in the modified intent-to-treat (ITT) population and type I IFN-high subpopulation.  The study result was considered pos. if the primary end point was met in either of the 2 study populations.  The Type I error rate was controlled at 0.10 (2-sided), within each of the 2 study populations for the primary end point anal.  Results: The primary end point was met by more patients treated with anifrolumab (34.3% of 99 for 300 mg and 28.8% of 104 for 1,000 mg) than placebo (17.6% of 102) (P = 0.014 for 300 mg and P = 0.063 for 1,000 mg, vs. placebo), with greater effect size in patients with a high IFN signature at baseline (13.2% in placebo-treated patients vs. 36.0% [P = 0.004] and 28.2% [P = 0.029]) in patients treated with anifrolumab 300 mg and 1,000 mg, resp.  At week 52, patients treated with anifrolumab achieved greater responses in SRI(4) (40.2% vs. 62.6% [P < 0.001] and 53.8% [P = 0.043] with placebo, anifrolumab 300 mg, and anifrolumab 1,000 mg, resp.), BICLA (25.7% vs. 53.5% [P < 0.001] and 41.2% [P = 0.018], resp.), modified SRI(6) (28.4% vs. 49.5% [P = 0.002] and 44.7% [P = 0.015], resp.), major clin. response (BILAG 2004 C or better in all organ domains from week 24 through week 52) (6.9% vs. 19.2% [P = 0.012] and 17.3% [P = 0.025], resp.), and several other global and organ-specific end points.  Herpes zoster was more frequent in the anifrolumab-treated patients (2.0% with placebo treatment vs. 5.1% and 9.5% with anifrolumab 300 mg and 1,000 mg, resp.), as were cases reported as influenza (2.0% vs. 6.1% and 7.6%, resp.), in the anifrolumab treatment groups.  Incidence of serious adverse events was similar between groups (18.8% vs. 16.2% and 17.1%, resp.).  Conclusion: Anifrolumab substantially reduced disease activity compared with placebo across multiple clin. end points in the patients with moderate-to-severe SLE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOnuGe2pgO6LVg90H21EOLACvtfcHk0lhW7DlTN7l9nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslWrs7Y%253D&md5=c7f5b70586a8cbc0fafb2651a5f98b32</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fart.39962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.39962%26sid%3Dliteratum%253Aachs%26aulast%3DFurie%26aufirst%3DR.%26aulast%3DKhamashta%26aufirst%3DM.%26aulast%3DMerrill%26aufirst%3DJ.%2BT.%26aulast%3DWerth%26aufirst%3DV.%2BP.%26aulast%3DKalunian%26aufirst%3DK.%26aulast%3DBrohawn%26aufirst%3DP.%26aulast%3DIllei%26aufirst%3DG.%2BG.%26aulast%3DDrappa%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYoo%26aufirst%3DS.%26aulast%3DInvestigators%26aufirst%3DC.%2BD.%2BS.%26atitle%3DAnifrolumab%252C%2520an%2520Anti-Interferon-alpha%2520Receptor%2520Monoclonal%2520Antibody%252C%2520in%2520Moderate-to-Severe%2520Systemic%2520Lupus%2520Erythematosus%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26spage%3D376%26epage%3D386%26doi%3D10.1002%2Fart.39962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frieder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivelevitch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haugh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menter, A.</span></span> <span> </span><span class="NLM_article-title">Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1002/cpt.893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1002%2Fcpt.893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=28960267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVCrsLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2018&pages=88-101&author=J.+Friederauthor=D.+Kivelevitchauthor=I.+Haughauthor=I.+Watsonauthor=A.+Menter&title=Anti-IL-23+and+Anti-IL-17+Biologic+Agents+for+the+Treatment+of+Immune-Mediated+Inflammatory+Conditions&doi=10.1002%2Fcpt.893"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions</span></div><div class="casAuthors">Frieder, Jillian; Kivelevitch, Dario; Haugh, Isabel; Watson, Ian; Menter, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-101</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Advancements in the immunopathogenesis of psoriasis have identified interleukin (IL)-23 and IL-17 as fundamental contributors in the immune pathways of the disease.  Leveraging these promising therapeutic targets has led to the emergence of a no. of anti-IL-23 and -17 biol. agents with the potential to treat multiple conditions with common underlying pathol.  The unprecedented clin. efficacy of these agents in the treatment of psoriasis has paved way for their evaluation in diseases such as psoriatic arthritis, Crohn's disease, rheumatoid arthritis, in addn. to other immune-mediated conditions.  Here we review the IL-23/IL-17 immune pathways and discuss the key clin. and safety data of the anti-IL-23 and anti-IL-17 biol. agents in psoriasis and other immune-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKyNWmqZ8oPLVg90H21EOLACvtfcHk0lhW7DlTN7l9nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVCrsLzM&md5=81434ac64afe2233d8118b31708cb2be</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fcpt.893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.893%26sid%3Dliteratum%253Aachs%26aulast%3DFrieder%26aufirst%3DJ.%26aulast%3DKivelevitch%26aufirst%3DD.%26aulast%3DHaugh%26aufirst%3DI.%26aulast%3DWatson%26aufirst%3DI.%26aulast%3DMenter%26aufirst%3DA.%26atitle%3DAnti-IL-23%2520and%2520Anti-IL-17%2520Biologic%2520Agents%2520for%2520the%2520Treatment%2520of%2520Immune-Mediated%2520Inflammatory%2520Conditions%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2018%26volume%3D103%26spage%3D88%26epage%3D101%26doi%3D10.1002%2Fcpt.893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van Vollenhoven, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsokos, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevrier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triebel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, S.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Ustekinumab, an Interleukin 12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Results of a Phase 2, Randomized Placebo-Controlled Study [abstract]</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">Suppl 10</span>),  <span class="NLM_fpage">abstract 6L</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=abstract+6L&issue=Suppl+10&author=R.+van+Vollenhovenauthor=B.+H.+Hahnauthor=G.+C.+Tsokosauthor=C.+Wagnerauthor=P.+Lipskyauthor=B.+Hsuauthor=M.+Chevrierauthor=R.+Gordonauthor=M.+Triebelauthor=S.+Rose&title=Efficacy+and+Safety+of+Ustekinumab%2C+an+Interleukin+12%2F23+Inhibitor%2C+in+Patients+with+Active+Systemic+Lupus+Erythematosus%3A+Results+of+a+Phase+2%2C+Randomized+Placebo-Controlled+Study+%5Babstract%5D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BVollenhoven%26aufirst%3DR.%26aulast%3DHahn%26aufirst%3DB.%2BH.%26aulast%3DTsokos%26aufirst%3DG.%2BC.%26aulast%3DWagner%26aufirst%3DC.%26aulast%3DLipsky%26aufirst%3DP.%26aulast%3DHsu%26aufirst%3DB.%26aulast%3DChevrier%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DR.%26aulast%3DTriebel%26aufirst%3DM.%26aulast%3DRose%26aufirst%3DS.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Ustekinumab%252C%2520an%2520Interleukin%252012%252F23%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Active%2520Systemic%2520Lupus%2520Erythematosus%253A%2520Results%2520of%2520a%2520Phase%25202%252C%2520Randomized%2520Placebo-Controlled%2520Study%2520%255Babstract%255D%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26issue%3DSuppl%252010%26spage%3Dabstract%25206L" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernest, C.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tham, L. S.</span></span> <span> </span><span class="NLM_article-title">Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis</span>. <i>CPT: Pharmacometrics Syst. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">804</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1002/psp4.12251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1002%2Fpsp4.12251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=28891251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Kgs7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=804-813&author=X.+Zhangauthor=L.+Chuaauthor=C.+Ernestauthor=W.+Maciasauthor=T.+Rooneyauthor=L.+S.+Tham&title=Dose%2FExposure-Response+Modeling+to+Support+Dosing+Recommendation+for+Phase+III+Development+of+Baricitinib+in+Patients+with+Rheumatoid+Arthritis&doi=10.1002%2Fpsp4.12251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis</span></div><div class="casAuthors">Zhang, Xin; Chua, Laiyi; Ernest, Charles II; Macias, William; Rooney, Terence; Tham, Lai San</div><div class="citationInfo"><span class="NLM_cas:title">CPT: Pharmacometrics & Systems Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">804-813</span>CODEN:
                <span class="NLM_cas:coden">CPSPBR</span>;
        ISSN:<span class="NLM_cas:issn">2163-8306</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Baricitinib is an oral inhibitor of Janus kinases (JAKs), selective for JAK1 and 2.  It demonstrated dose-dependent efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) in a phase IIb study up to 24 wk.  Population pharmacokinetic/pharmacodynamic (PopPK/PD) models were developed to characterize concn.-time profiles and dose/exposure-response (D/E-R) relationships for the key efficacy (proportion of patients achieving American College of Rheumatol. 20%, 50%, or 70% response rate) and safety endpoints (incidence of anemia) for the phase IIb study.  The modeling suggested that 4 mg q.d. was likely to offer the optimum risk/benefit balance, whereas 2 mg q.d. had the potential for adequate efficacy.  In addn., at the same total daily dose, a twice-daily regimen is not expected to provide an advantage over q.d. dosing for the efficacy or safety endpoints.  The model-based simulations formed the rationale for key aspects of dosing, such as dose levels and dosing frequency for phase III development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol_-dsqYG9W7Vg90H21EOLACvtfcHk0ljriLD0jkIulQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Kgs7rM&md5=fbcb534ccd2176e636535d99762bb22c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fpsp4.12251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsp4.12251%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DChua%26aufirst%3DL.%26aulast%3DErnest%26aufirst%3DC.%26aulast%3DMacias%26aufirst%3DW.%26aulast%3DRooney%26aufirst%3DT.%26aulast%3DTham%26aufirst%3DL.%2BS.%26atitle%3DDose%252FExposure-Response%2520Modeling%2520to%2520Support%2520Dosing%2520Recommendation%2520for%2520Phase%2520III%2520Development%2520of%2520Baricitinib%2520in%2520Patients%2520with%2520Rheumatoid%2520Arthritis%26jtitle%3DCPT%253A%2520Pharmacometrics%2520Syst.%2520Pharmacol.%26date%3D2017%26volume%3D6%26spage%3D804%26epage%3D813%26doi%3D10.1002%2Fpsp4.12251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Namour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhoutte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigerinck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van’t Klooster, G.</span></span> <span> </span><span class="NLM_article-title">An active metabolite contributes to the pharmacodynamics and efficacy of GLPG0634, a selective JAK1 inhibitor</span>. <i>Arthritis Rheum</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">Suppl 10</span>),  <span class="NLM_fpage">1795</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=23553790" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=1795&issue=Suppl+10&author=F.+Namourauthor=R.+Galienauthor=F.+Vanhoutteauthor=P.+Wigerinckauthor=G.+van%E2%80%99t+Klooster&title=An+active+metabolite+contributes+to+the+pharmacodynamics+and+efficacy+of+GLPG0634%2C+a+selective+JAK1+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNamour%26aufirst%3DF.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DVanhoutte%26aufirst%3DF.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3Dvan%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26atitle%3DAn%2520active%2520metabolite%2520contributes%2520to%2520the%2520pharmacodynamics%2520and%2520efficacy%2520of%2520GLPG0634%252C%2520a%2520selective%2520JAK1%2520inhibitor%26jtitle%3DArthritis%2520Rheum%26date%3D2013%26volume%3D65%26issue%3DSuppl%252010%26spage%3D1795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishore, N.</span></span> <span> </span><span class="NLM_article-title">Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.209304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1124%2Fjpet.113.209304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=24218541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=165-173&author=M.+E.+Dowtyauthor=M.+I.+Jessonauthor=S.+Ghoshauthor=J.+Leeauthor=D.+M.+Meyerauthor=S.+Krishnaswamiauthor=N.+Kishore&title=Preclinical+to+clinical+translation+of+tofacitinib%2C+a+Janus+kinase+inhibitor%2C+in+rheumatoid+arthritis&doi=10.1124%2Fjpet.113.209304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical to clinical translation of tofacitinib, a janus kinase inhibitor, in rheumatoid arthritis</span></div><div class="casAuthors">Dowty, Martin E.; Jesson, Michael I.; Ghosh, Sarbani; Lee, Jamie; Meyer, Debra M.; Krishnaswami, Sriram; Kishore, Nandini</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-173, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A crit. piece in the translation of preclin. studies to clin. trials is the detn. of dosing regimens that allow max. therapeutic benefit with min. toxicity.  The preclin. pharmacokinetic (PK)/pharmacodynamic (PD) profile of tofacitinib, an oral Janus kinase (JAK) inhibitor, in a mouse collagen-induced arthritis (mCIA) model was compared with clin. PK/PD data from patients with rheumatoid arthritis (RA).  Preclin. evaluations included target modulation and PK/PD modeling based on continuous s.c. infusion or oral once- or twice-daily (BID) dosing paradigms in mice.  The human PK/PD profile was obtained from pooled data from four phase 2 studies in patients with RA, and maximal effect models were used to evaluate efficacy after 12 wk of tofacitinib treatment (1-15 mg BID).  In mCIA, the main driver of efficacy was inhibition of cytokine receptor signaling mediated by JAK1 heterodimers, but not JAK2 homodimers, and continuous daily inhibition was not required to maintain efficacy.  Projected efficacy could be predicted from total daily exposure irresp. of the oral dosing paradigm, with a total steady-state plasma concn. achieving 50% of the maximal response (Cave50) of ∼100 nM.  Tofacitinib potency (ED50) in clin. studies was ∼3.5 mg BID (90% confidence interval: 2.3, 5.5) or total Cave50 of ∼40 nM, derived using Disease Activity Scores from patients with RA.  The collective clin. and preclin. data indicated the importance of Cave as a driver of efficacy, rather than max. or min. plasma concn. (Cmax or Cmin), where Cave50 values were within ∼2-fold of each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDs-lnT0HFF7Vg90H21EOLACvtfcHk0lj3KaNFYCSC4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D&md5=faed45ef8eabb5e1bde0819702f26ffa</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.209304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.209304%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DKishore%26aufirst%3DN.%26atitle%3DPreclinical%2520to%2520clinical%2520translation%2520of%2520tofacitinib%252C%2520a%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D165%26epage%3D173%26doi%3D10.1124%2Fjpet.113.209304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutmacher, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furst, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikranian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nduaka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span> <span> </span><span class="NLM_article-title">Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">753</span>, <span class="refDoi"> DOI: 10.1002/cpt.576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1002%2Fcpt.576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=27859030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslKju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2017&pages=745-753&author=M.+Lambaauthor=M.+M.+Hutmacherauthor=D.+E.+Furstauthor=A.+Dikranianauthor=M.+E.+Dowtyauthor=D.+Conradoauthor=T.+Stockauthor=C.+Nduakaauthor=J.+Cookauthor=S.+Krishnaswami&title=Model-Informed+Development+and+Registration+of+a+Once-Daily+Regimen+of+Extended-Release+Tofacitinib&doi=10.1002%2Fcpt.576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib</span></div><div class="casAuthors">Lamba, M.; Hutmacher, M. M.; Furst, D. E.; Dikranian, A.; Dowty, M. E.; Conrado, D.; Stock, T.; Nduaka, C.; Cook, J.; Krishnaswami, S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">745-753</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Extended-release (XR) formulations enable less frequent dosing vs. conventional (e.g., immediate release (IR)) formulations.  Regulatory registration of such formulations typically requires pharmacokinetic (PK) and clin. efficacy data.  Here we illustrate a model-informed, exposure-response (E-R) approach to translate controlled trial data from one formulation to another without a phase III trial, using a tofacitinib case study.  Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA).  E-R analyses were conducted using validated clin. endpoints from phase II dose-response and nonclin. dose fractionation studies of the IR formulation.  Consistent with the delay in clin. response dynamics relative to PK, av. concn. was established as the relevant PK parameter for tofacitinib efficacy and supported pharmacodynamic similarity.  These evaluations, alongside demonstrated equivalence in total systemic exposure between IR and XR formulations, provided the basis for the regulatory approval of tofacitinib XR once daily by the US Food and Drug Administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpS1owg4oUA7Vg90H21EOLACvtfcHk0lhKBxL_FByJOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslKju78%253D&md5=28cb7216bd6ee2d4691b90b8fe57368f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fcpt.576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.576%26sid%3Dliteratum%253Aachs%26aulast%3DLamba%26aufirst%3DM.%26aulast%3DHutmacher%26aufirst%3DM.%2BM.%26aulast%3DFurst%26aufirst%3DD.%2BE.%26aulast%3DDikranian%26aufirst%3DA.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DConrado%26aufirst%3DD.%26aulast%3DStock%26aufirst%3DT.%26aulast%3DNduaka%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DKrishnaswami%26aufirst%3DS.%26atitle%3DModel-Informed%2520Development%2520and%2520Registration%2520of%2520a%2520Once-Daily%2520Regimen%2520of%2520Extended-Release%2520Tofacitinib%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D101%26spage%3D745%26epage%3D753%26doi%3D10.1002%2Fcpt.576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanhoutte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voloshyn, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanislavchuk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meuleners, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van ’t Klooster, G.</span></span> <span> </span><span class="NLM_article-title">Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1949</span>– <span class="NLM_lpage">1959</span>, <span class="refDoi"> DOI: 10.1002/art.40186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1002%2Fart.40186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=28622463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFyrurjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=1949-1959&author=F.+Vanhoutteauthor=M.+Mazurauthor=O.+Voloshynauthor=M.+Stanislavchukauthor=A.+Van+der+Aaauthor=F.+Namourauthor=R.+Galienauthor=L.+Meulenersauthor=G.+van+%E2%80%99t+Klooster&title=Efficacy%2C+Safety%2C+Pharmacokinetics%2C+and+Pharmacodynamics+of+Filgotinib%2C+a+Selective+JAK-1+Inhibitor%2C+After+Short-Term+Treatment+of+Rheumatoid+Arthritis%3A+Results+of+Two+Randomized+Phase+IIa+Trials&doi=10.1002%2Fart.40186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials</span></div><div class="casAuthors">Vanhoutte, Frederic; Mazur, Minodora; Voloshyn, Oleksandr; Stanislavchuk, Mykola; Van der Aa, Annegret; Namour, Florence; Galien, Rene; Meuleners, Luc; van 't Klooster, Gerben</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1949-1959</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : JAK inhibitors have shown efficacy in rheumatoid arthritis (RA).  We undertook this study to test our hypothesis that selective inhibition of JAK-1 would combine good efficacy with a better safety profile compared with less selective JAK inhibitors.  Methods : In two 4-wk exploratory, double-blind, placebo-controlled phase IIa trials, 127 RA patients with an insufficient response to methotrexate (MTX) received filgotinib (GLPG0634, GS-6034) oral capsules (100 mg twice daily or 30, 75, 150, 200, or 300 mg once daily) or placebo, added onto a stable regimen of MTX, to evaluate safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of filgotinib.  The primary efficacy end point was the no. and percentage of patients in each treatment group meeting the American College of Rheumatol. 20% improvement criteria (achieving an ACR20 response) at week 4.  Results : Treatment with filgotinib at 75-300 mg met the primary end point and showed early onset of efficacy.  ACR20 response rates progressively increased to week 4, and the Disease Activity Score in 28 joints using the C-reactive protein (CRP) level decreased.  Marked and sustained improvements were obsd. in serum CRP level and other PD markers.  The PK of filgotinib and its major metabolite was dose proportional over the 30-300 mg range.  Early side effects seen with other less selective JAK inhibitors were not obsd. (e.g., there was no worsening of anemia [JAK-2 inhibition related], no effects on liver transaminases, and no increase in low-d. lipoprotein or total cholesterol).  A limited decrease in neutrophils without neutropenia was consistent with immunomodulatory effects through JAK-1 inhibition.  There were no infections.  Overall, filgotinib was well tolerated.  Events related to study drug were mild or moderate and transient during therapy, and the most common such event was nausea.  Conclusion : Selective inhibition of JAK-1 with filgotinib shows initial efficacy in RA with an encouraging safety profile in these exploratory studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7oTo2cM5so7Vg90H21EOLACvtfcHk0lhEK6FWH8BatA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFyrurjP&md5=b704bd2b69231f1aa95815120b8cf922</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fart.40186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.40186%26sid%3Dliteratum%253Aachs%26aulast%3DVanhoutte%26aufirst%3DF.%26aulast%3DMazur%26aufirst%3DM.%26aulast%3DVoloshyn%26aufirst%3DO.%26aulast%3DStanislavchuk%26aufirst%3DM.%26aulast%3DVan%2Bder%2BAa%26aufirst%3DA.%26aulast%3DNamour%26aufirst%3DF.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DMeuleners%26aufirst%3DL.%26aulast%3Dvan%2B%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26atitle%3DEfficacy%252C%2520Safety%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520of%2520Filgotinib%252C%2520a%2520Selective%2520JAK-1%2520Inhibitor%252C%2520After%2520Short-Term%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%253A%2520Results%2520of%2520Two%2520Randomized%2520Phase%2520IIa%2520Trials%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26spage%3D1949%26epage%3D1959%26doi%3D10.1002%2Fart.40186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breedveld, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombs, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgos-Vargas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerbini, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S. H.</span></span> <span> </span><span class="NLM_article-title">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1895</span>– <span class="NLM_lpage">1905</span>, <span class="refDoi"> DOI: 10.1002/art.24567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1002%2Fart.24567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=19565475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=1895-1905&author=J.+M.+Kremerauthor=B.+J.+Bloomauthor=F.+C.+Breedveldauthor=J.+H.+Coombsauthor=M.+P.+Fletcherauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=R.+Burgos-Vargasauthor=B.+Wilkinsonauthor=C.+A.+Zerbiniauthor=S.+H.+Zwillich&title=The+safety+and+efficacy+of+a+JAK+inhibitor+in+patients+with+active+rheumatoid+arthritis%3A+Results+of+a+double-blind%2C+placebo-controlled+phase+IIa+trial+of+three+dosage+levels+of+CP-690%2C550+versus+placebo&doi=10.1002%2Fart.24567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span></div><div class="casAuthors">Kremer, Joel M.; Bloom, Bradley J.; Breedveld, Ferdinand C.; Coombs, John H.; Fletcher, Mark P.; Gruben, David; Krishnaswami, Sriram; Burgos-Vargas, Ruben; Wilkinson, Bethanie; Zerbini, Cristiano A. F.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1895-1905</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">To det. the efficacy, safety, and tolerability of 3 different dosages of CP-690,550, a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in whom methotrexate, etanercept, infliximab, or adalimumab caused an inadequate or toxic response.  Patients (n = 264) were randomized equally to receive placebo, 5 mg of CP-690,550,15 mg of CP-690,550, or 30 mg of CP-690,550 twice daily for 6 wk, and were followed up for an addnl. 6 wk after treatment.  The primary efficacy end point was the American College of Rheumatol. 20% improvement criteria (ACR20) response rate at 6 wk.  By week 6, the ACR20 response rates were 70.5%, 81.2%, and 76.8% in the 5 mg, 15 mg, and 30 mg twice daily groups, resp., compared with 29.2% in the placebo group (P < 0.001).  Improvements in disease activity in CP-690,550-treated patients compared with placebo were seen in all treatment groups as early as week 1.  ACR50 and ACR70 response rates significantly improved in all treatment groups by week 4.  The most common adverse events reported were headache and nausea.  The infection rate in both the 15 mg twice daily group and the 30 mg twice daily group was 30.4% (vs. 26.2% in the placebo group).  No opportunistic infections or deaths occurred.  Increases in mean low-d. lipoprotein cholesterol and high-d. lipoprotein cholesterol levels, and increases in mean serum creatinine level (0.04-0.06 mg/dL) were seen in all CP-690,550 treatment arms.  Our findings indicate that CP-690,550 is efficacious in the treatment of RA, resulting in rapid, statistically significant, and clin. meaningful redns. in the signs and symptoms of RA.  Further studies of CP-690,550 in RA are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBhxBhh_mG7rVg90H21EOLACvtfcHk0lhEK6FWH8BatA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D&md5=ab5fb34e43d8643871560c67bbbca07d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fart.24567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24567%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DBloom%26aufirst%3DB.%2BJ.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26aulast%3DCoombs%26aufirst%3DJ.%2BH.%26aulast%3DFletcher%26aufirst%3DM.%2BP.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DBurgos-Vargas%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DZerbini%26aufirst%3DC.%2BA.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DThe%2520safety%2520and%2520efficacy%2520of%2520a%2520JAK%2520inhibitor%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%253A%2520Results%2520of%2520a%2520double-blind%252C%2520placebo-controlled%2520phase%2520IIa%2520trial%2520of%2520three%2520dosage%2520levels%2520of%2520CP-690%252C550%2520versus%2520placebo%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D1895%26epage%3D1905%26doi%3D10.1002%2Fart.24567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strober, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buonanno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawabata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harness, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K.</span></span> <span> </span><span class="NLM_article-title">Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">992</span>– <span class="NLM_lpage">999</span>, <span class="refDoi"> DOI: 10.1111/bjd.12517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1111%2Fbjd.12517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=23855761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslakurzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2013&pages=992-999&author=B.+Stroberauthor=M.+Buonannoauthor=J.+D.+Clarkauthor=T.+Kawabataauthor=H.+Tanauthor=R.+Wolkauthor=H.+Valdezauthor=R.+G.+Langleyauthor=J.+Harnessauthor=A.+Menterauthor=K.+Papp&title=Effect+of+tofacitinib%2C+a+Janus+kinase+inhibitor%2C+on+haematological+parameters+during+12+weeks+of+psoriasis+treatment&doi=10.1111%2Fbjd.12517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment</span></div><div class="casAuthors">Strober, B.; Buonanno, M.; Clark, J. D.; Kawabata, T.; Tan, H.; Wolk, R.; Valdez, H.; Langley, R. G.; Harness, J.; Menter, A.; Papp, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">992-999</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : The Janus kinase (JAK) inhibitor, tofacitinib, has shown efficacy for the treatment of psoriasis in a phase IIb trial (A3921047; NCT00678210).  Objectives : To report haematol. data from the phase IIb trial, given the importance of JAK-dependent signalling in haematopoiesis.  Methods : Patients with moderate-to-severe chronic plaque psoriasis were randomized to receive tofacitinib 2, 5 or 15 mg, or placebo, twice daily over 12 wk.  Blood samples were collected at screening, baseline, weeks 2, 4, 8 and 12 during treatment, and weeks 14 and 16 during off-treatment follow-up.  Results : Baseline haematol. was similar across patients receiving tofacitinib 2 mg (n = 49), 5 mg (n = 49) or 15 mg (n = 49), or placebo (n = 50).  Tofacitinib conferred dose-dependent decreases in Hb, haematocrit and red blood cell counts, while reticulocyte counts initially declined, before recovering by week 8, and exceeding baseline levels after treatment cessation.  With regard to white blood cells, tofacitinib had no clear dose-dependent effects on basophils or monocytes, but appeared to be assocd. with transient or reversible dose-dependent decreases in neutrophil and eosinophil counts and transient increases in lymphocyte counts, which were primarily attributable to increases in B-cell counts.  Natural killer cell counts declined with tofacitinib.  Conclusions : Tofacitinib conferred tolerable, dose-dependent changes in haematol. parameters during short-term administration in patients with psoriasis.  The effects did not appear to be progressive, and were often transient or reversible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXc7wLFiJmW7Vg90H21EOLACvtfcHk0ljMM1xFeSxODw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslakurzP&md5=c8427f4813dc663ef97a2fce48f6fd08</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fbjd.12517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.12517%26sid%3Dliteratum%253Aachs%26aulast%3DStrober%26aufirst%3DB.%26aulast%3DBuonanno%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DKawabata%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DWolk%26aufirst%3DR.%26aulast%3DValdez%26aufirst%3DH.%26aulast%3DLangley%26aufirst%3DR.%2BG.%26aulast%3DHarness%26aufirst%3DJ.%26aulast%3DMenter%26aufirst%3DA.%26aulast%3DPapp%26aufirst%3DK.%26atitle%3DEffect%2520of%2520tofacitinib%252C%2520a%2520Janus%2520kinase%2520inhibitor%252C%2520on%2520haematological%2520parameters%2520during%252012%2520weeks%2520of%2520psoriasis%2520treatment%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2013%26volume%3D169%26spage%3D992%26epage%3D999%26doi%3D10.1111%2Fbjd.12517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menter, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elewski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buonanno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proulx, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolk, R.</span></span> <span> </span><span class="NLM_article-title">Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">961</span>, <span class="refDoi"> DOI: 10.1111/bjd.14018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1111%2Fbjd.14018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=26149717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyns73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2015&pages=949-961&author=K.+A.+Pappauthor=M.+A.+Menterauthor=M.+Abeauthor=B.+Elewskiauthor=S.+R.+Feldmanauthor=A.+B.+Gottliebauthor=R.+Langleyauthor=T.+Lugerauthor=D.+Thaciauthor=M.+Buonannoauthor=P.+Guptaauthor=J.+Proulxauthor=S.+Lanauthor=R.+Wolk&title=Tofacitinib%2C+an+oral+Janus+kinase+inhibitor%2C+for+the+treatment+of+chronic+plaque+psoriasis%3A+results+from+two+randomized%2C+placebo-controlled%2C+phase+III+trials&doi=10.1111%2Fbjd.14018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials</span></div><div class="casAuthors">Papp, K. A.; Menter, M. A.; Abe, M.; Elewski, B.; Feldman, S. R.; Gottlieb, A. B.; Langley, R.; Luger, T.; Thaci, D.; Buonanno, M.; Gupta, P.; Proulx, J.; Lan, S.; Wolk, R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">949-961</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis.  Objectives : To det. the 16-wk efficacy and safety of two oral tofacitinib doses vs. placebo in patients with moderate-to-severe chronic plaque psoriasis.  Methods : Patients in two similarly designed phase III studies (OPT Pivotal 1, NCT01276639, n = 901; OPT Pivotal 2, NCT01309737, n = 960) were initially randomized 2 : 2 : 1 to tofacitinib 10 or 5 mg or placebo, twice daily.  Coprimary efficacy end points (week 16) included the proportion of patients achieving Physician's Global Assessment (PGA) of 'clear' or 'almost clear' (PGA response) and the proportion achieving ≥ 75% redn. in Psoriasis Area and Severity Index (PASI 75).  Results : Across OPT Pivotal 1 and OPT Pivotal 2, 745 patients received tofacitinib 5 mg, 741 received tofacitinib 10 mg and 373 received placebo.  At week 16, a greater proportion of patients achieved PGA responses with tofacitinib 5 and 10 mg twice daily vs. placebo (OPT Pivotal 1, 41·9% and 59·2% vs. 9·0%; OPT Pivotal 2, 46·0% and 59·1% vs. 10·9%; all P < 0·001).  Higher PASI 75 rates were obsd. with tofacitinib vs. placebo (OPT Pivotal 1, 39·9%, 59·2% and 6·2%, resp., for tofacitinib 5 and 10 mg twice daily and placebo; OPT Pivotal 2, 46·0%, 59·6% and 11·4%; all P < 0·001 vs. placebo).  Adverse event (AE) rates appeared generally similar across groups; rates of serious AEs, infections, malignancies and discontinuations due to AEs were low.  Twelve patients reported herpes zoster across the tofacitinib treatment groups in both studies vs. none in the resp. placebo groups.  The most common AE across groups was nasopharyngitis.  Conclusions : Oral tofacitinib demonstrated significant efficacy vs. placebo during the initial 16 wk of treatment in patients with moderate-to-severe psoriasis.  Safety findings were consistent with prior studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTWaBXP7bJbLVg90H21EOLACvtfcHk0lj92MID887XAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyns73E&md5=2029ed12ccdeaeb36ab87425a8c534c1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14018%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DMenter%26aufirst%3DM.%2BA.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DElewski%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26aulast%3DGottlieb%26aufirst%3DA.%2BB.%26aulast%3DLangley%26aufirst%3DR.%26aulast%3DLuger%26aufirst%3DT.%26aulast%3DThaci%26aufirst%3DD.%26aulast%3DBuonanno%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DProulx%26aufirst%3DJ.%26aulast%3DLan%26aufirst%3DS.%26aulast%3DWolk%26aufirst%3DR.%26atitle%3DTofacitinib%252C%2520an%2520oral%2520Janus%2520kinase%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520chronic%2520plaque%2520psoriasis%253A%2520results%2520from%2520two%2520randomized%252C%2520placebo-controlled%252C%2520phase%2520III%2520trials%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2015%26volume%3D173%26spage%3D949%26epage%3D961%26doi%3D10.1111%2Fbjd.14018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wollenhaupt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nduaka, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benda, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komuro, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riese, R. J.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">837</span>– <span class="NLM_lpage">852</span>, <span class="refDoi"> DOI: 10.3899/jrheum.130683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.3899%2Fjrheum.130683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=24692527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyiurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=837-852&author=J.+Wollenhauptauthor=J.+Silverfieldauthor=E.+B.+Leeauthor=J.+R.+Curtisauthor=S.+P.+Woodauthor=K.+Somaauthor=C.+I.+Nduakaauthor=B.+Bendaauthor=D.+Grubenauthor=H.+Nakamuraauthor=Y.+Komuroauthor=S.+H.+Zwillichauthor=L.+Wangauthor=R.+J.+Riese&title=Safety+and+efficacy+of+tofacitinib%2C+an+oral+janus+kinase+inhibitor%2C+for+the+treatment+of+rheumatoid+arthritis+in+open-label%2C+longterm+extension+studies&doi=10.3899%2Fjrheum.130683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies</span></div><div class="casAuthors">Wollenhaupt, Juergen; Silverfield, Joel; Lee, Eun Bong; Curtis, Jeffrey R.; Wood, Susan P.; Soma, Koshika; Nduaka, Chudy I.; Benda, Birgitta; Gruben, David; Nakamura, Hiroyuki; Komuro, Yoshihiro; Zwillich, Samuel H.; Wang, Lisy; Riese, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">837-852</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective: To describe the longterm safety and efficacy profile of tofacitinib in patients with moderate to severe active rheumatoid arthritis (RA).  Methods: Data were pooled from 2 open-label studies (NCT00413699, NCT00661661) involving patients who had participated in qualifying phase I, II, or III index studies of tofacitinib.  Safety data included over 60 mo of observation; efficacy data are reported up to Month 48.  Treatment was initiated with tofacitinib 5 or 10 mg twice daily.  Primary endpoints were adverse events (AE) and lab. safety data.  Secondary endpoints included American College of Rheumatol. (ACR) response rates, and Disease Activity Score (28 joints) (DAS28)-4[erythrocyte sedimentation rate (ESR)] and Health Assessment Questionnaire-Disability Index (HAQ-DI) assessments.  Results: Overall, 4102 patients were treated for 5963 patient-years; mean (max.) treatment duration was 531 (1844) days; 20.8% of patients discontinued treatment over 60 mo.  The most common AE were nasopharyngitis (12.7%) and upper respiratory tract infection (10.5%).  Serious AE were reported in 15.4% of patients with an exposure-estd. incidence rate of 11.1 events/100 patient-years.  Serious infections were reported in 4.5% of patients with an exposure-estd. incidence rate of 3.1 events/100 patient-years (95% CI: 2.66-3.55).  Mean values for lab. variables were stable over time and consistent with phase II and III studies.  Persistent efficacy was demonstrated through Month 48, as measured by ACR response rate (ACR20/50/70) DAS28-4-ESR, and HAQ-DI.  Safety and efficacy were similar for patients receiving tofacitinib as monotherapy or with background nonbiol. disease-modifying antirheumatic drugs.  Conclusion: Tofacitinib demonstrated consistent safety and persistent efficacy over 48 mo in patients with RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Scjk1FOYMrVg90H21EOLACvtfcHk0lj92MID887XAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyiurbJ&md5=0c8cf68569627b3948b6c275ec69d8df</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.130683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.130683%26sid%3Dliteratum%253Aachs%26aulast%3DWollenhaupt%26aufirst%3DJ.%26aulast%3DSilverfield%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26aulast%3DWood%26aufirst%3DS.%2BP.%26aulast%3DSoma%26aufirst%3DK.%26aulast%3DNduaka%26aufirst%3DC.%2BI.%26aulast%3DBenda%26aufirst%3DB.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DKomuro%26aufirst%3DY.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRiese%26aufirst%3DR.%2BJ.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520tofacitinib%252C%2520an%2520oral%2520janus%2520kinase%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%2520in%2520open-label%252C%2520longterm%2520extension%2520studies%26jtitle%3DJ.%2520Rheumatol.%26date%3D2014%26volume%3D41%26spage%3D837%26epage%3D852%26doi%3D10.3899%2Fjrheum.130683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorarensen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juba, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span> <span> </span><span class="NLM_article-title">ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual JAK Kinase isoforms to cellular signaling</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1552</span>– <span class="NLM_lpage">1558</span>, <span class="refDoi"> DOI: 10.1021/cb5002125</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5002125" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1552-1558&author=A.+Thorarensenauthor=M.+E.+Bankerauthor=A.+Fensomeauthor=J.+B.+Telliezauthor=B.+Jubaauthor=F.+Vincentauthor=R.+M.+Czerwinskiauthor=A.+Casimiro-Garcia&title=ATP-mediated+kinome+selectivity%3A+the+missing+link+in+understanding+the+contribution+of+individual+JAK+Kinase+isoforms+to+cellular+signaling&doi=10.1021%2Fcb5002125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling</span></div><div class="casAuthors">Thorarensen, Atli; Banker, Mary Ellen; Fensome, Andrew; Telliez, Jean-Baptiste; Juba, Brian; Vincent, Fabien; Czerwinski, Robert M.; Casimiro-Garcia, Agustin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1552-1558</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases constitute an important class of therapeutic targets being explored both by academia and the pharmaceutical industry.  The major focus of this effort was directed toward the identification of ATP competitive inhibitors.  Although it has long been recognized that the intracellular concn. of ATP is very different from the concns. utilized in biochem. enzyme assays, little thought has been devoted to incorporating this discrepancy into our understanding of translation from enzyme inhibition to cellular function.  Significant work has been dedicated to the discovery of JAK kinase inhibitors; however, a disconnect between enzyme and cellular function is prominently displayed in the literature for this class of inhibitors.  Herein, we demonstrate utilizing the four JAK family members (JAK1, JAK2, JAK3, and TYK2) that the difference in the ATP Km of each individual kinase has a significant impact on the enzyme to cell inhibition translation.  We evaluated a large no. of JAK inhibitors in enzymic assays utilizing either 1 mM ATP or Km ATP for the four isoforms as well as in primary cell assays.  This data set provided the opportunity to examine individual kinase contributions to the heterodimeric kinase complexes mediating cellular signaling.  In contrast to a recent study, we demonstrate that for IL-15 cytokine signaling it is sufficient to inhibit either JAK1 or JAK3 to fully inhibit downstream STAT5 phosphorylation.  This addnl. data thus provides a crit. piece of information explaining why JAK1 has incorrectly been thought to have a dominant role over JAK3.  Beyond enabling a deeper understanding of JAK signaling, conducting similar analyses for other kinases by taking into account potency at high ATP rather than Km ATP may provide crucial insights into a compd.'s activity and selectivity in cellular contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYiMVl7OpPFLVg90H21EOLACvtfcHk0lhtLv086DeaTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D&md5=c87874cb1748e13eef2aa241ecef3e79</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fcb5002125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5002125%26sid%3Dliteratum%253Aachs%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26aulast%3DJuba%26aufirst%3DB.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26atitle%3DATP-mediated%2520kinome%2520selectivity%253A%2520the%2520missing%2520link%2520in%2520understanding%2520the%2520contribution%2520of%2520individual%2520JAK%2520Kinase%2520isoforms%2520to%2520cellular%2520signaling%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1552%26epage%3D1558%26doi%3D10.1021%2Fcb5002125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keefer, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, R. R.</span></span> <span> </span><span class="NLM_article-title">Interpretable, Probability-Based Confidence Metric for Continuous Quantitative Structure–Activity Relationship Models</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">368</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1021/ci300554t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci300554t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Cit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=368-383&author=C.+E.+Keeferauthor=G.+W.+Kauffmanauthor=R.+R.+Gupta&title=Interpretable%2C+Probability-Based+Confidence+Metric+for+Continuous+Quantitative+Structure%E2%80%93Activity+Relationship+Models&doi=10.1021%2Fci300554t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Interpretable, Probability-Based Confidence Metric for Continuous Quantitative Structure-Activity Relationship Models</span></div><div class="casAuthors">Keefer, Christopher E.; Kauffman, Gregory W.; Gupta, Rishi Raj</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">368-383</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A great deal of research has gone into the development of robust confidence in prediction and applicability domain (AD) measures for quant. structure-activity relationship (QSAR) models in recent years.  Much of the attention has historically focused on structural similarity, which can be defined in many forms and flavors.  A concept that is frequently overlooked in the realm of the QSAR applicability domain is how the local activity landscape plays a role in how accurate a prediction is or is not.  In this work, we describe an approach that pairs information about both the chem. similarity and activity landscape of a test compd.'s neighborhood into a single calcd. confidence value.  We also present an approach for converting this value into an interpretable confidence metric that has a simple and informative meaning across data sets.  The approach will be introduced to the reader in the context of models built upon four diverse literature data sets.  The steps we will outline include the definition of similarity used to det. nearest neighbors (NN), how we incorporate the NN activity landscape with a similarity-weighted root-mean-square distance (wRMSD) value, and how that value is then calibrated to generate an intuitive confidence metric for prospective application.  Finally, we will illustrate the prospective performance of the approach on five proprietary models whose predictions and confidence metrics have been tracked for more than a year.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqvcorWVQ5O7Vg90H21EOLACvtfcHk0lglejV-uYLaeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Cit74%253D&md5=14d2b7d42f91b5e4e90fa53b6266a178</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fci300554t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci300554t%26sid%3Dliteratum%253Aachs%26aulast%3DKeefer%26aufirst%3DC.%2BE.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DGupta%26aufirst%3DR.%2BR.%26atitle%3DInterpretable%252C%2520Probability-Based%2520Confidence%2520Metric%2520for%2520Continuous%2520Quantitative%2520Structure%25E2%2580%2593Activity%2520Relationship%2520Models%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D368%26epage%3D383%26doi%3D10.1021%2Fci300554t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Should the incorporation of structural alerts be restricted in drug design? An analysis of structure-toxicity trends with aniline-based drugs</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.2174/0929867321666141112122118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.2174%2F0929867321666141112122118" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=438-464&author=A.+S.+Kalgutkar&title=Should+the+incorporation+of+structural+alerts+be+restricted+in+drug+design%3F+An+analysis+of+structure-toxicity+trends+with+aniline-based+drugs&doi=10.2174%2F0929867321666141112122118"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F0929867321666141112122118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867321666141112122118%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DShould%2520the%2520incorporation%2520of%2520structural%2520alerts%2520be%2520restricted%2520in%2520drug%2520design%253F%2520An%2520analysis%2520of%2520structure-toxicity%2520trends%2520with%2520aniline-based%2520drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D438%26epage%3D464%26doi%3D10.2174%2F0929867321666141112122118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span> <span> </span><span class="NLM_article-title">Water’s Role in Compound Design for Drug Discovery</span>. In  <i>CCG UGM and Conference</i>, <span class="NLM_publisher-loc">Montral, Canada</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=H.+Zhu&title=Water%E2%80%99s+Role+in+Compound+Design+for+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DH.%26atitle%3DWater%25E2%2580%2599s%2520Role%2520in%2520Compound%2520Design%2520for%2520Drug%2520Discovery%26jtitle%3DCCG%2520UGM%2520and%2520Conference%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, J. C.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickerson-Nutter, C. L.</span></span> <span> </span><span class="NLM_article-title">Utility of animal models for identification of potential therapeutics for rheumatoid arthritis</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1505</span>– <span class="NLM_lpage">1515</span>, <span class="refDoi"> DOI: 10.1136/ard.2007.076430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1136%2Fard.2007.076430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=18055474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2gsbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2008&pages=1505-1515&author=M.+Hegenauthor=J.+C.+Keithauthor=M.+Collinsauthor=C.+L.+Nickerson-Nutter&title=Utility+of+animal+models+for+identification+of+potential+therapeutics+for+rheumatoid+arthritis&doi=10.1136%2Fard.2007.076430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Utility of animal models for identification of potential therapeutics for rheumatoid arthritis</span></div><div class="casAuthors">Hegen, M.; Keith, J. C., Jr.; Collins, M.; Nickerson-Nutter, C. L.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1505-1515</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  Animal models of rheumatoid arthritis (RA) are widely used for testing potential new therapies for RA.  However, the question of which animal model is most predictive of therapeutic efficacy in human RA commonly arises in data evaluation.  A retrospective review of the animal models used to evaluate approved, pending RA therapies, and compds. that were discontinued during phase II or III clin. trials found that the three most commonly used models were adjuvant-induced arthritis (AIA) in rats and collagen-induced arthritis (CIA) in rats and mice.  Limited data were found for more recently developed genetically modified animal models.  Examn. of the efficacy of various compds. in these animal models revealed that a compd.'s therapeutic efficacy, rather than prophylactic efficacy, in AIA and CIA models was more predictive of clin. efficacy in human RA than data from either model alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruwo5lHLFB3bVg90H21EOLACvtfcHk0lglejV-uYLaeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2gsbbP&md5=417b41682141901273229dacb8f63283</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1136%2Fard.2007.076430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2007.076430%26sid%3Dliteratum%253Aachs%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DKeith%26aufirst%3DJ.%2BC.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26atitle%3DUtility%2520of%2520animal%2520models%2520for%2520identification%2520of%2520potential%2520therapeutics%2520for%2520rheumatoid%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2008%26volume%3D67%26spage%3D1505%26epage%3D1515%26doi%3D10.1136%2Fard.2007.076430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banfield, C.</span>; <span class="NLM_string-name">Scaramozza, M.</span>; <span class="NLM_string-name">Zhang, W.</span>; <span class="NLM_string-name">Kieras, E.</span>; <span class="NLM_string-name">Page, K. M.</span>; <span class="NLM_string-name">Fensome, A.</span>; <span class="NLM_string-name">Vincent, M.</span>; <span class="NLM_string-name">Dowty, M. E.</span>; <span class="NLM_string-name">Goteti, K.</span>; <span class="NLM_string-name">Winkle, P. J.</span>; <span class="NLM_string-name">Peeva, E.</span></span> <span> </span><span class="NLM_article-title">The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis</span>.  <i>Journal of Clinical Pharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=C.+Banfield&author=M.+Scaramozza&author=W.+Zhang&author=E.+Kieras&author=K.+M.+Page&author=A.+Fensome&author=M.+Vincent&author=M.+E.+Dowty&author=K.+Goteti&author=P.+J.+Winkle&author=E.+Peeva&title=The+Safety%2C+Tolerability%2C+Pharmacokinetics%2C+and+Pharmacodynamics+of+a+TYK2%2FJAK1+Inhibitor+%28PF-06700841%29+in+Healthy+Subjects+and+Patients+With+Plaque+Psoriasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBanfield%26aufirst%3DC.%26atitle%3DThe%2520Safety%252C%2520Tolerability%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520of%2520a%2520TYK2%252FJAK1%2520Inhibitor%2520%2528PF-06700841%2529%2520in%2520Healthy%2520Subjects%2520and%2520Patients%2520With%2520Plaque%2520Psoriasis%26jtitle%3DJournal%2520of%2520Clinical%2520Pharmacology%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korniski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmons, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gormley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommers, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenbrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasselli, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, T. E.</span></span> <span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>400</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2010.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+Patnyauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.+C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6&doi=10.1016%2Fj.jmb.2010.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0lgTCxqQhH5juA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.%2BC.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433%26doi%3D10.1016%2Fj.jmb.2010.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajamohan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoth, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoghegan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subashi, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaila, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurumbail, R. G.</span></span> <span> </span><span class="NLM_article-title">Development of a high-throughput crystal structure-determination platform for JAK1 using a novel metal-chelator soaking system</span>. <i>Acta Crystallogr., Sect. F: Struct. Biol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">840</span>– <span class="NLM_lpage">845</span>, <span class="refDoi"> DOI: 10.1107/S2053230X16016356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1107%2FS2053230X16016356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=27827355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVWmt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2016&pages=840-845&author=N.+L.+Caspersauthor=S.+Hanauthor=F.+Rajamohanauthor=L.+R.+Hothauthor=K.+F.+Geogheganauthor=T.+A.+Subashiauthor=M.+L.+Vazquezauthor=N.+Kailaauthor=N.+Croninauthor=E.+Johnsonauthor=R.+G.+Kurumbail&title=Development+of+a+high-throughput+crystal+structure-determination+platform+for+JAK1+using+a+novel+metal-chelator+soaking+system&doi=10.1107%2FS2053230X16016356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a high-throughput crystal structure-determination platform for JAK1 using a novel metal-chelator soaking system</span></div><div class="casAuthors">Caspers, Nicole L.; Han, Seungil; Rajamohan, Francis; Hoth, Lise R.; Geoghegan, Kieran F.; Subashi, Timothy A.; Vazquez, Michael L.; Kaila, Neelu; Cronin, Ciaran N.; Johnson, Eric; Kurumbail, Ravi G.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">840-845</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Crystals of phosphorylated JAK1 kinase domain were initially generated in complex with nucleotide (ADP) and magnesium.  The tightly bound Mg2+-ADP at the ATP-binding site proved recalcitrant to ligand displacement.  Addn. of a molar excess of EDTA helped to dislodge the divalent metal ion, promoting the release of ADP and allowing facile exchange with ATP-competitive small-mol. ligands.  Many kinases require the presence of a stabilizing ligand in the ATP site for crystn.  This procedure could be useful for developing co-crystn. systems with an exchangeable ligand to enable structure-based drug design of other protein kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1j6dvXhIlZbVg90H21EOLACvtfcHk0lj7cDKSFVthpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVWmt7zI&md5=b4c15c4bc3deb1e54710882a70607ec8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1107%2FS2053230X16016356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X16016356%26sid%3Dliteratum%253Aachs%26aulast%3DCaspers%26aufirst%3DN.%2BL.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DRajamohan%26aufirst%3DF.%26aulast%3DHoth%26aufirst%3DL.%2BR.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DSubashi%26aufirst%3DT.%2BA.%26aulast%3DVazquez%26aufirst%3DM.%2BL.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DCronin%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DE.%26aulast%3DKurumbail%26aufirst%3DR.%2BG.%26atitle%3DDevelopment%2520of%2520a%2520high-throughput%2520crystal%2520structure-determination%2520platform%2520for%2520JAK1%2520using%2520a%2520novel%2520metal-chelator%2520soaking%2520system%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2016%26volume%3D72%26spage%3D840%26epage%3D845%26doi%3D10.1107%2FS2053230X16016356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vonrhein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flensburg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paciorek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Womack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span></span> <span> </span><span class="NLM_article-title">Data processing and analysis with the autoPROC toolbox</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1107/S0907444911007773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1107%2FS0907444911007773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=21460447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=293-302&author=C.+Vonrheinauthor=C.+Flensburgauthor=P.+Kellerauthor=A.+Sharffauthor=O.+Smartauthor=W.+Paciorekauthor=T.+Womackauthor=G.+Bricogne&title=Data+processing+and+analysis+with+the+autoPROC+toolbox&doi=10.1107%2FS0907444911007773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Data processing and analysis with the autoPROC toolbox</span></div><div class="casAuthors">Vonrhein, Clemens; Flensburg, Claus; Keller, Peter; Sharff, Andrew; Smart, Oliver; Paciorek, Wlodek; Womack, Thomas; Bricogne, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">293-302</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A typical diffraction expt. will generate many images and data sets from different crystals in a very short time.  This creates a challenge for the high-throughput operation of modern synchrotron beamlines as well as for the subsequent data processing.  Novice users in particular may feel overwhelmed by the tables, plots and nos. that the different data-processing programs and software packages present to them.  Here, some of the more common problems that a user has to deal with when processing a set of images that will finally make up a processed data set are shown, concg. on difficulties that may often show up during the first steps along the path of turning the expt. (i.e. data collection) into a model (i.e. interpreted electron d.).  Difficulties such as unexpected crystal forms, issues in crystal handling and suboptimal choices of data-collection strategies can often be dealt with, or at least diagnosed, by analyzing specific data characteristics during processing.  In the end, one wants to distinguish problems over which one has no immediate control once the expt. is finished from problems that can be remedied a posteriori.  A new software package, autoPROC, is also presented that combines third-party processing programs with new tools and an automated workflow script that is intended to provide users with both guidance and insight into the offline processing of data affected by the difficulties mentioned above, with particular emphasis on the automated treatment of multi-sweep data sets collected on multi-axis goniostats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmah7iUrMLXLVg90H21EOLACvtfcHk0lhy1gMGyaMGKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D&md5=a0a3579f6b371b6312819883864aa80d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1107%2FS0907444911007773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444911007773%26sid%3Dliteratum%253Aachs%26aulast%3DVonrhein%26aufirst%3DC.%26aulast%3DFlensburg%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DP.%26aulast%3DSharff%26aufirst%3DA.%26aulast%3DSmart%26aufirst%3DO.%26aulast%3DPaciorek%26aufirst%3DW.%26aulast%3DWomack%26aufirst%3DT.%26aulast%3DBricogne%26aufirst%3DG.%26atitle%3DData%2520processing%2520and%2520analysis%2520with%2520the%2520autoPROC%2520toolbox%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D293%26epage%3D302%26doi%3D10.1107%2FS0907444911007773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span> <span> </span><span class="NLM_article-title">XDS</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1107/S0907444909047337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=20124692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=125-132&author=W.+Kabsch&title=XDS&doi=10.1107%2FS0907444909047337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0lhy1gMGyaMGKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DXDS%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D125%26epage%3D132%26doi%3D10.1107%2FS0907444909047337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krissinel, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. S.</span></span> <span> </span><span class="NLM_article-title">Overview of the CCP4 suite and current developments</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1107/S0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=21460441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=235-242&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+W.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+suite+and+current+developments&doi=10.1107%2FS0907444910045749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the CCP4 suite and current developments</span></div><div class="casAuthors">Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.; Dodson, Eleanor J.; Emsley, Paul; Evans, Phil R.; Keegan, Ronan M.; Krissinel, Eugene B.; Leslie, Andrew G. W.; McCoy, Airlie; McNicholas, Stuart J.; Murshudov, Garib N.; Pannu, Navraj S.; Potterton, Elizabeth A.; Powell, Harold R.; Read, Randy J.; Vagin, Alexei; Wilson, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  The CCP4 (Collaborative Computational Project, No. 4) software suite is a collection of programs and assocd. data and software libraries which can be used for macromol. structure detn. by X-ray crystallog.  The suite is designed to be flexible, allowing users a no. of methods of achieving their aims.  The programs are from a wide variety of sources but are connected by a common infrastructure provided by std. file formats, data objects and graphical interfaces.  Structure soln. by macromol. crystallog. is becoming increasingly automated and the CCP4 suite includes several automation pipelines.  After giving a brief description of the evolution of CCP4 over the last 30 years, an overview of the current suite is given.  While detailed descriptions are given in the accompanying articles, here it is shown how the individual programs contribute to a complete software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wWMMIol6UrVg90H21EOLACvtfcHk0ljJkZa0rOZutw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D&md5=c407e4d47bef46864be336d60147c17d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520suite%2520and%2520current%2520developments%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D235%26epage%3D242%26doi%3D10.1107%2FS0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span> <span> </span><span class="NLM_article-title">Refinement of Macromolecular Structures by the Maximum-Likelihood Method</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1107/S0907444996012255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+Macromolecular+Structures+by+the+Maximum-Likelihood+Method&doi=10.1107%2FS0907444996012255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0ljJkZa0rOZutw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520Macromolecular%2520Structures%2520by%2520the%2520Maximum-Likelihood%2520Method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255%26doi%3D10.1107%2FS0907444996012255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span> <i>RHOFIT</i>, v. 1.2.4; <span class="NLM_publisher-name">Global Phasing Ltd.</span>: <span class="NLM_publisher-loc">Cambridge, UK</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+RHOFIT%2C+v.+1.2.4%3B+Global+Phasing+Ltd.%3A+Cambridge%2C+UK%2C+2014."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DRHOFIT%26pub%3DGlobal%2520Phasing%2520Ltd%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span> <i>BUSTER</i>, v. 2.8.0; <span class="NLM_publisher-name">Global Phasing Ltd.</span>: <span class="NLM_publisher-loc">Cambridge, UK</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+BUSTER%2C+v.+2.8.0%3B+Global+Phasing+Ltd.%3A+Cambridge%2C+UK%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DBUSTER%26pub%3DGlobal%2520Phasing%2520Ltd%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and development of Coot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lijQAfAuaNKpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+pan+assay+interference+compounds+%28PAINS%29+from+screening+libraries+and+for+their+exclusion+in+bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0ljIY_6fbvzdyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520pan%2520assay%2520interference%2520compounds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520for%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J-.B.</span></span> <span> </span><span class="NLM_article-title">An Updated Analysis of In vitro Cytokine Inhibition Profiles of a Number of Janus Kinase Inhibitors at Clinically Maningful Concentrations</span>. <i>United European Gastroenterology Journal</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">abstract 1770</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=abstract+1770&author=M.+E.+Dowtyauthor=T.+H.+Linauthor=L.+Wangauthor=J.+M.+Jussifauthor=L.+Liauthor=E.+Moyauthor=J-.B.+Telliez&title=An+Updated+Analysis+of+In+vitro+Cytokine+Inhibition+Profiles+of+a+Number+of+Janus+Kinase+Inhibitors+at+Clinically+Maningful+Concentrations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DJussif%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DMoy%26aufirst%3DE.%26aulast%3DTelliez%26aufirst%3DJ-.B.%26atitle%3DAn%2520Updated%2520Analysis%2520of%2520In%2520vitro%2520Cytokine%2520Inhibition%2520Profiles%2520of%2520a%2520Number%2520of%2520Janus%2520Kinase%2520Inhibitors%2520at%2520Clinically%2520Maningful%2520Concentrations%26jtitle%3DUnited%2520European%2520Gastroenterology%2520Journal%26date%3D2017%26volume%3D5%26spage%3Dabstract%25201770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span> <span> </span><span class="NLM_article-title">Predicting clearance in humans from in vitro data</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.2174/156802611794480873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.2174%2F156802611794480873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=21320062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=334-339&author=R.+S.+Obach&title=Predicting+clearance+in+humans+from+in+vitro+data&doi=10.2174%2F156802611794480873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting clearance in humans from in vitro data</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">334-339</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The use of in vitro metab. in scaling to predict human clearance of new chem. entities has become a commonplace activity in the research and development of new drugs.  The measurement of in vitro lability in human liver microsomes, a rich source of drug metabolizing cytochrome P 450 enzymes, has become a high throughput screen in many research organizations which is a testament to its usefulness in drug design.  In this chapter, the methods used to scale in vitro intrinsic clearance data to predict in vivo clearance are described.  Importantly, the numerous assumptions that are required in order to use in vitro data in this manner are laid out.  These include assumptions regarding the scaling process as well as tech. aspects of the generation of the in vitro data.  Finally, some other drug clearance processes that have been emerging as important are described with regard to ongoing research efforts to develop clearance prediction methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHL7BnSTNtWbVg90H21EOLACvtfcHk0lj4pFgMZ-reWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSntbk%253D&md5=38df8707bb77fdc8b6bb6ef2144a79da</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.2174%2F156802611794480873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611794480873%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPredicting%2520clearance%2520in%2520humans%2520from%2520in%2520vitro%2520data%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D334%26epage%3D339%26doi%3D10.2174%2F156802611794480873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hosea, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collard, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, R. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakar, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span> <span> </span><span class="NLM_article-title">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1177/0091270009333209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1177%2F0091270009333209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=19299532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=513-533&author=N.+A.+Hoseaauthor=W.+T.+Collardauthor=S.+Coleauthor=T.+S.+Maurerauthor=R.+X.+Fangauthor=H.+Jonesauthor=S.+M.+Kakarauthor=Y.+Nakaiauthor=B.+J.+Smithauthor=R.+Websterauthor=K.+Beaumont&title=Prediction+of+human+pharmacokinetics+from+preclinical+information%3A+comparative+accuracy+of+quantitative+prediction+approaches&doi=10.1177%2F0091270009333209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span></div><div class="casAuthors">Hosea, Natilie A.; Collard, Wendy T.; Cole, Susan; Maurer, Tristan S.; Fang, Rick X.; Jones, Hannah; Kakar, Shefali M.; Nakai, Yasuhiro; Smith, Bill J.; Webster, Rob; Beaumont, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">513-533</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Quant. prediction of human pharmacokinetics is crit. in assessing the viability of drug candidates and in detg. first-in-human dosing.  Numerous prediction methodologies, incorporating both in vitro and preclin. in vivo data, have been developed in recent years, each with advantages and disadvantages.  However, the lack of a comprehensive data set, both preclin. and clin., has limited efforts to evaluate the optimal strategy (or strategies) that results in quant. predictions of human pharmacokinetics.  To address this issue, the authors conducted a retrospective anal. using 50 proprietary compds. for which in vitro, preclin. pharmacokinetic data and oral single-dose human pharmacokinetic data were available.  Five predictive strategies, involving either allometry or use of unbound intrinsic clearance from microsomes or hepatocytes, were then compared for their ability to predict human oral clearance, half-life through predictions of systemic clearance, vol. of distribution, and bioavailability.  Use of a single-species scaling approach with rat, dog, or monkey was as accurate as or more accurate than using multiple-species allometry.  For those compds. cleared almost exclusively by P 450-mediated pathways, scaling from human liver microsomes was as predictive as single-species scaling of clearance based on data from rat, dog, or monkey.  These data suggest that use of predictive methods involving either single-species in vivo data or in vitro human liver microsomes can quant. predict human in vivo pharmacokinetics and suggest the possibility of streamlining the predictive methodol. through use of a single species or use only of human in vitro microsomal prepns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg67HcwS4O4LVg90H21EOLACvtfcHk0lj4pFgMZ-reWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D&md5=a0941d53fe43392f8fb1562ee546705e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1177%2F0091270009333209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009333209%26sid%3Dliteratum%253Aachs%26aulast%3DHosea%26aufirst%3DN.%2BA.%26aulast%3DCollard%26aufirst%3DW.%2BT.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DFang%26aufirst%3DR.%2BX.%26aulast%3DJones%26aufirst%3DH.%26aulast%3DKakar%26aufirst%3DS.%2BM.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DBeaumont%26aufirst%3DK.%26atitle%3DPrediction%2520of%2520human%2520pharmacokinetics%2520from%2520preclinical%2520information%253A%2520comparative%2520accuracy%2520of%2520quantitative%2520prediction%2520approaches%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D513%26epage%3D533%26doi%3D10.1177%2F0091270009333209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 41 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Maria S. Brown, Michaella A. Caporello, Adam E. Goetz, Amber M. Johnson, Kris N. Jones, Kevin M. Knopf, Samir A. Kulkarni, Taegyo Lee, Bryan Li, Cuong V. Lu, Javier Magano, Angela L. A. Puchlopek-Dermenci, Giselle P. Reyes, Sally Gut Ruggeri, Lulin Wei, Gerald A. Weisenburger, Richard A. Wisdom, <span class="NLM_string-name hlFld-ContribAuthor">Mengtan Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Streamlined Synthesis of a Bicyclic Amine Moiety Using an Enzymatic Amidation and Identification of a Novel Solid Form. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2021,</strong> <em>25 </em>
                                    (6)
                                     , 1419-1430. <a href="https://doi.org/10.1021/acs.oprd.1c00120" title="DOI URL">https://doi.org/10.1021/acs.oprd.1c00120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.1c00120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.1c00120%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DStreamlined%252BSynthesis%252Bof%252Ba%252BBicyclic%252BAmine%252BMoiety%252BUsing%252Ban%252BEnzymatic%252BAmidation%252Band%252BIdentification%252Bof%252Ba%252BNovel%252BSolid%252BForm%26aulast%3DBrown%26aufirst%3DMaria%2BS.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D06042021%26date%3D27052021%26volume%3D25%26issue%3D6%26spage%3D1419%26epage%3D1430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mingsong Shi, Lun Wang, Penghui Li, Jiang Liu, Lijuan Chen, <span class="NLM_string-name hlFld-ContribAuthor">Dingguo Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Dasatinib–SIK2 Binding Elucidated by Homology Modeling, Molecular Docking, and Dynamics Simulations. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2021,</strong> <em>6 </em>
                                    (16)
                                     , 11025-11038. <a href="https://doi.org/10.1021/acsomega.1c00947" title="DOI URL">https://doi.org/10.1021/acsomega.1c00947</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.1c00947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.1c00947%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DDasatinib%2525E2%252580%252593SIK2%252BBinding%252BElucidated%252Bby%252BHomology%252BModeling%25252C%252BMolecular%252BDocking%25252C%252Band%252BDynamics%252BSimulations%26aulast%3DShi%26aufirst%3DMingsong%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D21022021%26date%3D06042021%26date%3D15042021%26volume%3D6%26issue%3D16%26spage%3D11025%26epage%3D11038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Aaron F. Baldwin, Michaella A. Caporello, Guoyong Chen, Adam E. Goetz, Weifeng Hu, Chengfeng Jin, Kevin M. Knopf, Zhifeng Li, Cuong V. Lu, Sebastien Monfette, Angela L. A. Puchlopek-Dermenci, <span class="NLM_string-name hlFld-ContribAuthor">Feng Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Kilogram-Scale Preparation of an Aminopyrazole Building Block via Copper-Catalyzed Aryl Amidation. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2021,</strong> <em>25 </em>
                                    (4)
                                     , 1065-1073. <a href="https://doi.org/10.1021/acs.oprd.1c00066" title="DOI URL">https://doi.org/10.1021/acs.oprd.1c00066</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.1c00066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.1c00066%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DKilogram-Scale%252BPreparation%252Bof%252Ban%252BAminopyrazole%252BBuilding%252BBlock%252Bvia%252BCopper-Catalyzed%252BAryl%252BAmidation%26aulast%3DBaldwin%26aufirst%3DAaron%2BF.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D22022021%26date%3D06042021%26volume%3D25%26issue%3D4%26spage%3D1065%26epage%3D1073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chufeng Zhang, Wenyan Qi, Yong Li, Minghai Tang, Tao Yang, Kongjun Liu, Yong Chen, Dexin Deng, Mingli Xiang, <span class="NLM_string-name hlFld-ContribAuthor">Lijuan Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (4)
                                     , 1966-1988. <a href="https://doi.org/10.1021/acs.jmedchem.0c01468" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01468</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01468%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B3-%2525284-%2525282-%252528%2525281H-Indol-5-yl%252529amino%252529-5-fluoropyrimidin-4-yl%252529-1H-pyrazol-1-yl%252529propanenitrile%252BDerivatives%252Bas%252BSelective%252BTYK2%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BInflammatory%252BBowel%252BDisease%26aulast%3DZhang%26aufirst%3DChufeng%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D28082020%26date%3D16022021%26volume%3D64%26issue%3D4%26spage%3D1966%26epage%3D1988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chunjian Liu, James Lin, Charles Langevine, Daniel Smith, Jianqing Li, John S. Tokarski, Javed Khan, Max Ruzanov, Joann Strnad, Adriana Zupa-Fernandez, Lihong Cheng, Kathleen M. Gillooly, David Shuster, Yifan Zhang, Anil Thankappan, Kim W. McIntyre, Charu Chaudhry, Paul A. Elzinga, Manoj Chiney, Anjaneya Chimalakonda, Louis J. Lombardo, John E. Macor, Percy H. Carter, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">David S. Weinstein</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 677-694. <a href="https://doi.org/10.1021/acs.jmedchem.0c01698" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01698</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01698%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBMS-986202%25253A%252BA%252BClinical%252BTyk2%252BInhibitor%252Bthat%252BBinds%252Bto%252BTyk2%252BJH2%26aulast%3DLiu%26aufirst%3DChunjian%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D28092020%26date%3D28122020%26volume%3D64%26issue%3D1%26spage%3D677%26epage%3D694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Brian S. Gerstenberger, Catherine Ambler, Eric P. Arnold, Mary-Ellen Banker, Matthew F. Brown, James D. Clark, Alpay Dermenci, Martin E. Dowty, Andrew Fensome, Susan Fish, Matthew M. Hayward, Martin Hegen, Brett D. Hollingshead, John D. Knafels, David W. Lin, Tsung H. Lin, Dafydd R. Owen, Eddine Saiah, Raman Sharma, Felix F. Vajdos, Li Xing, Xiaojing Yang, Xin Yang, <span class="NLM_string-name hlFld-ContribAuthor">Stephen W. Wright</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13561-13577. <a href="https://doi.org/10.1021/acs.jmedchem.0c00948" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00948</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00948%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BTyrosine%252BKinase%252B2%252B%252528TYK2%252529%252BInhibitor%252B%252528PF-06826647%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%26aulast%3DGerstenberger%26aufirst%3DBrian%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03062020%26date%3D25082020%26date%3D05082020%26volume%3D63%26issue%3D22%26spage%3D13561%26epage%3D13577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Debasmita Saha, Anupreet Kharbanda, Wei Yan, Naga Rajiv Lakkaniga, Brendan Frett, <span class="NLM_string-name hlFld-ContribAuthor">Hong-Yu Li</span>. </span><span class="cited-content_cbyCitation_article-title">The Exploration of Chirality for Improved Druggability within the Human Kinome. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (2)
                                     , 441-469. <a href="https://doi.org/10.1021/acs.jmedchem.9b00640" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00640%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BExploration%252Bof%252BChirality%252Bfor%252BImproved%252BDruggability%252Bwithin%252Bthe%252BHuman%252BKinome%26aulast%3DSaha%26aufirst%3DDebasmita%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D15042019%26date%3D09102019%26date%3D24092019%26volume%3D63%26issue%3D2%26spage%3D441%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sébastien L. Degorce, Rana Anjum, Andrew Bloecher, Rodrigo J. Carbajo, Keith S. Dillman, Lisa Drew, Christopher T. Halsall, Eva M. Lenz, Nicola A. Lindsay, Michele F. Mayo, Jennifer H. Pink, Graeme R. Robb, Alan Rosen, James S. Scott, <span class="NLM_string-name hlFld-ContribAuthor">Yafeng Xue</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88L265P Mutant Diffuse Large B Cell Lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (21)
                                     , 9918-9930. <a href="https://doi.org/10.1021/acs.jmedchem.9b01346" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01346</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01346%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BSeries%252Bof%252B5-Azaquinazolines%252Bas%252BOrally%252BEfficacious%252BIRAK4%252BInhibitors%252BTargeting%252BMyD88L265P%252BMutant%252BDiffuse%252BLarge%252BB%252BCell%252BLymphoma%26aulast%3DDegorce%26aufirst%3DS%25C3%25A9bastien%2BL.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15082019%26date%3D01112019%26date%3D17102019%26volume%3D62%26issue%3D21%26spage%3D9918%26epage%3D9930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ryan Moslin, Yanlei Zhang, Stephen T. Wrobleski, Shuqun Lin, Michael Mertzman, Steven Spergel, John S. Tokarski, Joann Strnad, Kathleen Gillooly, Kim W. McIntyre, Adriana Zupa-Fernandez, Lihong Cheng, Huadong Sun, Charu Chaudhry, Christine Huang, Celia D’Arienzo, Elizabeth Heimrich, Xiaoxia Yang, Jodi K. Muckelbauer, ChiehYing Chang, Jeffrey Tredup, Dawn Mulligan, Dianlin Xie, Nelly Aranibar, Manoj Chiney, James R. Burke, Louis Lombardo, Percy H. Carter, <span class="NLM_string-name hlFld-ContribAuthor">David S. Weinstein</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 8953-8972. <a href="https://doi.org/10.1021/acs.jmedchem.9b00443" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00443</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00443%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BN-Methyl%252BNicotinamide%252Band%252BN-Methyl%252BPyridazine-3-Carboxamide%252BPseudokinase%252BDomain%252BLigands%252Bas%252BHighly%252BSelective%252BAllosteric%252BInhibitors%252Bof%252BTyrosine%252BKinase%252B2%252B%252528TYK2%252529%26aulast%3DMoslin%26aufirst%3DRyan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D17072019%26volume%3D62%26issue%3D20%26spage%3D8953%26epage%3D8972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Stephen T. Wrobleski, Ryan Moslin, Shuqun Lin, Yanlei Zhang, Steven Spergel, James Kempson, John S. Tokarski, Joann Strnad, Adriana Zupa-Fernandez, Lihong Cheng, David Shuster, Kathleen Gillooly, Xiaoxia Yang, Elizabeth Heimrich, Kim W. McIntyre, Charu Chaudhry, Javed Khan, Max Ruzanov, Jeffrey Tredup, Dawn Mulligan, Dianlin Xie, Huadong Sun, Christine Huang, Celia D’Arienzo, Nelly Aranibar, Manoj Chiney, Anjaneya Chimalakonda, William J. Pitts, Louis Lombardo, Percy H. Carter, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">David S. Weinstein</span>. </span><span class="cited-content_cbyCitation_article-title">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 8973-8995. <a href="https://doi.org/10.1021/acs.jmedchem.9b00444" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00444</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00444%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHighly%252BSelective%252BInhibition%252Bof%252BTyrosine%252BKinase%252B2%252B%252528TYK2%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%25253A%252BDiscovery%252Bof%252Bthe%252BAllosteric%252BInhibitor%252BBMS-986165%26aulast%3DWrobleski%26aufirst%3DStephen%2BT.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D18072019%26volume%3D62%26issue%3D20%26spage%3D8973%26epage%3D8995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Christel J Menet</span>. </span><span class="cited-content_cbyCitation_article-title">A Dual Inhibition, a Better Solution: Development of a JAK1/TYK2 inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (19)
                                     , 8594-8596. <a href="https://doi.org/10.1021/acs.jmedchem.8b01397" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01397</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01397%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BDual%252BInhibition%25252C%252Ba%252BBetter%252BSolution%25253A%252BDevelopment%252Bof%252Ba%252BJAK1%25252FTYK2%252Binhibitor%26aulast%3DMenet%26aufirst%3DChristel%2BJ%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D07092018%26date%3D25092018%26volume%3D61%26issue%3D19%26spage%3D8594%26epage%3D8596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kajal  Sharma</span>, <span class="hlFld-ContribAuthor ">Shalki  Choudhary</span>, <span class="hlFld-ContribAuthor ">Om  Silakari</span>. </span><span class="cited-content_cbyCitation_article-title">Portraying molecular modulation and therapeutic aspects of psoriasis: Retrospection and current status. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1243 </em>, 130770. <a href="https://doi.org/10.1016/j.molstruc.2021.130770" title="DOI URL">https://doi.org/10.1016/j.molstruc.2021.130770</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2021.130770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2021.130770%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DPortraying%252Bmolecular%252Bmodulation%252Band%252Btherapeutic%252Baspects%252Bof%252Bpsoriasis%25253A%252BRetrospection%252Band%252Bcurrent%252Bstatus%26aulast%3DSharma%26aufirst%3DKajal%26date%3D2021%26volume%3D1243%26spage%3D130770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvio  Danese</span>, <span class="hlFld-ContribAuthor ">Laurent  Peyrin-Biroulet</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise. </span><span class="cited-content_cbyCitation_journal-name">Inflammatory Bowel Diseases</span><span> <strong>2021,</strong> <em>8 </em><a href="https://doi.org/10.1093/ibd/izab135" title="DOI URL">https://doi.org/10.1093/ibd/izab135</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/ibd/izab135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fibd%2Fizab135%26sid%3Dliteratum%253Aachs%26jtitle%3DInflammatory%2520Bowel%2520Diseases%26atitle%3DSelective%252BTyrosine%252BKinase%252B2%252BInhibition%252Bfor%252BTreatment%252Bof%252BInflammatory%252BBowel%252BDisease%25253A%252BNew%252BHope%252Bon%252Bthe%252BRise%26aulast%3DDanese%26aufirst%3DSilvio%26date%3D2021%26date%3D2021%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luke A.  Greenhough</span>, <span class="hlFld-ContribAuthor ">Gabriella  Clarke</span>, <span class="hlFld-ContribAuthor ">Alexander N.  Phillipou</span>, <span class="hlFld-ContribAuthor ">Faith  Mazani</span>, <span class="hlFld-ContribAuthor ">Bhumika  Karamshi</span>, <span class="hlFld-ContribAuthor ">Sam  Rowe</span>, <span class="hlFld-ContribAuthor ">Paul  Rowland</span>, <span class="hlFld-ContribAuthor ">Cassie  Messenger</span>, <span class="hlFld-ContribAuthor ">Carl P.  Haslam</span>, <span class="hlFld-ContribAuthor ">Ryan P.  Bingham</span>, <span class="hlFld-ContribAuthor ">Peter D.  Craggs</span>. </span><span class="cited-content_cbyCitation_article-title">Reducing False Positives through the Application of Fluorescence Lifetime Technology: A Comparative Study Using TYK2 Kinase as a Model System. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2021,</strong> <em>26 </em>
                                    (5)
                                     , 663-675. <a href="https://doi.org/10.1177/24725552211002472" title="DOI URL">https://doi.org/10.1177/24725552211002472</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/24725552211002472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F24725552211002472%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DReducing%252BFalse%252BPositives%252Bthrough%252Bthe%252BApplication%252Bof%252BFluorescence%252BLifetime%252BTechnology%25253A%252BA%252BComparative%252BStudy%252BUsing%252BTYK2%252BKinase%252Bas%252Ba%252BModel%252BSystem%26aulast%3DGreenhough%26aufirst%3DLuke%2BA.%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D5%26spage%3D663%26epage%3D675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert M.  Borzilleri</span>, <span class="hlFld-ContribAuthor ">Amy C.  Hart</span>, <span class="hlFld-ContribAuthor ">Ryan  Moslin</span>, <span class="hlFld-ContribAuthor ">John S.  Tokarski</span>, <span class="hlFld-ContribAuthor ">Stephen T.  Wrobleski</span>. </span><span class="cited-content_cbyCitation_article-title">JAK
              Family Inhibitors for Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-86. <a href="https://doi.org/10.1002/0471266949.bmc279" title="DOI URL">https://doi.org/10.1002/0471266949.bmc279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc279%26sid%3Dliteratum%253Aachs%26atitle%3DJAK%252BFamily%252BInhibitors%252Bfor%252BAutoimmune%252BDiseases%26aulast%3DBorzilleri%26aufirst%3DRobert%2BM.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D86%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonie C S  De Vries</span>, <span class="hlFld-ContribAuthor ">Mohammed  Ghiboub</span>, <span class="hlFld-ContribAuthor ">Patricia H P  van Hamersveld</span>, <span class="hlFld-ContribAuthor ">Olaf  Welting</span>, <span class="hlFld-ContribAuthor ">Caroline  Verseijden</span>, <span class="hlFld-ContribAuthor ">Matthew J  Bell</span>, <span class="hlFld-ContribAuthor ">Inmaculada  Rioja</span>, <span class="hlFld-ContribAuthor ">Rabinder K  Prinjha</span>, <span class="hlFld-ContribAuthor ">Pim J  Koelink</span>, <span class="hlFld-ContribAuthor ">Birgit  Strobl</span>, <span class="hlFld-ContribAuthor ">Mathias  Müller</span>, <span class="hlFld-ContribAuthor ">Geert R  D’Haens</span>, <span class="hlFld-ContribAuthor ">Manon E  Wildenberg</span>, <span class="hlFld-ContribAuthor ">Wouter J  De Jonge</span>. </span><span class="cited-content_cbyCitation_article-title">Tyrosine Kinase 2 Signalling Drives Pathogenic T cells in Colitis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Crohn's and Colitis</span><span> <strong>2021,</strong> <em>15 </em>
                                    (4)
                                     , 617-630. <a href="https://doi.org/10.1093/ecco-jcc/jjaa199" title="DOI URL">https://doi.org/10.1093/ecco-jcc/jjaa199</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/ecco-jcc/jjaa199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fecco-jcc%2Fjjaa199%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Crohn%2527s%2520and%2520Colitis%26atitle%3DTyrosine%252BKinase%252B2%252BSignalling%252BDrives%252BPathogenic%252BT%252Bcells%252Bin%252BColitis%26aulast%3DDe%2BVries%26aufirst%3DLeonie%2BC%2BS%26date%3D2021%26date%3D2020%26volume%3D15%26issue%3D4%26spage%3D617%26epage%3D630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiamin  Zheng</span>, <span class="hlFld-ContribAuthor ">Jun  Wu</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Hong C.  Shen</span>, <span class="hlFld-ContribAuthor ">Ge  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127862. <a href="https://doi.org/10.1016/j.bmcl.2021.127862" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127862%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall%252Bmolecule%252Bapproaches%252Bto%252Btreat%252Bautoimmune%252Band%252Binflammatory%252Bdiseases%252B%252528Part%252BI%252529%25253A%252BKinase%252Binhibitors%26aulast%3DZheng%26aufirst%3DJiamin%26date%3D2021%26volume%3D38%26spage%3D127862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher R.  Donnelly</span>, <span class="hlFld-ContribAuthor ">Changyu  Jiang</span>, <span class="hlFld-ContribAuthor ">Amanda S.  Andriessen</span>, <span class="hlFld-ContribAuthor ">Kaiyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Zilong  Wang</span>, <span class="hlFld-ContribAuthor ">Huiping  Ding</span>, <span class="hlFld-ContribAuthor ">Junli  Zhao</span>, <span class="hlFld-ContribAuthor ">Xin  Luo</span>, <span class="hlFld-ContribAuthor ">Michael S.  Lee</span>, <span class="hlFld-ContribAuthor ">Yu L.  Lei</span>, <span class="hlFld-ContribAuthor ">William  Maixner</span>, <span class="hlFld-ContribAuthor ">Mei-Chuan  Ko</span>, <span class="hlFld-ContribAuthor ">Ru-Rong  Ji</span>. </span><span class="cited-content_cbyCitation_article-title">STING controls nociception via type I interferon signalling in sensory neurons. </span><span class="cited-content_cbyCitation_journal-name">Nature</span><span> <strong>2021,</strong> <em>591 </em>
                                    (7849)
                                     , 275-280. <a href="https://doi.org/10.1038/s41586-020-03151-1" title="DOI URL">https://doi.org/10.1038/s41586-020-03151-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41586-020-03151-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41586-020-03151-1%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%26atitle%3DSTING%252Bcontrols%252Bnociception%252Bvia%252Btype%252BI%252Binterferon%252Bsignalling%252Bin%252Bsensory%252Bneurons%26aulast%3DDonnelly%26aufirst%3DChristopher%2BR.%26date%3D2021%26date%3D2021%26volume%3D591%26issue%3D7849%26spage%3D275%26epage%3D280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brett  King</span>, <span class="hlFld-ContribAuthor ">Emma  Guttman-Yassky</span>, <span class="hlFld-ContribAuthor ">Elena  Peeva</span>, <span class="hlFld-ContribAuthor ">Anindita  Banerjee</span>, <span class="hlFld-ContribAuthor ">Rodney  Sinclair</span>, <span class="hlFld-ContribAuthor ">Ana B.  Pavel</span>, <span class="hlFld-ContribAuthor ">Linda  Zhu</span>, <span class="hlFld-ContribAuthor ">Lori Ann  Cox</span>, <span class="hlFld-ContribAuthor ">Brittany  Craiglow</span>, <span class="hlFld-ContribAuthor ">Linda  Chen</span>, <span class="hlFld-ContribAuthor ">Christopher  Banfield</span>, <span class="hlFld-ContribAuthor ">Karen  Page</span>, <span class="hlFld-ContribAuthor ">Weidong  Zhang</span>, <span class="hlFld-ContribAuthor ">Michael S.  Vincent</span>. </span><span class="cited-content_cbyCitation_article-title">A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Academy of Dermatology</span><span> <strong>2021,</strong> <em>128 </em><a href="https://doi.org/10.1016/j.jaad.2021.03.050" title="DOI URL">https://doi.org/10.1016/j.jaad.2021.03.050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jaad.2021.03.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jaad.2021.03.050%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Academy%2520of%2520Dermatology%26atitle%3DA%252Bphase%252B2a%252Brandomized%25252C%252Bplacebo-controlled%252Bstudy%252Bto%252Bevaluate%252Bthe%252Befficacy%252Band%252Bsafety%252Bof%252Bthe%252Boral%252BJanus%252Bkinase%252Binhibitors%252Britlecitinib%252Band%252Bbrepocitinib%252Bin%252Balopecia%252Bareata%25253A%252B24-week%252Bresults%26aulast%3DKing%26aufirst%3DBrett%26date%3D2021%26volume%3D128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuang S.  Wu</span>, <span class="hlFld-ContribAuthor ">Kathy  Fernando</span>, <span class="hlFld-ContribAuthor ">Charlotte  Allerton</span>, <span class="hlFld-ContribAuthor ">Kathrin U.  Jansen</span>, <span class="hlFld-ContribAuthor ">Michael S.  Vincent</span>, <span class="hlFld-ContribAuthor ">Mikael  Dolsten</span>. </span><span class="cited-content_cbyCitation_article-title">Reviving an R&D pipeline: a step change in the Phase II success rate. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2021,</strong> <em>26 </em>
                                    (2)
                                     , 308-314. <a href="https://doi.org/10.1016/j.drudis.2020.10.019" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.10.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.10.019%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DReviving%252Ban%252BR%252526D%252Bpipeline%25253A%252Ba%252Bstep%252Bchange%252Bin%252Bthe%252BPhase%252BII%252Bsuccess%252Brate%26aulast%3DWu%26aufirst%3DShuang%2BS.%26date%3D2021%26volume%3D26%26issue%3D2%26spage%3D308%26epage%3D314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kymbat S  Adekenova</span>, <span class="hlFld-ContribAuthor ">Peter B  Wyatt</span>, <span class="hlFld-ContribAuthor ">Sergazy M  Adekenov</span>. </span><span class="cited-content_cbyCitation_article-title">The preparation and properties of 1,1-difluorocyclopropane derivatives. </span><span class="cited-content_cbyCitation_journal-name">Beilstein Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>17 </em>, 245-272. <a href="https://doi.org/10.3762/bjoc.17.25" title="DOI URL">https://doi.org/10.3762/bjoc.17.25</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3762/bjoc.17.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3762%2Fbjoc.17.25%26sid%3Dliteratum%253Aachs%26jtitle%3DBeilstein%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DThe%252Bpreparation%252Band%252Bproperties%252Bof%252B1%25252C1-difluorocyclopropane%252Bderivatives%26aulast%3DAdekenova%26aufirst%3DKymbat%2BS%26date%3D2021%26date%3D2021%26volume%3D17%26spage%3D245%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cristian  Hernandez-Rocha</span>, <span class="hlFld-ContribAuthor ">Niels  Vande Casteele</span>. </span><span class="cited-content_cbyCitation_article-title">JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Pharmacology</span><span> <strong>2020,</strong> <em>55 </em>, 99-109. <a href="https://doi.org/10.1016/j.coph.2020.10.010" title="DOI URL">https://doi.org/10.1016/j.coph.2020.10.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.coph.2020.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.coph.2020.10.010%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Pharmacology%26atitle%3DJAK%252Binhibitors%25253A%252Bcurrent%252Bposition%252Bin%252Btreatment%252Bstrategies%252Bfor%252Buse%252Bin%252Binflammatory%252Bbowel%252Bdisease%26aulast%3DHernandez-Rocha%26aufirst%3DCristian%26date%3D2020%26volume%3D55%26spage%3D99%26epage%3D109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seth B.  Forman</span>, <span class="hlFld-ContribAuthor ">David M.  Pariser</span>, <span class="hlFld-ContribAuthor ">Yves  Poulin</span>, <span class="hlFld-ContribAuthor ">Michael S.  Vincent</span>, <span class="hlFld-ContribAuthor ">Steven A.  Gilbert</span>, <span class="hlFld-ContribAuthor ">Elizabeth M.  Kieras</span>, <span class="hlFld-ContribAuthor ">Ruolun  Qiu</span>, <span class="hlFld-ContribAuthor ">Dahong  Yu</span>, <span class="hlFld-ContribAuthor ">Jocelyne  Papacharalambous</span>, <span class="hlFld-ContribAuthor ">Christopher  Tehlirian</span>, <span class="hlFld-ContribAuthor ">Elena  Peeva</span>. </span><span class="cited-content_cbyCitation_article-title">TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial. </span><span class="cited-content_cbyCitation_journal-name">Journal of Investigative Dermatology</span><span> <strong>2020,</strong> <em>140 </em>
                                    (12)
                                     , 2359-2370.e5. <a href="https://doi.org/10.1016/j.jid.2020.03.962" title="DOI URL">https://doi.org/10.1016/j.jid.2020.03.962</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jid.2020.03.962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jid.2020.03.962%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Investigative%2520Dermatology%26atitle%3DTYK2%25252FJAK1%252BInhibitor%252BPF-06700841%252Bin%252BPatients%252Bwith%252BPlaque%252BPsoriasis%25253A%252BPhase%252BIIa%25252C%252BRandomized%25252C%252BDouble-Blind%25252C%252BPlacebo-Controlled%252BTrial%26aulast%3DForman%26aufirst%3DSeth%2BB.%26date%3D2020%26volume%3D140%26issue%3D12%26spage%3D2359%26epage%3D2370.e5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian S.  Gerstenberger</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Banker</span>, <span class="hlFld-ContribAuthor ">James D.  Clark</span>, <span class="hlFld-ContribAuthor ">Martin E.  Dowty</span>, <span class="hlFld-ContribAuthor ">Andrew  Fensome</span>, <span class="hlFld-ContribAuthor ">Roger  Gifford</span>, <span class="hlFld-ContribAuthor ">Matthew C.  Griffor</span>, <span class="hlFld-ContribAuthor ">Martin  Hegen</span>, <span class="hlFld-ContribAuthor ">Brett D.  Hollingshead</span>, <span class="hlFld-ContribAuthor ">John D.  Knafels</span>, <span class="hlFld-ContribAuthor ">Tsung H.  Lin</span>, <span class="hlFld-ContribAuthor ">James F.  Smith</span>, <span class="hlFld-ContribAuthor ">Felix F.  Vajdos</span>. </span><span class="cited-content_cbyCitation_article-title">Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-65762-y" title="DOI URL">https://doi.org/10.1038/s41598-020-65762-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-65762-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-65762-y%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DDemonstration%252Bof%252BIn%252BVitro%252Bto%252BIn%252BVivo%252BTranslation%252Bof%252Ba%252BTYK2%252BInhibitor%252BThat%252BShows%252BCross%252BSpecies%252BPotency%252BDifferences%26aulast%3DGerstenberger%26aufirst%3DBrian%2BS.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giulia  Roda</span>, <span class="hlFld-ContribAuthor ">Arianna  Dal Buono</span>, <span class="hlFld-ContribAuthor ">Marjorie  Argollo</span>, <span class="hlFld-ContribAuthor ">Silvio  Danese</span>. </span><span class="cited-content_cbyCitation_article-title">JAK selectivity: more precision less troubles. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Gastroenterology & Hepatology</span><span> <strong>2020,</strong> <em>14 </em>
                                    (9)
                                     , 789-796. <a href="https://doi.org/10.1080/17474124.2020.1780120" title="DOI URL">https://doi.org/10.1080/17474124.2020.1780120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17474124.2020.1780120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17474124.2020.1780120%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Gastroenterology%2520%2526%2520Hepatology%26atitle%3DJAK%252Bselectivity%25253A%252Bmore%252Bprecision%252Bless%252Btroubles%26aulast%3DRoda%26aufirst%3DGiulia%26date%3D2020%26date%3D2020%26volume%3D14%26issue%3D9%26spage%3D789%26epage%3D796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karen M.  Page</span>, <span class="hlFld-ContribAuthor ">Mayte  Suarez-Farinas</span>, <span class="hlFld-ContribAuthor ">Maria  Suprun</span>, <span class="hlFld-ContribAuthor ">Weidong  Zhang</span>, <span class="hlFld-ContribAuthor ">Sandra  Garcet</span>, <span class="hlFld-ContribAuthor ">Judilyn  Fuentes-Duculan</span>, <span class="hlFld-ContribAuthor ">Xuan  Li</span>, <span class="hlFld-ContribAuthor ">Matthew  Scaramozza</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Kieras</span>, <span class="hlFld-ContribAuthor ">Christopher  Banfield</span>, <span class="hlFld-ContribAuthor ">James D.  Clark</span>, <span class="hlFld-ContribAuthor ">Andrew  Fensome</span>, <span class="hlFld-ContribAuthor ">James G.  Krueger</span>, <span class="hlFld-ContribAuthor ">Elena  Peeva</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Investigative Dermatology</span><span> <strong>2020,</strong> <em>140 </em>
                                    (8)
                                     , 1546-1555.e4. <a href="https://doi.org/10.1016/j.jid.2019.11.027" title="DOI URL">https://doi.org/10.1016/j.jid.2019.11.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jid.2019.11.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jid.2019.11.027%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Investigative%2520Dermatology%26atitle%3DMolecular%252Band%252BCellular%252BResponses%252Bto%252Bthe%252BTYK2%25252FJAK1%252BInhibitor%252BPF-06700841%252BReveal%252BReduction%252Bof%252BSkin%252BInflammation%252Bin%252BPlaque%252BPsoriasis%26aulast%3DPage%26aufirst%3DKaren%2BM.%26date%3D2020%26volume%3D140%26issue%3D8%26spage%3D1546%26epage%3D1555.e4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pavine L C  Lefevre</span>, <span class="hlFld-ContribAuthor ">Niels  Vande Casteele</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Crohn's and Colitis</span><span> <strong>2020,</strong> <em>14 </em>
                                    (Supplement_2)
                                     , S725-S736. <a href="https://doi.org/10.1093/ecco-jcc/jjaa014" title="DOI URL">https://doi.org/10.1093/ecco-jcc/jjaa014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/ecco-jcc/jjaa014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fecco-jcc%2Fjjaa014%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Crohn%2527s%2520and%2520Colitis%26atitle%3DClinical%252BPharmacology%252Bof%252BJanus%252BKinase%252BInhibitors%252Bin%252BInflammatory%252BBowel%252BDisease%26aulast%3DLefevre%26aufirst%3DPavine%2BL%2BC%26date%3D2020%26date%3D2020%26volume%3D14%26issue%3DSupplement_2%26spage%3DS725%26epage%3DS736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gerhard  Rogler</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy of JAK inhibitors in Crohn’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Crohn's and Colitis</span><span> <strong>2020,</strong> <em>14 </em>
                                    (Supplement_2)
                                     , S746-S754. <a href="https://doi.org/10.1093/ecco-jcc/jjz186" title="DOI URL">https://doi.org/10.1093/ecco-jcc/jjz186</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/ecco-jcc/jjz186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fecco-jcc%2Fjjz186%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Crohn%2527s%2520and%2520Colitis%26atitle%3DEfficacy%252Bof%252BJAK%252Binhibitors%252Bin%252BCrohn%2525E2%252580%252599s%252BDisease%26aulast%3DRogler%26aufirst%3DGerhard%26date%3D2020%26date%3D2019%26volume%3D14%26issue%3DSupplement_2%26spage%3DS746%26epage%3DS754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kuan  Lu</span>, <span class="hlFld-ContribAuthor ">Weibin  Wu</span>, <span class="hlFld-ContribAuthor ">Cunlong  Zhang</span>, <span class="hlFld-ContribAuthor ">Zijian  Liu</span>, <span class="hlFld-ContribAuthor ">Boren  Xiao</span>, <span class="hlFld-ContribAuthor ">Zigao  Yuan</span>, <span class="hlFld-ContribAuthor ">Anqi  Li</span>, <span class="hlFld-ContribAuthor ">Dawei  Chen</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (14)
                                     , 127225. <a href="https://doi.org/10.1016/j.bmcl.2020.127225" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127225</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127225%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Btriazolo%252B%25255B1%25252C5-a%25255D%252Bpyridine%252Bderivatives%252Bas%252Bnovel%252BJAK1%25252F2%252Binhibitors%26aulast%3DLu%26aufirst%3DKuan%26date%3D2020%26volume%3D30%26issue%3D14%26spage%3D127225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Azucena  Salas</span>, <span class="hlFld-ContribAuthor ">Cristian  Hernandez-Rocha</span>, <span class="hlFld-ContribAuthor ">Marjolijn  Duijvestein</span>, <span class="hlFld-ContribAuthor ">William  Faubion</span>, <span class="hlFld-ContribAuthor ">Dermot  McGovern</span>, <span class="hlFld-ContribAuthor ">Severine  Vermeire</span>, <span class="hlFld-ContribAuthor ">Stefania  Vetrano</span>, <span class="hlFld-ContribAuthor ">Niels  Vande Casteele</span>. </span><span class="cited-content_cbyCitation_article-title">JAK–STAT pathway targeting for the treatment of inflammatory bowel disease. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Gastroenterology & Hepatology</span><span> <strong>2020,</strong> <em>17 </em>
                                    (6)
                                     , 323-337. <a href="https://doi.org/10.1038/s41575-020-0273-0" title="DOI URL">https://doi.org/10.1038/s41575-020-0273-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41575-020-0273-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41575-020-0273-0%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Gastroenterology%2520%2526%2520Hepatology%26atitle%3DJAK%2525E2%252580%252593STAT%252Bpathway%252Btargeting%252Bfor%252Bthe%252Btreatment%252Bof%252Binflammatory%252Bbowel%252Bdisease%26aulast%3DSalas%26aufirst%3DAzucena%26date%3D2020%26date%3D2020%26volume%3D17%26issue%3D6%26spage%3D323%26epage%3D337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew  Fensome</span>, <span class="hlFld-ContribAuthor ">Catherine M.  Ambler</span>, <span class="hlFld-ContribAuthor ">Eric  Arnold</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Banker</span>, <span class="hlFld-ContribAuthor ">James D.  Clark</span>, <span class="hlFld-ContribAuthor ">Martin E.  Dowty</span>, <span class="hlFld-ContribAuthor ">Ivan V.  Efremov</span>, <span class="hlFld-ContribAuthor ">Andrew  Flick</span>, <span class="hlFld-ContribAuthor ">Brian S.  Gerstenberger</span>, <span class="hlFld-ContribAuthor ">Roger S.  Gifford</span>, <span class="hlFld-ContribAuthor ">Ariamala  Gopalsamy</span>, <span class="hlFld-ContribAuthor ">Martin  Hegen</span>, <span class="hlFld-ContribAuthor ">Jason  Jussif</span>, <span class="hlFld-ContribAuthor ">David C.  Limburg</span>, <span class="hlFld-ContribAuthor ">Tsung H.  Lin</span>, <span class="hlFld-ContribAuthor ">Betsy S.  Pierce</span>, <span class="hlFld-ContribAuthor ">Raman  Sharma</span>, <span class="hlFld-ContribAuthor ">John I.  Trujillo</span>, <span class="hlFld-ContribAuthor ">Felix F.  Vajdos</span>, <span class="hlFld-ContribAuthor ">Fabien  Vincent</span>, <span class="hlFld-ContribAuthor ">Zhao-Kui  Wan</span>, <span class="hlFld-ContribAuthor ">Li  Xing</span>, <span class="hlFld-ContribAuthor ">Xiaojing  Yang</span>, <span class="hlFld-ContribAuthor ">Xin  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (10)
                                     , 115481. <a href="https://doi.org/10.1016/j.bmc.2020.115481" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115481</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115481%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Boptimization%252Bof%252Ba%252Bseries%252Bof%252B4-%2525283-azabicyclo%25255B3.1.0%25255Dhexan-3-yl%252529pyrimidin-2-amines%25253A%252BDual%252Binhibitors%252Bof%252BTYK2%252Band%252BJAK1%26aulast%3DFensome%26aufirst%3DAndrew%26date%3D2020%26volume%3D28%26issue%3D10%26spage%3D115481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael L.  Frisoli</span>, <span class="hlFld-ContribAuthor ">Kingsley  Essien</span>, <span class="hlFld-ContribAuthor ">John E.  Harris</span>. </span><span class="cited-content_cbyCitation_article-title">Vitiligo: Mechanisms of Pathogenesis and Treatment. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Immunology</span><span> <strong>2020,</strong> <em>38 </em>
                                    (1)
                                     , 621-648. <a href="https://doi.org/10.1146/annurev-immunol-100919-023531" title="DOI URL">https://doi.org/10.1146/annurev-immunol-100919-023531</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-immunol-100919-023531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-immunol-100919-023531%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Immunology%26atitle%3DVitiligo%25253A%252BMechanisms%252Bof%252BPathogenesis%252Band%252BTreatment%26aulast%3DFrisoli%26aufirst%3DMichael%2BL.%26date%3D2020%26volume%3D38%26issue%3D1%26spage%3D621%26epage%3D648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuya  Li</span>, <span class="hlFld-ContribAuthor ">Fangping  Wan</span>, <span class="hlFld-ContribAuthor ">Hantao  Shu</span>, <span class="hlFld-ContribAuthor ">Tao  Jiang</span>, <span class="hlFld-ContribAuthor ">Dan  Zhao</span>, <span class="hlFld-ContribAuthor ">Jianyang  Zeng</span>. </span><span class="cited-content_cbyCitation_article-title">MONN: A Multi-objective Neural Network for Predicting Compound-Protein Interactions and Affinities. </span><span class="cited-content_cbyCitation_journal-name">Cell Systems</span><span> <strong>2020,</strong> <em>10 </em>
                                    (4)
                                     , 308-322.e11. <a href="https://doi.org/10.1016/j.cels.2020.03.002" title="DOI URL">https://doi.org/10.1016/j.cels.2020.03.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cels.2020.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cels.2020.03.002%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Systems%26atitle%3DMONN%25253A%252BA%252BMulti-objective%252BNeural%252BNetwork%252Bfor%252BPredicting%252BCompound-Protein%252BInteractions%252Band%252BAffinities%26aulast%3DLi%26aufirst%3DShuya%26date%3D2020%26volume%3D10%26issue%3D4%26spage%3D308%26epage%3D322.e11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengfei  Xu</span>, <span class="hlFld-ContribAuthor ">Pei  Shen</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Xi  Xu</span>, <span class="hlFld-ContribAuthor ">Raoling  Ge</span>, <span class="hlFld-ContribAuthor ">Xinying  Cheng</span>, <span class="hlFld-ContribAuthor ">Qiuyu  Chen</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">JuBo  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112155. <a href="https://doi.org/10.1016/j.ejmech.2020.112155" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112155%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DJanus%252Bkinases%252B%252528JAKs%252529%25253A%252BThe%252Befficient%252Btherapeutic%252Btargets%252Bfor%252Bautoimmune%252Bdiseases%252Band%252Bmyeloproliferative%252Bdisorders%26aulast%3DXu%26aufirst%3DPengfei%26date%3D2020%26volume%3D192%26spage%3D112155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashley  Jarvis</span>, <span class="hlFld-ContribAuthor ">Gilles  Ouvry</span>. </span><span class="cited-content_cbyCitation_article-title">Essential ingredients for rational drug design. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (20)
                                     , 126674. <a href="https://doi.org/10.1016/j.bmcl.2019.126674" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126674</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126674%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DEssential%252Bingredients%252Bfor%252Brational%252Bdrug%252Bdesign%26aulast%3DJarvis%26aufirst%3DAshley%26date%3D2019%26volume%3D29%26issue%3D20%26spage%3D126674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvio  Danese</span>, <span class="hlFld-ContribAuthor ">Marjorie  Argollo</span>, <span class="hlFld-ContribAuthor ">Catherine  Le Berre</span>, <span class="hlFld-ContribAuthor ">Laurent  Peyrin-Biroulet</span>. </span><span class="cited-content_cbyCitation_article-title">JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?. </span><span class="cited-content_cbyCitation_journal-name">Gut</span><span> <strong>2019,</strong> <em>68 </em>
                                    (10)
                                     , 1893-1899. <a href="https://doi.org/10.1136/gutjnl-2019-318448" title="DOI URL">https://doi.org/10.1136/gutjnl-2019-318448</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1136/gutjnl-2019-318448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1136%2Fgutjnl-2019-318448%26sid%3Dliteratum%253Aachs%26jtitle%3DGut%26atitle%3DJAK%252Bselectivity%252Bfor%252Binflammatory%252Bbowel%252Bdisease%252Btreatment%25253A%252Bdoes%252Bit%252Bclinically%252Bmatter%25253F%26aulast%3DDanese%26aufirst%3DSilvio%26date%3D2019%26date%3D2019%26volume%3D68%26issue%3D10%26spage%3D1893%26epage%3D1899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elham Y.  Al-Barghouthy</span>, <span class="hlFld-ContribAuthor ">Areej  Abuhammad</span>, <span class="hlFld-ContribAuthor ">Mutasem O.  Taha</span>. </span><span class="cited-content_cbyCitation_article-title">QSAR-guided pharmacophore modeling and subsequent virtual screening identify novel TYK2 inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2019,</strong> <em>28 </em>
                                    (9)
                                     , 1368-1387. <a href="https://doi.org/10.1007/s00044-019-02377-7" title="DOI URL">https://doi.org/10.1007/s00044-019-02377-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-019-02377-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-019-02377-7%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DQSAR-guided%252Bpharmacophore%252Bmodeling%252Band%252Bsubsequent%252Bvirtual%252Bscreening%252Bidentify%252Bnovel%252BTYK2%252Binhibitor%26aulast%3DAl-Barghouthy%26aufirst%3DElham%2BY.%26date%3D2019%26date%3D2019%26volume%3D28%26issue%3D9%26spage%3D1368%26epage%3D1387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kevin S.  Currie</span>, <span class="hlFld-ContribAuthor ">Leena  Patel</span>, <span class="hlFld-ContribAuthor ">Kassandra F.  Sedillo</span>. </span><span class="cited-content_cbyCitation_article-title">Small-molecule agents for the treatment of inflammatory bowel disease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (16)
                                     , 2034-2041. <a href="https://doi.org/10.1016/j.bmcl.2019.06.042" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.06.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.06.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.06.042%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall-molecule%252Bagents%252Bfor%252Bthe%252Btreatment%252Bof%252Binflammatory%252Bbowel%252Bdisease%26aulast%3DCurrie%26aufirst%3DKevin%2BS.%26date%3D2019%26volume%3D29%26issue%3D16%26spage%3D2034%26epage%3D2041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shanni  Hong</span>, <span class="hlFld-ContribAuthor ">Pi  Ding</span>, <span class="hlFld-ContribAuthor ">Yu  Luo</span>, <span class="hlFld-ContribAuthor ">Tian  Gao</span>, <span class="hlFld-ContribAuthor ">Ye  Zhang</span>, <span class="hlFld-ContribAuthor ">Renjun  Pei</span>. </span><span class="cited-content_cbyCitation_article-title">Aptamer‐integrated α‐Gal liposomes as bispecific agents to trigger immune response for killing tumor cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomedical Materials Research Part A</span><span> <strong>2019,</strong> <em>107 </em>
                                    (6)
                                     , 1176-1183. <a href="https://doi.org/10.1002/jbm.a.36609" title="DOI URL">https://doi.org/10.1002/jbm.a.36609</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jbm.a.36609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjbm.a.36609%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomedical%2520Materials%2520Research%2520Part%2520A%26atitle%3DAptamer%2525E2%252580%252590integrated%252B%2525CE%2525B1%2525E2%252580%252590Gal%252Bliposomes%252Bas%252Bbispecific%252Bagents%252Bto%252Btrigger%252Bimmune%252Bresponse%252Bfor%252Bkilling%252Btumor%252Bcells%26aulast%3DHong%26aufirst%3DShanni%26date%3D2019%26date%3D2019%26volume%3D107%26issue%3D6%26spage%3D1176%26epage%3D1183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Chen</span>, <span class="hlFld-ContribAuthor ">Pan  Jiang</span>, <span class="hlFld-ContribAuthor ">Jinsong  Li</span>, <span class="hlFld-ContribAuthor ">Zijian  Xie</span>, <span class="hlFld-ContribAuthor ">Yunhui  Xu</span>, <span class="hlFld-ContribAuthor ">Wei  Qu</span>, <span class="hlFld-ContribAuthor ">Feng  Feng</span>, <span class="hlFld-ContribAuthor ">Wenyuan  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Periplocin promotes wound healing through the activation of Src/ERK and PI3K/Akt pathways mediated by Na/K-ATPase. </span><span class="cited-content_cbyCitation_journal-name">Phytomedicine</span><span> <strong>2019,</strong> <em>57 </em>, 72-83. <a href="https://doi.org/10.1016/j.phymed.2018.12.015" title="DOI URL">https://doi.org/10.1016/j.phymed.2018.12.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phymed.2018.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phymed.2018.12.015%26sid%3Dliteratum%253Aachs%26jtitle%3DPhytomedicine%26atitle%3DPeriplocin%252Bpromotes%252Bwound%252Bhealing%252Bthrough%252Bthe%252Bactivation%252Bof%252BSrc%25252FERK%252Band%252BPI3K%25252FAkt%252Bpathways%252Bmediated%252Bby%252BNa%25252FK-ATPase%26aulast%3DChen%26aufirst%3DLei%26date%3D2019%26volume%3D57%26spage%3D72%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xingrui  He</span>, <span class="hlFld-ContribAuthor ">Xiabin  Chen</span>, <span class="hlFld-ContribAuthor ">Hancheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Tian  Xie</span>, <span class="hlFld-ContribAuthor ">Xiang-Yang  Ye</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2019,</strong> <em>29 </em>
                                    (2)
                                     , 137-149. <a href="https://doi.org/10.1080/13543776.2019.1567713" title="DOI URL">https://doi.org/10.1080/13543776.2019.1567713</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1567713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1567713%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DSelective%252BTyk2%252Binhibitors%252Bas%252Bpotential%252Btherapeutic%252Bagents%25253A%252Ba%252Bpatent%252Breview%252B%2525282015%2525E2%252580%2525932018%252529%26aulast%3DHe%26aufirst%3DXingrui%26date%3D2019%26date%3D2019%26volume%3D29%26issue%3D2%26spage%3D137%26epage%3D149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. JAK inhibitors on the market and in late stage clinical development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Basic mechanism of JAK/STAT mediated cytokine signaling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structure of compound <b>8</b> in complex with TYK2, resolved to 2.0 Å (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBK">6DBK</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. R-group nomenclature for 2,4-diamino pyrimidines <b>8</b>–<b>25</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures for compounds <b>11</b>–<b>15</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of compounds <b>16</b>–<b>19</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compounds <b>16</b> and <b>18</b> modeled in the ATP binding site of TYK2, based upon APO protein PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBK">6DBK</a>..</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures of acylated 3,8-diazabicyclo[3.2.1]octane derivatives <b>20</b>–<b>25</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (a) Crystal structure of <b>23</b> with TYK2 (2.37 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBM">6DBM</a>); spheres represent simulated apo waters, colored by Δ<i>H</i>: blue represents negative Δ<i>H</i> stable water, red represents positive Δ<i>H</i> unstable water. (b) End view of <b>23</b> looking toward the hinge of the protein, showing proximity to key simulated water molecules (spheres) W1, W3, and W12, colored by Δ<i>H</i> as in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>a. (c) Model of <b>25</b> bound to TYK2 based upon PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBM">6DBM</a>, showing proximity of fluorine atoms to electrostatically negative (red) region of the binding pocket formed by carbonyl oxygens of Asp-1041 and Asn-1028.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0010.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (a) <b>23</b> bound to JAK1 (2.48 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBN">6DBN</a>). Spheres represent simulated waters. colored by Δ<i>H</i>: blue represents negative Δ<i>H</i> stable water, and red represents positive Δ<i>H</i> unstable water. (b) End view showing proximity of simulated waters, and associated energy values, to the amide moiety of <b>23</b> bound to JAK1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0011.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Radial plot of cytokine inhibition IC<sub><i>xx</i></sub> relative to the IFNα IC<sub>80</sub> for compound <b>23</b>, derived from potency in human whole blood assays and predicted average daily human plasma drug concentration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0012.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Activity of compound <b>23</b> in the rat AIA model following a therapeutic dosing paradigm. Immunized rats were enrolled into groups and dosed with either: 30, 10, or 3 mg/kg <b>23</b> or vehicle PO. Compared to vehicle (left panel), treatment with PF-06700841 significantly reduced disease severity as measured by plethysmograph in the 30 mg/kg (Day 1 to 7), 10 mg/kg (Day 1 to 7), and 3 mg/kg (Day 2 to 7) dose groups (<i>p</i> ≤ 0.05, <i>t</i> test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0013.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of Diamine Analogs <b>8</b>–<b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TEA or DIPEA, 10–50 °C, 1–18 h, 47–96%; (b) (i) 4 N HCl, 10–20 °C, 15–16 h, (ii) cyclopropanecarboxylic acid or 2-cyanoacetic acid, HATU, DIPEA or TEA, rt, 15–60 h, 26–100%; (c) aryl amine, i-PrOH or dioxane, 1–16 h, 85–140 °C, 38–65%; (d) (i) aryl amine, Pd cat, Cs<sub>2</sub>CO<sub>3</sub> or NaOtBu, 100–145 °C, 0.5–4 h, 21–95%; (ii) 4 N HCl, 20–25 °C, 1–18 h, 86–99% (e) for amides, carboxylic acid, DIPEA or TEA, HATU, rt, 1–18 h, 18–89%; (f) for ureas, alkyl-1<i>H</i>-imidazole-1-carboxamide, EtOH, 60 °C, 3 h, 59–70%.</p></p></figure><figure data-id="sch2" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/medium/jm-2018-009177_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0014.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 3,8-Diazabicyclo[3.2.1]octane <b>23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00917/20181004/images/large/jm-2018-009177_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00917&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (<i>S</i>)-1-phenylethan-1-ol (1.2 equiv), DCC (1.2 equiv), DMAP (0.1 equiv), rt, 18 h, 72%; (b) 1 N NaOH (3 equiv), MeOH, rt, 1.5 h, 76%; (c) 2,4-dichloropyrimidine (1.1 equiv), TEA (1.3 equiv), MeOH, rt, 18 h, 71%; (d) 1-methyl-1<i>H</i>-pyrazol-4-ylamine hydrochloride (1.1 equiv), i-PrOH, MW 140 °C, 1 h, 99%; (e) <b>33</b> (1.2 equiv) HATU (1.2 equiv), DIPEA (2 equiv), DCM, rt, 18 h, 60%; (f) 2 N TsOH in H<sub>2</sub>O, MeCN, rt, overnight, 71%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62718" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62718" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 43 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liongue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, A. C.</span></span> <span> </span><span class="NLM_article-title">Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease</span>. <i>Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">2506</span>, <span class="refDoi"> DOI: 10.1016/j.molimm.2006.11.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1016%2Fj.molimm.2006.11.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=17208301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVSmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2007&pages=2497-2506&author=L.+A.+O%E2%80%99Sullivanauthor=C.+Liongueauthor=R.+S.+Lewisauthor=S.+E.+Stephensonauthor=A.+C.+Ward&title=Cytokine+receptor+signaling+through+the+Jak-Stat-Socs+pathway+in+disease&doi=10.1016%2Fj.molimm.2006.11.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease</span></div><div class="casAuthors">O'Sullivan, Lynda A.; Liongue, Clifford; Lewis, Rowena S.; Stephenson, Sarah E. M.; Ward, Alister C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2497-2506</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The complexity of multicellular organisms is dependent on systems enabling cells to respond to specific stimuli.  Cytokines and their receptors are one such system, whose perturbation can lead to a variety of disease states.  This review represents an overview of our current understanding of the cytokine receptors, Janus kinases (Jaks), Signal transducers and activators of transcription (Stats) and Suppressors of cytokine signaling (Socs), focusing on their contribution to diseases of an immune or hematol. nature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRJCsJ5di3XbVg90H21EOLACvtfcHk0lgACRrjmNXBAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVSmur8%253D&md5=0011026cc2b9be7e0d7cdb854aab300a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.molimm.2006.11.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molimm.2006.11.025%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DL.%2BA.%26aulast%3DLiongue%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DR.%2BS.%26aulast%3DStephenson%26aufirst%3DS.%2BE.%26aulast%3DWard%26aufirst%3DA.%2BC.%26atitle%3DCytokine%2520receptor%2520signaling%2520through%2520the%2520Jak-Stat-Socs%2520pathway%2520in%2520disease%26jtitle%3DMol.%2520Immunol.%26date%3D2007%26volume%3D44%26spage%3D2497%26epage%3D2506%26doi%3D10.1016%2Fj.molimm.2006.11.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1038%2Fnrd.2017.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=29104284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=843-862&author=D.+M.+Schwartzauthor=Y.+Kannoauthor=A.+Villarinoauthor=M.+Wardauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=JAK+inhibition+as+a+therapeutic+strategy+for+immune+and+inflammatory+diseases&doi=10.1038%2Fnrd.2017.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Kanno, Yuka; Villarino, Alejandro; Ward, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-862</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts to target their assocd. signalling pathways.  Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-mol. inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.  Building on the clin. success of first-generation jakinibs, second-generation compds. that claim to be more selective are currently undergoing development and proceeding to clin. trials.  However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs.  This Review discusses the biol. of jakinibs from a translational perspective, focusing on recent insights from clin. trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TNpGT01l8rVg90H21EOLACvtfcHk0lgACRrjmNXBAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO&md5=4607422f83f94c0c7194935d6d460c31</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.201%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DVillarino%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJAK%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520immune%2520and%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D843%26epage%3D862%26doi%3D10.1038%2Fnrd.2017.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.+B.+Telliez&title=Discovery+and+development+of+Janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0li4bXPrzfH5nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520and%2520development%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covington, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favata, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeleswaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">5298</span>– <span class="NLM_lpage">5307</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0902819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.4049%2Fjimmunol.0902819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=20363976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=5298-5307&author=J.+S.+Fridmanauthor=P.+A.+Scherleauthor=R.+Collinsauthor=T.+C.+Burnauthor=Y.+Liauthor=J.+Liauthor=M.+B.+Covingtonauthor=B.+Thomasauthor=P.+Collierauthor=M.+F.+Favataauthor=X.+Wenauthor=J.+Shiauthor=R.+McGeeauthor=P.+J.+Haleyauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=S.+Yeleswaramauthor=G.+Hollisauthor=R.+C.+Newtonauthor=B.+Metcalfauthor=S.+M.+Friedmanauthor=K.+Vaddi&title=Selective+inhibition+of+JAK1+and+JAK2+is+efficacious+in+rodent+models+of+arthritis%3A+preclinical+characterization+of+INCB028050&doi=10.4049%2Fjimmunol.0902819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050</span></div><div class="casAuthors">Fridman, Jordan S.; Scherle, Peggy A.; Collins, Robert; Burn, Timothy C.; Li, Yanlong; Li, Jun; Covington, Maryanne B.; Thomas, Beth; Collier, Paul; Favata, Margaret F.; Wen, Xiaoming; Shi, Jack; McGee, Ryan; Haley, Patrick J.; Shepard, Stacey; Rodgers, James D.; Yeleswaram, Swamy; Hollis, Greg; Newton, Robert C.; Metcalf, Brian; Friedman, Steven M.; Vaddi, Kris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5298-5307</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases such as rheumatoid arthritis.  Kinase inhibitors have shown promising oral disease-modifying antirheumatic drug potential with efficacy similar to anti-TNF biologics.  Direct and indirect inhibition of the JAKs, with small mol. inhibitors like CP-690,550 and INCB018424 or neutralizing Abs, such as the anti-IL6 receptor Ab tocilizumab, have demonstrated rapid and sustained improvement in clin. measures of disease, consistent with their resp. preclin. expts.  Therefore, it is of interest to identify optimized JAK inhibitors with unique profiles to maximize therapeutic opportunities.  INCB028050 is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).  INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concns. <50 nM.  Significant efficacy, as assessed by improvements in clin., histol. and radiog. signs of disease, was achieved in the rat adjuvant arthritis model with doses of INCB028050 providing partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3.  Diminution of inflammatory Th1 and Th17 assocd. cytokine mRNA levels was obsd. in the draining lymph nodes of treated rats.  INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematol. effects.  These data suggest that fractional inhibition of JAK1 and JAK2 is sufficient for significant activity in autoimmune disease models.  Clin. evaluation of INCB028050 in RA is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4QiklQbX72bVg90H21EOLACvtfcHk0li4bXPrzfH5nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D&md5=30b22f275eb2ba2dbca7fb7bec768bb9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902819%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%2BB.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DFavata%26aufirst%3DM.%2BF.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DR.%26aulast%3DHaley%26aufirst%3DP.%2BJ.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DFriedman%26aufirst%3DS.%2BM.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DSelective%2520inhibition%2520of%2520JAK1%2520and%2520JAK2%2520is%2520efficacious%2520in%2520rodent%2520models%2520of%2520arthritis%253A%2520preclinical%2520characterization%2520of%2520INCB028050%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D5298%26epage%3D5307%26doi%3D10.4049%2Fjimmunol.0902819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Rompaey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Aar, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement-Lacroix, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smets, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepescheux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christophe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrath, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandeghinste, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vayssiere, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brys, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van ’t Klooster, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">3568</span>– <span class="NLM_lpage">3577</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1201348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.4049%2Fjimmunol.1201348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=24006460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2nsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=3568-3577&author=L.+Van+Rompaeyauthor=R.+Galienauthor=E.+M.+van+der%0AAarauthor=P.+Clement-Lacroixauthor=L.+Nellesauthor=B.+Smetsauthor=L.+Lepescheuxauthor=T.+Christopheauthor=K.+Conrathauthor=N.+Vandeghinsteauthor=B.+Vayssiereauthor=S.+De+Vosauthor=S.+Fletcherauthor=R.+Brysauthor=G.+van+%E2%80%99t+Kloosterauthor=J.+H.+Feyenauthor=C.+Menet&title=Preclinical+characterization+of+GLPG0634%2C+a+selective+inhibitor+of+JAK1%2C+for+the+treatment+of+inflammatory+diseases&doi=10.4049%2Fjimmunol.1201348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases</span></div><div class="casAuthors">Van Rompaey, Luc; Galien, Rene; van der Aar, Ellen M.; Clement-Lacroix, Philippe; Nelles, Luc; Smets, Bart; Lepescheux, Lien; Christophe, Thierry; Conrath, Katja; Vandeghinste, Nick; Vayssiere, Beatrice; De Vos, Steve; Fletcher, Stephen; Brys, Reginald; van 't Klooster, Gerben; Feyen, Jean H. M.; Menet, Christel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3568-3577</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The JAKs receive continued interest as therapeutic targets for autoimmune, inflammatory, and oncol. diseases.  JAKs play crit. roles in the development and biol. of the hematopoietic system, as evidenced by mouse and human genetics.  JAK1 is crit. for the signal transduction of many type I and type II inflammatory cytokine receptors.  In a search for JAK small mol. inhibitors, GLPG0634 was identified as a lead compd. belonging to a novel class of JAK inhibitors.  It displayed a JAK1/JAK2 inhibitor profile in biochem. assays, but subsequent studies in cellular and whole blood assays revealed a selectivity of ∼30-fold for JAK1- over JAK2-dependent signaling.  GLPG0634 dose-dependently inhibited Th1 and Th2 differentiation and to a lesser extent the differentiation of Th17 cells in vitro.  GLPG0634 was well exposed in rodents upon oral dosing, and exposure levels correlated with repression of Mx2 expression in leukocytes.  Oral dosing of GLPG0634 in a therapeutic set-up in a collagen-induced arthritis model in rodents resulted in a significant dose-dependent redn. of the disease progression.  Paw swelling, bone and cartilage degrdn., and levels of inflammatory cytokines were reduced by GLPG0634 treatment.  Efficacy of GLPG0634 in the collagen-induced arthritis models was comparable to the results obtained with etanercept.  In conclusion, the JAK1 selective inhibitor GLPG0634 is a promising novel therapeutic with potential for oral treatment of rheumatoid arthritis and possibly other immune-inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOIeLPk4kdvbVg90H21EOLACvtfcHk0lijNDFY_o9-Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2nsLzI&md5=01042ebac904fecbcdffe494e456c199</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1201348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1201348%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3Dvan%2Bder%2BAar%26aufirst%3DE.%2BM.%26aulast%3DClement-Lacroix%26aufirst%3DP.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DSmets%26aufirst%3DB.%26aulast%3DLepescheux%26aufirst%3DL.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DConrath%26aufirst%3DK.%26aulast%3DVandeghinste%26aufirst%3DN.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DDe%2BVos%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DBrys%26aufirst%3DR.%26aulast%3Dvan%2B%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26aulast%3DFeyen%26aufirst%3DJ.%2BH.%26aulast%3DMenet%26aufirst%3DC.%26atitle%3DPreclinical%2520characterization%2520of%2520GLPG0634%252C%2520a%2520selective%2520inhibitor%2520of%2520JAK1%252C%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D3568%26epage%3D3577%26doi%3D10.4049%2Fjimmunol.1201348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinblatt, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burmester, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meerwein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Othman, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pangan, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jungerwirth, S.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2857</span>– <span class="NLM_lpage">2866</span>, <span class="refDoi"> DOI: 10.1002/art.39808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1002%2Fart.39808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=27390150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGgsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=2857-2866&author=M.+C.+Genoveseauthor=J.+S.+Smolenauthor=M.+E.+Weinblattauthor=G.+R.+Burmesterauthor=S.+Meerweinauthor=H.+S.+Campauthor=L.+Wangauthor=A.+A.+Othmanauthor=N.+Khanauthor=A.+L.+Panganauthor=S.+Jungerwirth&title=Efficacy+and+Safety+of+ABT-494%2C+a+Selective+JAK-1+Inhibitor%2C+in+a+Phase+IIb+Study+in+Patients+With+Rheumatoid+Arthritis+and+an+Inadequate+Response+to+Methotrexate&doi=10.1002%2Fart.39808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate</span></div><div class="casAuthors">Genovese, Mark C.; Smolen, Josef S.; Weinblatt, Michael E.; Burmester, Gerd R.; Meerwein, Sebastian; Camp, Heidi S.; Wang, Li; Othman, Ahmed A.; Khan, Nasser; Pangan, Aileen L.; Jungerwirth, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2857-2866</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To evaluate the efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in patients with moderate-to-severe rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX).  Methods : Three hundred RA patients receiving stable doses of MTX were randomly assigned equally to receive immediate-release ABT-494 at 3, 6, 12, or 18 mg twice daily, 24 mg once daily, or placebo for 12 wk.  The primary efficacy end point was the proportion of patients meeting the American College of Rheumatol. 20% improvement criteria (achieving an ACR20 response) at week 12, as detd. using the last observation carried forward method.  Results : At week 12, the proportion of ACR20 responses was higher with ABT-494 (62%, 68%, 80%, 64%, and 76% for the 3, 6, 12, 18, and 24 mg doses, resp.) than with placebo (46%) (using nonresponder imputation) (P < 0.05 for the 6, 12, and 24 mg doses).  There was a significant dose-response relationship among all ABT-494 doses (P < 0.001).  The proportions of patients achieving ACR50 and ACR70 responses were significantly higher for all ABT-494 doses (except the 12 mg dose for the ACR70 response) than for placebo, as were changes in the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP).  Rapid improvement was demonstrated by significant differences in ACR20 response rates and changes in the DAS28-CRP for all doses compared with placebo at week 2 (the first postbaseline visit).  The incidence of adverse events was similar across groups; most were mild, and infections were the most frequent.  One serious infection (community-acquired pneumonia) occurred with ABT-494 at 12 mg.  There were dose-dependent increases in high-d. lipoprotein (HDL) and low-d. lipoprotein (LDL) cholesterol, but the LDL cholesterol:HDL cholesterol ratios were unchanged through week 12.  Mean Hb levels remained stable at lower doses, but decreases were obsd. at higher doses.  Conclusion : This study evaluated a broad range of doses of ABT-494 in RA patients with an inadequate response to MTX.  ABT-494 demonstrated efficacy, with a safety and tolerability profile similar to that of other JAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc0MsK02mgIbVg90H21EOLACvtfcHk0lj_h29XlPyJWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGgsL3I&md5=5d4bf383496b2153fede781caf6ba0c7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fart.39808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.39808%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DWeinblatt%26aufirst%3DM.%2BE.%26aulast%3DBurmester%26aufirst%3DG.%2BR.%26aulast%3DMeerwein%26aufirst%3DS.%26aulast%3DCamp%26aufirst%3DH.%2BS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DOthman%26aufirst%3DA.%2BA.%26aulast%3DKhan%26aufirst%3DN.%26aulast%3DPangan%26aufirst%3DA.%2BL.%26aulast%3DJungerwirth%26aufirst%3DS.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520ABT-494%252C%2520a%2520Selective%2520JAK-1%2520Inhibitor%252C%2520in%2520a%2520Phase%2520IIb%2520Study%2520in%2520Patients%2520With%2520Rheumatoid%2520Arthritis%2520and%2520an%2520Inadequate%2520Response%2520to%2520Methotrexate%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2016%26volume%3D68%26spage%3D2857%26epage%3D2866%26doi%3D10.1002%2Fart.39808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintas-Cardama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manshouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caulder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waeltz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3109</span>– <span class="NLM_lpage">3117</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-04-214957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1182%2Fblood-2009-04-214957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=20130243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=3109-3117&author=A.+Quintas-Cardamaauthor=K.+Vaddiauthor=P.+Liuauthor=T.+Manshouriauthor=J.+Liauthor=P.+A.+Scherleauthor=E.+Caulderauthor=X.+Wenauthor=Y.+Liauthor=P.+Waeltzauthor=M.+Ruparauthor=T.+Burnauthor=Y.+Loauthor=J.+Kelleyauthor=M.+Covingtonauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=P.+Haleyauthor=H.+Kantarjianauthor=J.+S.+Fridmanauthor=S.+Verstovsek&title=Preclinical+characterization+of+the+selective+JAK1%2F2+inhibitor+INCB018424%3A+therapeutic+implications+for+the+treatment+of+myeloproliferative+neoplasms&doi=10.1182%2Fblood-2009-04-214957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Vaddi, Kris; Liu, Phillip; Manshouri, Taghi; Li, Jun; Scherle, Peggy A.; Caulder, Eian; Wen, Xiaoming; Li, Yanlong; Waeltz, Paul; Rupar, Mark; Burn, Timothy; Lo, Yvonne; Kelley, Jennifer; Covington, Maryanne; Shepard, Stacey; Rodgers, James D.; Haley, Patrick; Kantarjian, Hagop; Fridman, Jordan S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3109-3117</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates myeloproliferative neoplasm (MPN) phenotypes in mice, establishing JAK2 inhibition as a potential therapeutic strategy.  Although most polycythemia vera patients carry the JAK2V617F mutation, half of those with essential thrombocythemia or primary myelofibrosis do not, suggesting alternative mechanisms for constitutive JAK-STAT signaling in MPNs.  Most patients with primary myelofibrosis have elevated levels of JAK-dependent proinflammatory cytokines (eg, interleukin-6) consistent with our observation of JAK1 hyperactivation.  Accordingly, we evaluated the effectiveness of selective JAK1/2 inhibition in exptl. models relevant to MPNs and report on the effects of INCB018424, the first potent, selective, oral JAK1/JAK2 inhibitor to enter the clinic.  INCB018424 inhibited interleukin-6 signaling (50% inhibitory concn. [IC50] = 281nM), and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127nM).  In primary cultures, INCB018424 preferentially suppressed erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67nM) vs. healthy donors (IC50 > 400nM).  In a mouse model of JAK2V617F+ MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects.  Preliminary clin. results support these preclin. data and establish INCB018424 as a promising oral agent for the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvKGz1l6Y-CbVg90H21EOLACvtfcHk0lj_h29XlPyJWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D&md5=cd52b7013d76ed00ca2df22444c45160</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-04-214957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-04-214957%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCaulder%26aufirst%3DE.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWaeltz%26aufirst%3DP.%26aulast%3DRupar%26aufirst%3DM.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DLo%26aufirst%3DY.%26aulast%3DKelley%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DHaley%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPreclinical%2520characterization%2520of%2520the%2520selective%2520JAK1%252F2%2520inhibitor%2520INCB018424%253A%2520therapeutic%2520implications%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D3109%26epage%3D3117%26doi%3D10.1182%2Fblood-2009-04-214957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Argollo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindryckx, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyrin-Biroulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danese, S.</span></span> <span> </span><span class="NLM_article-title">Novel therapeutic targets for inflammatory bowel disease</span>. <i>J. Autoimmun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1016/j.jaut.2017.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1016%2Fj.jaut.2017.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=28711286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFKhtL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2017&pages=103-116&author=M.+Argolloauthor=G.+Fiorinoauthor=P.+Hindryckxauthor=L.+Peyrin-Birouletauthor=S.+Danese&title=Novel+therapeutic+targets+for+inflammatory+bowel+disease&doi=10.1016%2Fj.jaut.2017.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Novel therapeutic targets for inflammatory bowel disease</span></div><div class="casAuthors">Argollo, Marjorie; Fiorino, Gionata; Hindryck, Pieter; Peyrin-Biroulet, Laurent; Danese, Silvio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Autoimmunity</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103-116</span>CODEN:
                <span class="NLM_cas:coden">JOAUEP</span>;
        ISSN:<span class="NLM_cas:issn">0896-8411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Inflammatory bowel disease (IBD), including Crohn's disease (CD) and Ulcerative Colitis (UC), are immune mediated conditions assocd. with progressive damage of the inflamed gut tissue, and have a considerable impact on the patient's quality of life.  The pathogenesis remains uncertain, but it is clear that complex mechanisms assocd. with host and luminal factors are involved, generating an unbalance between pro- and anti-inflammatory signaling.  It is well established that the purpose of an adequate and complete control of the intestinal inflammation measured not only by clin. symptoms, but also with more objective data such as fecal biomarkers (calprotectin) and endoscopy.  The treat to target approach possibly correlates with minor risk for complications assocd. with IBD, specially surgery and cancer.  The most studied inflammatory pathway in IBD, is described to be dependent of the pro-inflammatory cytokine tumor necrosis factor-alfa (TNF-α), and compose the first line studies for development of biol. drugs, in this case, targeting specifically the action of TNF-α.  Even though, the use of anti-TNFs drugs are assocd. with improvement of the inflammation in some patients, a great portion do not respond at first or lose response over time.  These findings made clear about the possibility of other mechanisms involved in perpetuating the chronic inflammatory state.  Many years of intensive research have led to the identification of different inflammatory pathways that form the basis of the intensive drug development that we are experiencing today.  These novel drugs include agents that target leukocyte trafficking, Interleukin (IL) 23, Janus kinases (JAK), Sphingosine 1 phosphate (S1P) and Smad7, an inhibitor of the immunosuppressive cytokine transforming growth factor β1 (TGF-β1).  In this manuscript, we aim to review the most promising late-stage drug candidates for the treatment of IBD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrd3OxavnOtbVg90H21EOLACvtfcHk0lhIbzblxK1bkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFKhtL3K&md5=d9c71c3f750bd592d1318db0b9b09a50</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.jaut.2017.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaut.2017.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DArgollo%26aufirst%3DM.%26aulast%3DFiorino%26aufirst%3DG.%26aulast%3DHindryckx%26aufirst%3DP.%26aulast%3DPeyrin-Biroulet%26aufirst%3DL.%26aulast%3DDanese%26aufirst%3DS.%26atitle%3DNovel%2520therapeutic%2520targets%2520for%2520inflammatory%2520bowel%2520disease%26jtitle%3DJ.%2520Autoimmun.%26date%3D2017%26volume%3D85%26spage%3D103%26epage%3D116%26doi%3D10.1016%2Fj.jaut.2017.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D.</span>; <span class="NLM_string-name">Wrobleski, S.</span>; <span class="NLM_string-name">Moslin, R.</span>; <span class="NLM_string-name">Lin, S.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Spergel, S.</span>; <span class="NLM_string-name">Mertzman, M.</span>; <span class="NLM_string-name">Tokarski, J.</span>; <span class="NLM_string-name">Sun, H.</span>; <span class="NLM_string-name">Chiney, M.</span>; <span class="NLM_string-name">Elzinga, P.</span>; <span class="NLM_string-name">Aranibar, N.</span>; <span class="NLM_string-name">Chimalakonda, A.</span>; <span class="NLM_string-name">Strnad, J.</span>; <span class="NLM_string-name">Zupa-Fernandez, A.</span>; <span class="NLM_string-name">Cheng, L.</span>; <span class="NLM_string-name">Gillooly, K.</span>; <span class="NLM_string-name">McIntyre, K.</span>; <span class="NLM_string-name">Carter, P.</span>; <span class="NLM_string-name">Lombardo, L.</span>; <span class="NLM_string-name">Burke, J.</span>; <span class="NLM_string-name">Macor, J.</span></span> <i>Tilte</i>; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=D.+Weinstein&author=S.+Wrobleski&author=R.+Moslin&author=S.+Lin&author=Y.+Zhang&author=S.+Spergel&author=M.+Mertzman&author=J.+Tokarski&author=H.+Sun&author=M.+Chiney&author=P.+Elzinga&author=N.+Aranibar&author=A.+Chimalakonda&author=J.+Strnad&author=A.+Zupa-Fernandez&author=L.+Cheng&author=K.+Gillooly&author=K.+McIntyre&author=P.+Carter&author=L.+Lombardo&author=J.+Burke&author=J.+Macor&title=Tilte"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstein%26aufirst%3DD.%26btitle%3DTilte%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dendrou, C.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attfield, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jostins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuttikkatte, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faergeman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheeseman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neville, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawcer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVean, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fugger, L.</span></span> <span> </span><span class="NLM_article-title">Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">363ra149</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aag1974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1126%2Fscitranslmed.aag1974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=27807284" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=363ra149&author=C.%0AA.+Dendrouauthor=A.+Cortesauthor=L.+Shipmanauthor=H.+G.+Evansauthor=K.+E.+Attfieldauthor=L.+Jostinsauthor=T.+Barberauthor=G.+Kaurauthor=S.+B.+Kuttikkatteauthor=O.+A.+Leachauthor=C.+Deselauthor=S.+L.+Faergemanauthor=J.+Cheesemanauthor=M.+J.+Nevilleauthor=S.+Sawcerauthor=A.+Compstonauthor=A.+R.+Johnsonauthor=C.+Everettauthor=J.+I.+Bellauthor=F.+Karpeauthor=M.+Ultschauthor=C.+Eigenbrotauthor=G.+McVeanauthor=L.+Fugger&title=Resolving+TYK2+locus+genotype-to-phenotype+differences+in+autoimmunity&doi=10.1126%2Fscitranslmed.aag1974"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aag1974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aag1974%26sid%3Dliteratum%253Aachs%26aulast%3DDendrou%26aufirst%3DC.%2BA.%26aulast%3DCortes%26aufirst%3DA.%26aulast%3DShipman%26aufirst%3DL.%26aulast%3DEvans%26aufirst%3DH.%2BG.%26aulast%3DAttfield%26aufirst%3DK.%2BE.%26aulast%3DJostins%26aufirst%3DL.%26aulast%3DBarber%26aufirst%3DT.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DKuttikkatte%26aufirst%3DS.%2BB.%26aulast%3DLeach%26aufirst%3DO.%2BA.%26aulast%3DDesel%26aufirst%3DC.%26aulast%3DFaergeman%26aufirst%3DS.%2BL.%26aulast%3DCheeseman%26aufirst%3DJ.%26aulast%3DNeville%26aufirst%3DM.%2BJ.%26aulast%3DSawcer%26aufirst%3DS.%26aulast%3DCompston%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DBell%26aufirst%3DJ.%2BI.%26aulast%3DKarpe%26aufirst%3DF.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DMcVean%26aufirst%3DG.%26aulast%3DFugger%26aufirst%3DL.%26atitle%3DResolving%2520TYK2%2520locus%2520genotype-to-phenotype%2520differences%2520in%2520autoimmunity%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26spage%3D363ra149%26doi%3D10.1126%2Fscitranslmed.aag1974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Graaf, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandema, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anziano, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalonde, R. L.</span></span> <span> </span><span class="NLM_article-title">Model-based drug development: a rational approach to efficiently accelerate drug development</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">502</span>– <span class="NLM_lpage">514</span>, <span class="refDoi"> DOI: 10.1038/clpt.2013.54</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1038%2Fclpt.2013.54" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=23588322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1arsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2013&pages=502-514&author=P.+A.+Milliganauthor=M.+J.+Brownauthor=B.+Marchantauthor=S.+W.+Martinauthor=P.+H.+van+der+Graafauthor=N.+Bensonauthor=G.+Nucciauthor=D.+J.+Nicholsauthor=R.+A.+Boydauthor=J.+W.+Mandemaauthor=S.+Krishnaswamiauthor=S.+Zwillichauthor=D.+Grubenauthor=R.+J.+Anzianoauthor=T.+C.+Stockauthor=R.+L.+Lalonde&title=Model-based+drug+development%3A+a+rational+approach+to+efficiently+accelerate+drug+development&doi=10.1038%2Fclpt.2013.54"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development</span></div><div class="casAuthors">Milligan, P. A.; Brown, M. J.; Marchant, B.; Martin, S. W.; van der Graaf, P. H.; Benson, N.; Nucci, G.; Nichols, D. J.; Boyd, R. A.; Mandema, J. W.; Krishnaswami, S.; Zwillich, S.; Gruben, D.; Anziano, R. J.; Stock, T. C.; Lalonde, R. L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">502-514</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The pharmaceutical industry continues to face significant challenges.  Very few compds. that enter development reach the marketplace, and the investment required for each success can surpass 1.8 billion.  Despite attempts to improve efficiency and increase productivity, total investment continues to rise whereas the output of new medicines declines.  With costs increasing exponentially through each development phase, it is failure in phase II and phase III that is most wasteful.  In today's development paradigm, late-stage failure is principally a result of insufficient efficacy.  This is manifested as either a failure to differentiate sufficiently from placebo (shown for both novel and precedented mechanisms) or a failure to demonstrate sufficient differentiation from existing compds.  Set in this context, this article will discuss the role model-based drug development (MBDD) approaches can and do play in accelerating and optimizing compd. development strategies through a series of illustrative examples.  Clin. Pharmacol. & Therapeutics (2013); 93 6, 502-514. doi:10.1038/clpt.2013.54.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcq-yl0EkXMLVg90H21EOLACvtfcHk0li194DPlPPpkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1arsbs%253D&md5=89db09d5e3ea787abd2a7a610b496ea8</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2013.54&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2013.54%26sid%3Dliteratum%253Aachs%26aulast%3DMilligan%26aufirst%3DP.%2BA.%26aulast%3DBrown%26aufirst%3DM.%2BJ.%26aulast%3DMarchant%26aufirst%3DB.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3Dvan%2Bder%2BGraaf%26aufirst%3DP.%2BH.%26aulast%3DBenson%26aufirst%3DN.%26aulast%3DNucci%26aufirst%3DG.%26aulast%3DNichols%26aufirst%3DD.%2BJ.%26aulast%3DBoyd%26aufirst%3DR.%2BA.%26aulast%3DMandema%26aufirst%3DJ.%2BW.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DZwillich%26aufirst%3DS.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DAnziano%26aufirst%3DR.%2BJ.%26aulast%3DStock%26aufirst%3DT.%2BC.%26aulast%3DLalonde%26aufirst%3DR.%2BL.%26atitle%3DModel-based%2520drug%2520development%253A%2520a%2520rational%2520approach%2520to%2520efficiently%2520accelerate%2520drug%2520development%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D93%26spage%3D502%26epage%3D514%26doi%3D10.1038%2Fclpt.2013.54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keystone, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drescher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berclaz, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidelus-Gort, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luchi, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2014-206478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1136%2Fannrheumdis-2014-206478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=25431052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVSltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2015&pages=333-340&author=E.+C.+Keystoneauthor=P.+C.+Taylorauthor=E.+Drescherauthor=D.+E.+Schlichtingauthor=S.+D.+Beattieauthor=P.+Y.+Berclazauthor=C.+H.+Leeauthor=R.+K.+Fidelus-Gortauthor=M.+E.+Luchiauthor=T.+P.+Rooneyauthor=W.+L.+Maciasauthor=M.+C.+Genovese&title=Safety+and+efficacy+of+baricitinib+at+24+weeks+in+patients+with+rheumatoid+arthritis+who+have+had+an+inadequate+response+to+methotrexate&doi=10.1136%2Fannrheumdis-2014-206478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate</span></div><div class="casAuthors">Keystone, Edward C.; Taylor, Peter C.; Drescher, Edit; Schlichting, Douglas E.; Beattie, Scott D.; Berclaz, Pierre-Yves; Lee, Chin H.; Fidelus-Gort, Rosanne K.; Luchi, Monica E.; Rooney, Terence P.; Macias, William L.; Genovese, Mark C.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">333-340</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite treatment with methotrexate.  Methods In this phase IIb study, 301 patients were randomized 2:1:1:1:1 to receive once daily doses of placebo or 1, 2, 4 or 8 mg baricitinib for 12 wk.  Patients assigned to 2, 4 and 8 mg baricitinib continued blinded treatment for an addnl. 12 wk.  Patients assigned to placebo or 1 mg baricitinib were reassigned to 2 mg twice daily or 4 mg once daily baricitinib between weeks 12-24.  The primary endpoint was the proportion of patients in the combined 4 and 8 mg groups achieving an American College of Rheumatol. 20% (ACR20) response vs. placebo at week 12.  Results Significantly more patients in the combined baricitinib 4 and 8 mg groups compared with placebo achieved an ACR20 response at week 12 (76% vs 41%, p<0.001).  At week 12, significant differences vs. placebo were also obsd. in patients achieving ACR50, ACR70 and remission as measured by Disease Activity Score for 28-joint counts, Clin. Disease Activity Index and Simplified Disease Activity Index.  Patients receiving 2, 4, or 8 mg baricitinib maintained or improved in all measures through 24 wk.  Similar proportions of patients experienced at least one adverse event in the placebo and baricitinib groups.  Serious infections developed in three patients receiving baricitinib.  No cases of tuberculosis, herpes zoster, opportunistic infections or deaths were reported.  Dose-dependent decreases in Hb were obsd. with baricitinib.  Conclusions Baricitinib improved the signs and symptoms of RA in methotrexate inadequate responders with active disease.  Baricitinib was well tolerated with no unexpected safety findings through week 24.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz3lYB7HU_KbVg90H21EOLACvtfcHk0li194DPlPPpkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVSltbc%253D&md5=2f13c96c1c1dc5f68e69cd3e6da457b7</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2014-206478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2014-206478%26sid%3Dliteratum%253Aachs%26aulast%3DKeystone%26aufirst%3DE.%2BC.%26aulast%3DTaylor%26aufirst%3DP.%2BC.%26aulast%3DDrescher%26aufirst%3DE.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DBeattie%26aufirst%3DS.%2BD.%26aulast%3DBerclaz%26aufirst%3DP.%2BY.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DFidelus-Gort%26aufirst%3DR.%2BK.%26aulast%3DLuchi%26aufirst%3DM.%2BE.%26aulast%3DRooney%26aufirst%3DT.%2BP.%26aulast%3DMacias%26aufirst%3DW.%2BL.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520baricitinib%2520at%252024%2520weeks%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%2520who%2520have%2520had%2520an%2520inadequate%2520response%2520to%2520methotrexate%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2015%26volume%3D74%26spage%3D333%26epage%3D340%26doi%3D10.1136%2Fannrheumdis-2014-206478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamashta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrill, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werth, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalunian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brohawn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illei, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drappa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Investigators, C. D. S.</span></span> <span> </span><span class="NLM_article-title">Anifrolumab, an Anti-Interferon-alpha Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1002/art.39962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1002%2Fart.39962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=28130918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslWrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=376-386&author=R.+Furieauthor=M.+Khamashtaauthor=J.+T.+Merrillauthor=V.+P.+Werthauthor=K.+Kalunianauthor=P.+Brohawnauthor=G.+G.+Illeiauthor=J.+Drappaauthor=L.+Wangauthor=S.+Yooauthor=C.+D.+S.+Investigators&title=Anifrolumab%2C+an+Anti-Interferon-alpha+Receptor+Monoclonal+Antibody%2C+in+Moderate-to-Severe+Systemic+Lupus+Erythematosus&doi=10.1002%2Fart.39962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus</span></div><div class="casAuthors">Furie, Richard; Khamashta, Munther; Merrill, Joan T.; Werth, Victoria P.; Kalunian, Kenneth; Brohawn, Philip; Illei, Gabor G.; Drappa, Jorn; Wang, Liangwei; Yoo, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">376-386</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (SLE).  Methods: Patients (n = 305) were randomized to receive i.v. anifrolumab (300 mg or 1,000 mg) or placebo, in addn. to std. therapy, every 4 wk for 48 wk.  Randomization was stratified by SLE Disease Activity Index 2000 score (<10 or ≥10), oral corticosteroid dosage (<10 or ≥10 mg/day), and type I IFN gene signature test status (high or low) based on a 4-gene expression assay.  The primary end point was the percentage of patients achieving an SLE Responder Index (SRI[4]) response at week 24 with sustained redn. of oral corticosteroids (<10 mg/day and less than or equal to the dose at week 1 from week 12 through 24).  Other end points (including SRI[4], British Isles Lupus Assessment Group [BILAG]-based Composite Lupus Assessment [BICLA], modified SRI[6], and major clin. response) were assessed at week 52.  The primary end point was analyzed in the modified intent-to-treat (ITT) population and type I IFN-high subpopulation.  The study result was considered pos. if the primary end point was met in either of the 2 study populations.  The Type I error rate was controlled at 0.10 (2-sided), within each of the 2 study populations for the primary end point anal.  Results: The primary end point was met by more patients treated with anifrolumab (34.3% of 99 for 300 mg and 28.8% of 104 for 1,000 mg) than placebo (17.6% of 102) (P = 0.014 for 300 mg and P = 0.063 for 1,000 mg, vs. placebo), with greater effect size in patients with a high IFN signature at baseline (13.2% in placebo-treated patients vs. 36.0% [P = 0.004] and 28.2% [P = 0.029]) in patients treated with anifrolumab 300 mg and 1,000 mg, resp.  At week 52, patients treated with anifrolumab achieved greater responses in SRI(4) (40.2% vs. 62.6% [P < 0.001] and 53.8% [P = 0.043] with placebo, anifrolumab 300 mg, and anifrolumab 1,000 mg, resp.), BICLA (25.7% vs. 53.5% [P < 0.001] and 41.2% [P = 0.018], resp.), modified SRI(6) (28.4% vs. 49.5% [P = 0.002] and 44.7% [P = 0.015], resp.), major clin. response (BILAG 2004 C or better in all organ domains from week 24 through week 52) (6.9% vs. 19.2% [P = 0.012] and 17.3% [P = 0.025], resp.), and several other global and organ-specific end points.  Herpes zoster was more frequent in the anifrolumab-treated patients (2.0% with placebo treatment vs. 5.1% and 9.5% with anifrolumab 300 mg and 1,000 mg, resp.), as were cases reported as influenza (2.0% vs. 6.1% and 7.6%, resp.), in the anifrolumab treatment groups.  Incidence of serious adverse events was similar between groups (18.8% vs. 16.2% and 17.1%, resp.).  Conclusion: Anifrolumab substantially reduced disease activity compared with placebo across multiple clin. end points in the patients with moderate-to-severe SLE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOnuGe2pgO6LVg90H21EOLACvtfcHk0lh5ESAD0aywJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslWrs7Y%253D&md5=c7f5b70586a8cbc0fafb2651a5f98b32</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fart.39962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.39962%26sid%3Dliteratum%253Aachs%26aulast%3DFurie%26aufirst%3DR.%26aulast%3DKhamashta%26aufirst%3DM.%26aulast%3DMerrill%26aufirst%3DJ.%2BT.%26aulast%3DWerth%26aufirst%3DV.%2BP.%26aulast%3DKalunian%26aufirst%3DK.%26aulast%3DBrohawn%26aufirst%3DP.%26aulast%3DIllei%26aufirst%3DG.%2BG.%26aulast%3DDrappa%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYoo%26aufirst%3DS.%26aulast%3DInvestigators%26aufirst%3DC.%2BD.%2BS.%26atitle%3DAnifrolumab%252C%2520an%2520Anti-Interferon-alpha%2520Receptor%2520Monoclonal%2520Antibody%252C%2520in%2520Moderate-to-Severe%2520Systemic%2520Lupus%2520Erythematosus%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26spage%3D376%26epage%3D386%26doi%3D10.1002%2Fart.39962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frieder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivelevitch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haugh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menter, A.</span></span> <span> </span><span class="NLM_article-title">Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1002/cpt.893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1002%2Fcpt.893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=28960267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVCrsLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2018&pages=88-101&author=J.+Friederauthor=D.+Kivelevitchauthor=I.+Haughauthor=I.+Watsonauthor=A.+Menter&title=Anti-IL-23+and+Anti-IL-17+Biologic+Agents+for+the+Treatment+of+Immune-Mediated+Inflammatory+Conditions&doi=10.1002%2Fcpt.893"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions</span></div><div class="casAuthors">Frieder, Jillian; Kivelevitch, Dario; Haugh, Isabel; Watson, Ian; Menter, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-101</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Advancements in the immunopathogenesis of psoriasis have identified interleukin (IL)-23 and IL-17 as fundamental contributors in the immune pathways of the disease.  Leveraging these promising therapeutic targets has led to the emergence of a no. of anti-IL-23 and -17 biol. agents with the potential to treat multiple conditions with common underlying pathol.  The unprecedented clin. efficacy of these agents in the treatment of psoriasis has paved way for their evaluation in diseases such as psoriatic arthritis, Crohn's disease, rheumatoid arthritis, in addn. to other immune-mediated conditions.  Here we review the IL-23/IL-17 immune pathways and discuss the key clin. and safety data of the anti-IL-23 and anti-IL-17 biol. agents in psoriasis and other immune-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKyNWmqZ8oPLVg90H21EOLACvtfcHk0lh5ESAD0aywJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVCrsLzM&md5=81434ac64afe2233d8118b31708cb2be</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fcpt.893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.893%26sid%3Dliteratum%253Aachs%26aulast%3DFrieder%26aufirst%3DJ.%26aulast%3DKivelevitch%26aufirst%3DD.%26aulast%3DHaugh%26aufirst%3DI.%26aulast%3DWatson%26aufirst%3DI.%26aulast%3DMenter%26aufirst%3DA.%26atitle%3DAnti-IL-23%2520and%2520Anti-IL-17%2520Biologic%2520Agents%2520for%2520the%2520Treatment%2520of%2520Immune-Mediated%2520Inflammatory%2520Conditions%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2018%26volume%3D103%26spage%3D88%26epage%3D101%26doi%3D10.1002%2Fcpt.893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van Vollenhoven, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsokos, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevrier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triebel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, S.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Ustekinumab, an Interleukin 12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Results of a Phase 2, Randomized Placebo-Controlled Study [abstract]</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">Suppl 10</span>),  <span class="NLM_fpage">abstract 6L</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=abstract+6L&issue=Suppl+10&author=R.+van+Vollenhovenauthor=B.+H.+Hahnauthor=G.+C.+Tsokosauthor=C.+Wagnerauthor=P.+Lipskyauthor=B.+Hsuauthor=M.+Chevrierauthor=R.+Gordonauthor=M.+Triebelauthor=S.+Rose&title=Efficacy+and+Safety+of+Ustekinumab%2C+an+Interleukin+12%2F23+Inhibitor%2C+in+Patients+with+Active+Systemic+Lupus+Erythematosus%3A+Results+of+a+Phase+2%2C+Randomized+Placebo-Controlled+Study+%5Babstract%5D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BVollenhoven%26aufirst%3DR.%26aulast%3DHahn%26aufirst%3DB.%2BH.%26aulast%3DTsokos%26aufirst%3DG.%2BC.%26aulast%3DWagner%26aufirst%3DC.%26aulast%3DLipsky%26aufirst%3DP.%26aulast%3DHsu%26aufirst%3DB.%26aulast%3DChevrier%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DR.%26aulast%3DTriebel%26aufirst%3DM.%26aulast%3DRose%26aufirst%3DS.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Ustekinumab%252C%2520an%2520Interleukin%252012%252F23%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Active%2520Systemic%2520Lupus%2520Erythematosus%253A%2520Results%2520of%2520a%2520Phase%25202%252C%2520Randomized%2520Placebo-Controlled%2520Study%2520%255Babstract%255D%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26issue%3DSuppl%252010%26spage%3Dabstract%25206L" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernest, C.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tham, L. S.</span></span> <span> </span><span class="NLM_article-title">Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis</span>. <i>CPT: Pharmacometrics Syst. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">804</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1002/psp4.12251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1002%2Fpsp4.12251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=28891251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Kgs7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=804-813&author=X.+Zhangauthor=L.+Chuaauthor=C.+Ernestauthor=W.+Maciasauthor=T.+Rooneyauthor=L.+S.+Tham&title=Dose%2FExposure-Response+Modeling+to+Support+Dosing+Recommendation+for+Phase+III+Development+of+Baricitinib+in+Patients+with+Rheumatoid+Arthritis&doi=10.1002%2Fpsp4.12251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis</span></div><div class="casAuthors">Zhang, Xin; Chua, Laiyi; Ernest, Charles II; Macias, William; Rooney, Terence; Tham, Lai San</div><div class="citationInfo"><span class="NLM_cas:title">CPT: Pharmacometrics & Systems Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">804-813</span>CODEN:
                <span class="NLM_cas:coden">CPSPBR</span>;
        ISSN:<span class="NLM_cas:issn">2163-8306</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Baricitinib is an oral inhibitor of Janus kinases (JAKs), selective for JAK1 and 2.  It demonstrated dose-dependent efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) in a phase IIb study up to 24 wk.  Population pharmacokinetic/pharmacodynamic (PopPK/PD) models were developed to characterize concn.-time profiles and dose/exposure-response (D/E-R) relationships for the key efficacy (proportion of patients achieving American College of Rheumatol. 20%, 50%, or 70% response rate) and safety endpoints (incidence of anemia) for the phase IIb study.  The modeling suggested that 4 mg q.d. was likely to offer the optimum risk/benefit balance, whereas 2 mg q.d. had the potential for adequate efficacy.  In addn., at the same total daily dose, a twice-daily regimen is not expected to provide an advantage over q.d. dosing for the efficacy or safety endpoints.  The model-based simulations formed the rationale for key aspects of dosing, such as dose levels and dosing frequency for phase III development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol_-dsqYG9W7Vg90H21EOLACvtfcHk0li7r4pOBzu16A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Kgs7rM&md5=fbcb534ccd2176e636535d99762bb22c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fpsp4.12251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsp4.12251%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DChua%26aufirst%3DL.%26aulast%3DErnest%26aufirst%3DC.%26aulast%3DMacias%26aufirst%3DW.%26aulast%3DRooney%26aufirst%3DT.%26aulast%3DTham%26aufirst%3DL.%2BS.%26atitle%3DDose%252FExposure-Response%2520Modeling%2520to%2520Support%2520Dosing%2520Recommendation%2520for%2520Phase%2520III%2520Development%2520of%2520Baricitinib%2520in%2520Patients%2520with%2520Rheumatoid%2520Arthritis%26jtitle%3DCPT%253A%2520Pharmacometrics%2520Syst.%2520Pharmacol.%26date%3D2017%26volume%3D6%26spage%3D804%26epage%3D813%26doi%3D10.1002%2Fpsp4.12251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Namour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhoutte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigerinck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van’t Klooster, G.</span></span> <span> </span><span class="NLM_article-title">An active metabolite contributes to the pharmacodynamics and efficacy of GLPG0634, a selective JAK1 inhibitor</span>. <i>Arthritis Rheum</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">Suppl 10</span>),  <span class="NLM_fpage">1795</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=23553790" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=1795&issue=Suppl+10&author=F.+Namourauthor=R.+Galienauthor=F.+Vanhoutteauthor=P.+Wigerinckauthor=G.+van%E2%80%99t+Klooster&title=An+active+metabolite+contributes+to+the+pharmacodynamics+and+efficacy+of+GLPG0634%2C+a+selective+JAK1+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNamour%26aufirst%3DF.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DVanhoutte%26aufirst%3DF.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3Dvan%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26atitle%3DAn%2520active%2520metabolite%2520contributes%2520to%2520the%2520pharmacodynamics%2520and%2520efficacy%2520of%2520GLPG0634%252C%2520a%2520selective%2520JAK1%2520inhibitor%26jtitle%3DArthritis%2520Rheum%26date%3D2013%26volume%3D65%26issue%3DSuppl%252010%26spage%3D1795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishore, N.</span></span> <span> </span><span class="NLM_article-title">Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.209304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1124%2Fjpet.113.209304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=24218541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=165-173&author=M.+E.+Dowtyauthor=M.+I.+Jessonauthor=S.+Ghoshauthor=J.+Leeauthor=D.+M.+Meyerauthor=S.+Krishnaswamiauthor=N.+Kishore&title=Preclinical+to+clinical+translation+of+tofacitinib%2C+a+Janus+kinase+inhibitor%2C+in+rheumatoid+arthritis&doi=10.1124%2Fjpet.113.209304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical to clinical translation of tofacitinib, a janus kinase inhibitor, in rheumatoid arthritis</span></div><div class="casAuthors">Dowty, Martin E.; Jesson, Michael I.; Ghosh, Sarbani; Lee, Jamie; Meyer, Debra M.; Krishnaswami, Sriram; Kishore, Nandini</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-173, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A crit. piece in the translation of preclin. studies to clin. trials is the detn. of dosing regimens that allow max. therapeutic benefit with min. toxicity.  The preclin. pharmacokinetic (PK)/pharmacodynamic (PD) profile of tofacitinib, an oral Janus kinase (JAK) inhibitor, in a mouse collagen-induced arthritis (mCIA) model was compared with clin. PK/PD data from patients with rheumatoid arthritis (RA).  Preclin. evaluations included target modulation and PK/PD modeling based on continuous s.c. infusion or oral once- or twice-daily (BID) dosing paradigms in mice.  The human PK/PD profile was obtained from pooled data from four phase 2 studies in patients with RA, and maximal effect models were used to evaluate efficacy after 12 wk of tofacitinib treatment (1-15 mg BID).  In mCIA, the main driver of efficacy was inhibition of cytokine receptor signaling mediated by JAK1 heterodimers, but not JAK2 homodimers, and continuous daily inhibition was not required to maintain efficacy.  Projected efficacy could be predicted from total daily exposure irresp. of the oral dosing paradigm, with a total steady-state plasma concn. achieving 50% of the maximal response (Cave50) of ∼100 nM.  Tofacitinib potency (ED50) in clin. studies was ∼3.5 mg BID (90% confidence interval: 2.3, 5.5) or total Cave50 of ∼40 nM, derived using Disease Activity Scores from patients with RA.  The collective clin. and preclin. data indicated the importance of Cave as a driver of efficacy, rather than max. or min. plasma concn. (Cmax or Cmin), where Cave50 values were within ∼2-fold of each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDs-lnT0HFF7Vg90H21EOLACvtfcHk0liAmcG0345Gkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D&md5=faed45ef8eabb5e1bde0819702f26ffa</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.209304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.209304%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DKishore%26aufirst%3DN.%26atitle%3DPreclinical%2520to%2520clinical%2520translation%2520of%2520tofacitinib%252C%2520a%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D165%26epage%3D173%26doi%3D10.1124%2Fjpet.113.209304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutmacher, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furst, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikranian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nduaka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span> <span> </span><span class="NLM_article-title">Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">753</span>, <span class="refDoi"> DOI: 10.1002/cpt.576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1002%2Fcpt.576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=27859030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslKju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2017&pages=745-753&author=M.+Lambaauthor=M.+M.+Hutmacherauthor=D.+E.+Furstauthor=A.+Dikranianauthor=M.+E.+Dowtyauthor=D.+Conradoauthor=T.+Stockauthor=C.+Nduakaauthor=J.+Cookauthor=S.+Krishnaswami&title=Model-Informed+Development+and+Registration+of+a+Once-Daily+Regimen+of+Extended-Release+Tofacitinib&doi=10.1002%2Fcpt.576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib</span></div><div class="casAuthors">Lamba, M.; Hutmacher, M. M.; Furst, D. E.; Dikranian, A.; Dowty, M. E.; Conrado, D.; Stock, T.; Nduaka, C.; Cook, J.; Krishnaswami, S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">745-753</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Extended-release (XR) formulations enable less frequent dosing vs. conventional (e.g., immediate release (IR)) formulations.  Regulatory registration of such formulations typically requires pharmacokinetic (PK) and clin. efficacy data.  Here we illustrate a model-informed, exposure-response (E-R) approach to translate controlled trial data from one formulation to another without a phase III trial, using a tofacitinib case study.  Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA).  E-R analyses were conducted using validated clin. endpoints from phase II dose-response and nonclin. dose fractionation studies of the IR formulation.  Consistent with the delay in clin. response dynamics relative to PK, av. concn. was established as the relevant PK parameter for tofacitinib efficacy and supported pharmacodynamic similarity.  These evaluations, alongside demonstrated equivalence in total systemic exposure between IR and XR formulations, provided the basis for the regulatory approval of tofacitinib XR once daily by the US Food and Drug Administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpS1owg4oUA7Vg90H21EOLACvtfcHk0liAmcG0345Gkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslKju78%253D&md5=28cb7216bd6ee2d4691b90b8fe57368f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fcpt.576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.576%26sid%3Dliteratum%253Aachs%26aulast%3DLamba%26aufirst%3DM.%26aulast%3DHutmacher%26aufirst%3DM.%2BM.%26aulast%3DFurst%26aufirst%3DD.%2BE.%26aulast%3DDikranian%26aufirst%3DA.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DConrado%26aufirst%3DD.%26aulast%3DStock%26aufirst%3DT.%26aulast%3DNduaka%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DKrishnaswami%26aufirst%3DS.%26atitle%3DModel-Informed%2520Development%2520and%2520Registration%2520of%2520a%2520Once-Daily%2520Regimen%2520of%2520Extended-Release%2520Tofacitinib%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D101%26spage%3D745%26epage%3D753%26doi%3D10.1002%2Fcpt.576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanhoutte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voloshyn, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanislavchuk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meuleners, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van ’t Klooster, G.</span></span> <span> </span><span class="NLM_article-title">Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1949</span>– <span class="NLM_lpage">1959</span>, <span class="refDoi"> DOI: 10.1002/art.40186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1002%2Fart.40186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=28622463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFyrurjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=1949-1959&author=F.+Vanhoutteauthor=M.+Mazurauthor=O.+Voloshynauthor=M.+Stanislavchukauthor=A.+Van+der+Aaauthor=F.+Namourauthor=R.+Galienauthor=L.+Meulenersauthor=G.+van+%E2%80%99t+Klooster&title=Efficacy%2C+Safety%2C+Pharmacokinetics%2C+and+Pharmacodynamics+of+Filgotinib%2C+a+Selective+JAK-1+Inhibitor%2C+After+Short-Term+Treatment+of+Rheumatoid+Arthritis%3A+Results+of+Two+Randomized+Phase+IIa+Trials&doi=10.1002%2Fart.40186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials</span></div><div class="casAuthors">Vanhoutte, Frederic; Mazur, Minodora; Voloshyn, Oleksandr; Stanislavchuk, Mykola; Van der Aa, Annegret; Namour, Florence; Galien, Rene; Meuleners, Luc; van 't Klooster, Gerben</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1949-1959</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : JAK inhibitors have shown efficacy in rheumatoid arthritis (RA).  We undertook this study to test our hypothesis that selective inhibition of JAK-1 would combine good efficacy with a better safety profile compared with less selective JAK inhibitors.  Methods : In two 4-wk exploratory, double-blind, placebo-controlled phase IIa trials, 127 RA patients with an insufficient response to methotrexate (MTX) received filgotinib (GLPG0634, GS-6034) oral capsules (100 mg twice daily or 30, 75, 150, 200, or 300 mg once daily) or placebo, added onto a stable regimen of MTX, to evaluate safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of filgotinib.  The primary efficacy end point was the no. and percentage of patients in each treatment group meeting the American College of Rheumatol. 20% improvement criteria (achieving an ACR20 response) at week 4.  Results : Treatment with filgotinib at 75-300 mg met the primary end point and showed early onset of efficacy.  ACR20 response rates progressively increased to week 4, and the Disease Activity Score in 28 joints using the C-reactive protein (CRP) level decreased.  Marked and sustained improvements were obsd. in serum CRP level and other PD markers.  The PK of filgotinib and its major metabolite was dose proportional over the 30-300 mg range.  Early side effects seen with other less selective JAK inhibitors were not obsd. (e.g., there was no worsening of anemia [JAK-2 inhibition related], no effects on liver transaminases, and no increase in low-d. lipoprotein or total cholesterol).  A limited decrease in neutrophils without neutropenia was consistent with immunomodulatory effects through JAK-1 inhibition.  There were no infections.  Overall, filgotinib was well tolerated.  Events related to study drug were mild or moderate and transient during therapy, and the most common such event was nausea.  Conclusion : Selective inhibition of JAK-1 with filgotinib shows initial efficacy in RA with an encouraging safety profile in these exploratory studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7oTo2cM5so7Vg90H21EOLACvtfcHk0lhR2r17TtEDBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFyrurjP&md5=b704bd2b69231f1aa95815120b8cf922</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fart.40186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.40186%26sid%3Dliteratum%253Aachs%26aulast%3DVanhoutte%26aufirst%3DF.%26aulast%3DMazur%26aufirst%3DM.%26aulast%3DVoloshyn%26aufirst%3DO.%26aulast%3DStanislavchuk%26aufirst%3DM.%26aulast%3DVan%2Bder%2BAa%26aufirst%3DA.%26aulast%3DNamour%26aufirst%3DF.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DMeuleners%26aufirst%3DL.%26aulast%3Dvan%2B%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26atitle%3DEfficacy%252C%2520Safety%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520of%2520Filgotinib%252C%2520a%2520Selective%2520JAK-1%2520Inhibitor%252C%2520After%2520Short-Term%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%253A%2520Results%2520of%2520Two%2520Randomized%2520Phase%2520IIa%2520Trials%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26spage%3D1949%26epage%3D1959%26doi%3D10.1002%2Fart.40186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breedveld, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombs, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgos-Vargas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerbini, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S. H.</span></span> <span> </span><span class="NLM_article-title">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1895</span>– <span class="NLM_lpage">1905</span>, <span class="refDoi"> DOI: 10.1002/art.24567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1002%2Fart.24567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=19565475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=1895-1905&author=J.+M.+Kremerauthor=B.+J.+Bloomauthor=F.+C.+Breedveldauthor=J.+H.+Coombsauthor=M.+P.+Fletcherauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=R.+Burgos-Vargasauthor=B.+Wilkinsonauthor=C.+A.+Zerbiniauthor=S.+H.+Zwillich&title=The+safety+and+efficacy+of+a+JAK+inhibitor+in+patients+with+active+rheumatoid+arthritis%3A+Results+of+a+double-blind%2C+placebo-controlled+phase+IIa+trial+of+three+dosage+levels+of+CP-690%2C550+versus+placebo&doi=10.1002%2Fart.24567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span></div><div class="casAuthors">Kremer, Joel M.; Bloom, Bradley J.; Breedveld, Ferdinand C.; Coombs, John H.; Fletcher, Mark P.; Gruben, David; Krishnaswami, Sriram; Burgos-Vargas, Ruben; Wilkinson, Bethanie; Zerbini, Cristiano A. F.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1895-1905</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">To det. the efficacy, safety, and tolerability of 3 different dosages of CP-690,550, a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in whom methotrexate, etanercept, infliximab, or adalimumab caused an inadequate or toxic response.  Patients (n = 264) were randomized equally to receive placebo, 5 mg of CP-690,550,15 mg of CP-690,550, or 30 mg of CP-690,550 twice daily for 6 wk, and were followed up for an addnl. 6 wk after treatment.  The primary efficacy end point was the American College of Rheumatol. 20% improvement criteria (ACR20) response rate at 6 wk.  By week 6, the ACR20 response rates were 70.5%, 81.2%, and 76.8% in the 5 mg, 15 mg, and 30 mg twice daily groups, resp., compared with 29.2% in the placebo group (P < 0.001).  Improvements in disease activity in CP-690,550-treated patients compared with placebo were seen in all treatment groups as early as week 1.  ACR50 and ACR70 response rates significantly improved in all treatment groups by week 4.  The most common adverse events reported were headache and nausea.  The infection rate in both the 15 mg twice daily group and the 30 mg twice daily group was 30.4% (vs. 26.2% in the placebo group).  No opportunistic infections or deaths occurred.  Increases in mean low-d. lipoprotein cholesterol and high-d. lipoprotein cholesterol levels, and increases in mean serum creatinine level (0.04-0.06 mg/dL) were seen in all CP-690,550 treatment arms.  Our findings indicate that CP-690,550 is efficacious in the treatment of RA, resulting in rapid, statistically significant, and clin. meaningful redns. in the signs and symptoms of RA.  Further studies of CP-690,550 in RA are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBhxBhh_mG7rVg90H21EOLACvtfcHk0lhR2r17TtEDBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D&md5=ab5fb34e43d8643871560c67bbbca07d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fart.24567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24567%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DBloom%26aufirst%3DB.%2BJ.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26aulast%3DCoombs%26aufirst%3DJ.%2BH.%26aulast%3DFletcher%26aufirst%3DM.%2BP.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DBurgos-Vargas%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DZerbini%26aufirst%3DC.%2BA.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DThe%2520safety%2520and%2520efficacy%2520of%2520a%2520JAK%2520inhibitor%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%253A%2520Results%2520of%2520a%2520double-blind%252C%2520placebo-controlled%2520phase%2520IIa%2520trial%2520of%2520three%2520dosage%2520levels%2520of%2520CP-690%252C550%2520versus%2520placebo%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D1895%26epage%3D1905%26doi%3D10.1002%2Fart.24567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strober, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buonanno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawabata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harness, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K.</span></span> <span> </span><span class="NLM_article-title">Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">992</span>– <span class="NLM_lpage">999</span>, <span class="refDoi"> DOI: 10.1111/bjd.12517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1111%2Fbjd.12517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=23855761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslakurzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2013&pages=992-999&author=B.+Stroberauthor=M.+Buonannoauthor=J.+D.+Clarkauthor=T.+Kawabataauthor=H.+Tanauthor=R.+Wolkauthor=H.+Valdezauthor=R.+G.+Langleyauthor=J.+Harnessauthor=A.+Menterauthor=K.+Papp&title=Effect+of+tofacitinib%2C+a+Janus+kinase+inhibitor%2C+on+haematological+parameters+during+12+weeks+of+psoriasis+treatment&doi=10.1111%2Fbjd.12517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment</span></div><div class="casAuthors">Strober, B.; Buonanno, M.; Clark, J. D.; Kawabata, T.; Tan, H.; Wolk, R.; Valdez, H.; Langley, R. G.; Harness, J.; Menter, A.; Papp, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">992-999</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : The Janus kinase (JAK) inhibitor, tofacitinib, has shown efficacy for the treatment of psoriasis in a phase IIb trial (A3921047; NCT00678210).  Objectives : To report haematol. data from the phase IIb trial, given the importance of JAK-dependent signalling in haematopoiesis.  Methods : Patients with moderate-to-severe chronic plaque psoriasis were randomized to receive tofacitinib 2, 5 or 15 mg, or placebo, twice daily over 12 wk.  Blood samples were collected at screening, baseline, weeks 2, 4, 8 and 12 during treatment, and weeks 14 and 16 during off-treatment follow-up.  Results : Baseline haematol. was similar across patients receiving tofacitinib 2 mg (n = 49), 5 mg (n = 49) or 15 mg (n = 49), or placebo (n = 50).  Tofacitinib conferred dose-dependent decreases in Hb, haematocrit and red blood cell counts, while reticulocyte counts initially declined, before recovering by week 8, and exceeding baseline levels after treatment cessation.  With regard to white blood cells, tofacitinib had no clear dose-dependent effects on basophils or monocytes, but appeared to be assocd. with transient or reversible dose-dependent decreases in neutrophil and eosinophil counts and transient increases in lymphocyte counts, which were primarily attributable to increases in B-cell counts.  Natural killer cell counts declined with tofacitinib.  Conclusions : Tofacitinib conferred tolerable, dose-dependent changes in haematol. parameters during short-term administration in patients with psoriasis.  The effects did not appear to be progressive, and were often transient or reversible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXc7wLFiJmW7Vg90H21EOLACvtfcHk0lj1_gAl06-ifA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslakurzP&md5=c8427f4813dc663ef97a2fce48f6fd08</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fbjd.12517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.12517%26sid%3Dliteratum%253Aachs%26aulast%3DStrober%26aufirst%3DB.%26aulast%3DBuonanno%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DKawabata%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DWolk%26aufirst%3DR.%26aulast%3DValdez%26aufirst%3DH.%26aulast%3DLangley%26aufirst%3DR.%2BG.%26aulast%3DHarness%26aufirst%3DJ.%26aulast%3DMenter%26aufirst%3DA.%26aulast%3DPapp%26aufirst%3DK.%26atitle%3DEffect%2520of%2520tofacitinib%252C%2520a%2520Janus%2520kinase%2520inhibitor%252C%2520on%2520haematological%2520parameters%2520during%252012%2520weeks%2520of%2520psoriasis%2520treatment%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2013%26volume%3D169%26spage%3D992%26epage%3D999%26doi%3D10.1111%2Fbjd.12517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menter, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elewski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buonanno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proulx, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolk, R.</span></span> <span> </span><span class="NLM_article-title">Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">961</span>, <span class="refDoi"> DOI: 10.1111/bjd.14018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1111%2Fbjd.14018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=26149717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyns73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2015&pages=949-961&author=K.+A.+Pappauthor=M.+A.+Menterauthor=M.+Abeauthor=B.+Elewskiauthor=S.+R.+Feldmanauthor=A.+B.+Gottliebauthor=R.+Langleyauthor=T.+Lugerauthor=D.+Thaciauthor=M.+Buonannoauthor=P.+Guptaauthor=J.+Proulxauthor=S.+Lanauthor=R.+Wolk&title=Tofacitinib%2C+an+oral+Janus+kinase+inhibitor%2C+for+the+treatment+of+chronic+plaque+psoriasis%3A+results+from+two+randomized%2C+placebo-controlled%2C+phase+III+trials&doi=10.1111%2Fbjd.14018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials</span></div><div class="casAuthors">Papp, K. A.; Menter, M. A.; Abe, M.; Elewski, B.; Feldman, S. R.; Gottlieb, A. B.; Langley, R.; Luger, T.; Thaci, D.; Buonanno, M.; Gupta, P.; Proulx, J.; Lan, S.; Wolk, R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">949-961</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis.  Objectives : To det. the 16-wk efficacy and safety of two oral tofacitinib doses vs. placebo in patients with moderate-to-severe chronic plaque psoriasis.  Methods : Patients in two similarly designed phase III studies (OPT Pivotal 1, NCT01276639, n = 901; OPT Pivotal 2, NCT01309737, n = 960) were initially randomized 2 : 2 : 1 to tofacitinib 10 or 5 mg or placebo, twice daily.  Coprimary efficacy end points (week 16) included the proportion of patients achieving Physician's Global Assessment (PGA) of 'clear' or 'almost clear' (PGA response) and the proportion achieving ≥ 75% redn. in Psoriasis Area and Severity Index (PASI 75).  Results : Across OPT Pivotal 1 and OPT Pivotal 2, 745 patients received tofacitinib 5 mg, 741 received tofacitinib 10 mg and 373 received placebo.  At week 16, a greater proportion of patients achieved PGA responses with tofacitinib 5 and 10 mg twice daily vs. placebo (OPT Pivotal 1, 41·9% and 59·2% vs. 9·0%; OPT Pivotal 2, 46·0% and 59·1% vs. 10·9%; all P < 0·001).  Higher PASI 75 rates were obsd. with tofacitinib vs. placebo (OPT Pivotal 1, 39·9%, 59·2% and 6·2%, resp., for tofacitinib 5 and 10 mg twice daily and placebo; OPT Pivotal 2, 46·0%, 59·6% and 11·4%; all P < 0·001 vs. placebo).  Adverse event (AE) rates appeared generally similar across groups; rates of serious AEs, infections, malignancies and discontinuations due to AEs were low.  Twelve patients reported herpes zoster across the tofacitinib treatment groups in both studies vs. none in the resp. placebo groups.  The most common AE across groups was nasopharyngitis.  Conclusions : Oral tofacitinib demonstrated significant efficacy vs. placebo during the initial 16 wk of treatment in patients with moderate-to-severe psoriasis.  Safety findings were consistent with prior studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTWaBXP7bJbLVg90H21EOLACvtfcHk0lj1_gAl06-ifA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyns73E&md5=2029ed12ccdeaeb36ab87425a8c534c1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14018%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DMenter%26aufirst%3DM.%2BA.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DElewski%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26aulast%3DGottlieb%26aufirst%3DA.%2BB.%26aulast%3DLangley%26aufirst%3DR.%26aulast%3DLuger%26aufirst%3DT.%26aulast%3DThaci%26aufirst%3DD.%26aulast%3DBuonanno%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DProulx%26aufirst%3DJ.%26aulast%3DLan%26aufirst%3DS.%26aulast%3DWolk%26aufirst%3DR.%26atitle%3DTofacitinib%252C%2520an%2520oral%2520Janus%2520kinase%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520chronic%2520plaque%2520psoriasis%253A%2520results%2520from%2520two%2520randomized%252C%2520placebo-controlled%252C%2520phase%2520III%2520trials%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2015%26volume%3D173%26spage%3D949%26epage%3D961%26doi%3D10.1111%2Fbjd.14018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wollenhaupt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nduaka, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benda, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komuro, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riese, R. J.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">837</span>– <span class="NLM_lpage">852</span>, <span class="refDoi"> DOI: 10.3899/jrheum.130683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.3899%2Fjrheum.130683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=24692527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyiurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=837-852&author=J.+Wollenhauptauthor=J.+Silverfieldauthor=E.+B.+Leeauthor=J.+R.+Curtisauthor=S.+P.+Woodauthor=K.+Somaauthor=C.+I.+Nduakaauthor=B.+Bendaauthor=D.+Grubenauthor=H.+Nakamuraauthor=Y.+Komuroauthor=S.+H.+Zwillichauthor=L.+Wangauthor=R.+J.+Riese&title=Safety+and+efficacy+of+tofacitinib%2C+an+oral+janus+kinase+inhibitor%2C+for+the+treatment+of+rheumatoid+arthritis+in+open-label%2C+longterm+extension+studies&doi=10.3899%2Fjrheum.130683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies</span></div><div class="casAuthors">Wollenhaupt, Juergen; Silverfield, Joel; Lee, Eun Bong; Curtis, Jeffrey R.; Wood, Susan P.; Soma, Koshika; Nduaka, Chudy I.; Benda, Birgitta; Gruben, David; Nakamura, Hiroyuki; Komuro, Yoshihiro; Zwillich, Samuel H.; Wang, Lisy; Riese, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">837-852</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective: To describe the longterm safety and efficacy profile of tofacitinib in patients with moderate to severe active rheumatoid arthritis (RA).  Methods: Data were pooled from 2 open-label studies (NCT00413699, NCT00661661) involving patients who had participated in qualifying phase I, II, or III index studies of tofacitinib.  Safety data included over 60 mo of observation; efficacy data are reported up to Month 48.  Treatment was initiated with tofacitinib 5 or 10 mg twice daily.  Primary endpoints were adverse events (AE) and lab. safety data.  Secondary endpoints included American College of Rheumatol. (ACR) response rates, and Disease Activity Score (28 joints) (DAS28)-4[erythrocyte sedimentation rate (ESR)] and Health Assessment Questionnaire-Disability Index (HAQ-DI) assessments.  Results: Overall, 4102 patients were treated for 5963 patient-years; mean (max.) treatment duration was 531 (1844) days; 20.8% of patients discontinued treatment over 60 mo.  The most common AE were nasopharyngitis (12.7%) and upper respiratory tract infection (10.5%).  Serious AE were reported in 15.4% of patients with an exposure-estd. incidence rate of 11.1 events/100 patient-years.  Serious infections were reported in 4.5% of patients with an exposure-estd. incidence rate of 3.1 events/100 patient-years (95% CI: 2.66-3.55).  Mean values for lab. variables were stable over time and consistent with phase II and III studies.  Persistent efficacy was demonstrated through Month 48, as measured by ACR response rate (ACR20/50/70) DAS28-4-ESR, and HAQ-DI.  Safety and efficacy were similar for patients receiving tofacitinib as monotherapy or with background nonbiol. disease-modifying antirheumatic drugs.  Conclusion: Tofacitinib demonstrated consistent safety and persistent efficacy over 48 mo in patients with RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Scjk1FOYMrVg90H21EOLACvtfcHk0lhlao9HwIO0kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyiurbJ&md5=0c8cf68569627b3948b6c275ec69d8df</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.130683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.130683%26sid%3Dliteratum%253Aachs%26aulast%3DWollenhaupt%26aufirst%3DJ.%26aulast%3DSilverfield%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26aulast%3DWood%26aufirst%3DS.%2BP.%26aulast%3DSoma%26aufirst%3DK.%26aulast%3DNduaka%26aufirst%3DC.%2BI.%26aulast%3DBenda%26aufirst%3DB.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DKomuro%26aufirst%3DY.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRiese%26aufirst%3DR.%2BJ.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520tofacitinib%252C%2520an%2520oral%2520janus%2520kinase%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%2520in%2520open-label%252C%2520longterm%2520extension%2520studies%26jtitle%3DJ.%2520Rheumatol.%26date%3D2014%26volume%3D41%26spage%3D837%26epage%3D852%26doi%3D10.3899%2Fjrheum.130683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorarensen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juba, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span> <span> </span><span class="NLM_article-title">ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual JAK Kinase isoforms to cellular signaling</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1552</span>– <span class="NLM_lpage">1558</span>, <span class="refDoi"> DOI: 10.1021/cb5002125</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5002125" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1552-1558&author=A.+Thorarensenauthor=M.+E.+Bankerauthor=A.+Fensomeauthor=J.+B.+Telliezauthor=B.+Jubaauthor=F.+Vincentauthor=R.+M.+Czerwinskiauthor=A.+Casimiro-Garcia&title=ATP-mediated+kinome+selectivity%3A+the+missing+link+in+understanding+the+contribution+of+individual+JAK+Kinase+isoforms+to+cellular+signaling&doi=10.1021%2Fcb5002125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling</span></div><div class="casAuthors">Thorarensen, Atli; Banker, Mary Ellen; Fensome, Andrew; Telliez, Jean-Baptiste; Juba, Brian; Vincent, Fabien; Czerwinski, Robert M.; Casimiro-Garcia, Agustin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1552-1558</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases constitute an important class of therapeutic targets being explored both by academia and the pharmaceutical industry.  The major focus of this effort was directed toward the identification of ATP competitive inhibitors.  Although it has long been recognized that the intracellular concn. of ATP is very different from the concns. utilized in biochem. enzyme assays, little thought has been devoted to incorporating this discrepancy into our understanding of translation from enzyme inhibition to cellular function.  Significant work has been dedicated to the discovery of JAK kinase inhibitors; however, a disconnect between enzyme and cellular function is prominently displayed in the literature for this class of inhibitors.  Herein, we demonstrate utilizing the four JAK family members (JAK1, JAK2, JAK3, and TYK2) that the difference in the ATP Km of each individual kinase has a significant impact on the enzyme to cell inhibition translation.  We evaluated a large no. of JAK inhibitors in enzymic assays utilizing either 1 mM ATP or Km ATP for the four isoforms as well as in primary cell assays.  This data set provided the opportunity to examine individual kinase contributions to the heterodimeric kinase complexes mediating cellular signaling.  In contrast to a recent study, we demonstrate that for IL-15 cytokine signaling it is sufficient to inhibit either JAK1 or JAK3 to fully inhibit downstream STAT5 phosphorylation.  This addnl. data thus provides a crit. piece of information explaining why JAK1 has incorrectly been thought to have a dominant role over JAK3.  Beyond enabling a deeper understanding of JAK signaling, conducting similar analyses for other kinases by taking into account potency at high ATP rather than Km ATP may provide crucial insights into a compd.'s activity and selectivity in cellular contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYiMVl7OpPFLVg90H21EOLACvtfcHk0lhlao9HwIO0kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D&md5=c87874cb1748e13eef2aa241ecef3e79</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fcb5002125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5002125%26sid%3Dliteratum%253Aachs%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DTelliez%26aufirst%3DJ.%2BB.%26aulast%3DJuba%26aufirst%3DB.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26atitle%3DATP-mediated%2520kinome%2520selectivity%253A%2520the%2520missing%2520link%2520in%2520understanding%2520the%2520contribution%2520of%2520individual%2520JAK%2520Kinase%2520isoforms%2520to%2520cellular%2520signaling%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1552%26epage%3D1558%26doi%3D10.1021%2Fcb5002125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keefer, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, R. R.</span></span> <span> </span><span class="NLM_article-title">Interpretable, Probability-Based Confidence Metric for Continuous Quantitative Structure–Activity Relationship Models</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">368</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1021/ci300554t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci300554t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Cit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=368-383&author=C.+E.+Keeferauthor=G.+W.+Kauffmanauthor=R.+R.+Gupta&title=Interpretable%2C+Probability-Based+Confidence+Metric+for+Continuous+Quantitative+Structure%E2%80%93Activity+Relationship+Models&doi=10.1021%2Fci300554t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Interpretable, Probability-Based Confidence Metric for Continuous Quantitative Structure-Activity Relationship Models</span></div><div class="casAuthors">Keefer, Christopher E.; Kauffman, Gregory W.; Gupta, Rishi Raj</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">368-383</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A great deal of research has gone into the development of robust confidence in prediction and applicability domain (AD) measures for quant. structure-activity relationship (QSAR) models in recent years.  Much of the attention has historically focused on structural similarity, which can be defined in many forms and flavors.  A concept that is frequently overlooked in the realm of the QSAR applicability domain is how the local activity landscape plays a role in how accurate a prediction is or is not.  In this work, we describe an approach that pairs information about both the chem. similarity and activity landscape of a test compd.'s neighborhood into a single calcd. confidence value.  We also present an approach for converting this value into an interpretable confidence metric that has a simple and informative meaning across data sets.  The approach will be introduced to the reader in the context of models built upon four diverse literature data sets.  The steps we will outline include the definition of similarity used to det. nearest neighbors (NN), how we incorporate the NN activity landscape with a similarity-weighted root-mean-square distance (wRMSD) value, and how that value is then calibrated to generate an intuitive confidence metric for prospective application.  Finally, we will illustrate the prospective performance of the approach on five proprietary models whose predictions and confidence metrics have been tracked for more than a year.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqvcorWVQ5O7Vg90H21EOLACvtfcHk0lhlao9HwIO0kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Cit74%253D&md5=14d2b7d42f91b5e4e90fa53b6266a178</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fci300554t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci300554t%26sid%3Dliteratum%253Aachs%26aulast%3DKeefer%26aufirst%3DC.%2BE.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DGupta%26aufirst%3DR.%2BR.%26atitle%3DInterpretable%252C%2520Probability-Based%2520Confidence%2520Metric%2520for%2520Continuous%2520Quantitative%2520Structure%25E2%2580%2593Activity%2520Relationship%2520Models%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D368%26epage%3D383%26doi%3D10.1021%2Fci300554t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Should the incorporation of structural alerts be restricted in drug design? An analysis of structure-toxicity trends with aniline-based drugs</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.2174/0929867321666141112122118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.2174%2F0929867321666141112122118" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=438-464&author=A.+S.+Kalgutkar&title=Should+the+incorporation+of+structural+alerts+be+restricted+in+drug+design%3F+An+analysis+of+structure-toxicity+trends+with+aniline-based+drugs&doi=10.2174%2F0929867321666141112122118"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F0929867321666141112122118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867321666141112122118%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DShould%2520the%2520incorporation%2520of%2520structural%2520alerts%2520be%2520restricted%2520in%2520drug%2520design%253F%2520An%2520analysis%2520of%2520structure-toxicity%2520trends%2520with%2520aniline-based%2520drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D438%26epage%3D464%26doi%3D10.2174%2F0929867321666141112122118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span> <span> </span><span class="NLM_article-title">Water’s Role in Compound Design for Drug Discovery</span>. In  <i>CCG UGM and Conference</i>, <span class="NLM_publisher-loc">Montral, Canada</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=H.+Zhu&title=Water%E2%80%99s+Role+in+Compound+Design+for+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DH.%26atitle%3DWater%25E2%2580%2599s%2520Role%2520in%2520Compound%2520Design%2520for%2520Drug%2520Discovery%26jtitle%3DCCG%2520UGM%2520and%2520Conference%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, J. C.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickerson-Nutter, C. L.</span></span> <span> </span><span class="NLM_article-title">Utility of animal models for identification of potential therapeutics for rheumatoid arthritis</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1505</span>– <span class="NLM_lpage">1515</span>, <span class="refDoi"> DOI: 10.1136/ard.2007.076430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1136%2Fard.2007.076430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=18055474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2gsbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2008&pages=1505-1515&author=M.+Hegenauthor=J.+C.+Keithauthor=M.+Collinsauthor=C.+L.+Nickerson-Nutter&title=Utility+of+animal+models+for+identification+of+potential+therapeutics+for+rheumatoid+arthritis&doi=10.1136%2Fard.2007.076430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Utility of animal models for identification of potential therapeutics for rheumatoid arthritis</span></div><div class="casAuthors">Hegen, M.; Keith, J. C., Jr.; Collins, M.; Nickerson-Nutter, C. L.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1505-1515</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  Animal models of rheumatoid arthritis (RA) are widely used for testing potential new therapies for RA.  However, the question of which animal model is most predictive of therapeutic efficacy in human RA commonly arises in data evaluation.  A retrospective review of the animal models used to evaluate approved, pending RA therapies, and compds. that were discontinued during phase II or III clin. trials found that the three most commonly used models were adjuvant-induced arthritis (AIA) in rats and collagen-induced arthritis (CIA) in rats and mice.  Limited data were found for more recently developed genetically modified animal models.  Examn. of the efficacy of various compds. in these animal models revealed that a compd.'s therapeutic efficacy, rather than prophylactic efficacy, in AIA and CIA models was more predictive of clin. efficacy in human RA than data from either model alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruwo5lHLFB3bVg90H21EOLACvtfcHk0liaouNse4ZzLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2gsbbP&md5=417b41682141901273229dacb8f63283</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1136%2Fard.2007.076430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2007.076430%26sid%3Dliteratum%253Aachs%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DKeith%26aufirst%3DJ.%2BC.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26atitle%3DUtility%2520of%2520animal%2520models%2520for%2520identification%2520of%2520potential%2520therapeutics%2520for%2520rheumatoid%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2008%26volume%3D67%26spage%3D1505%26epage%3D1515%26doi%3D10.1136%2Fard.2007.076430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banfield, C.</span>; <span class="NLM_string-name">Scaramozza, M.</span>; <span class="NLM_string-name">Zhang, W.</span>; <span class="NLM_string-name">Kieras, E.</span>; <span class="NLM_string-name">Page, K. M.</span>; <span class="NLM_string-name">Fensome, A.</span>; <span class="NLM_string-name">Vincent, M.</span>; <span class="NLM_string-name">Dowty, M. E.</span>; <span class="NLM_string-name">Goteti, K.</span>; <span class="NLM_string-name">Winkle, P. J.</span>; <span class="NLM_string-name">Peeva, E.</span></span> <span> </span><span class="NLM_article-title">The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis</span>.  <i>Journal of Clinical Pharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=C.+Banfield&author=M.+Scaramozza&author=W.+Zhang&author=E.+Kieras&author=K.+M.+Page&author=A.+Fensome&author=M.+Vincent&author=M.+E.+Dowty&author=K.+Goteti&author=P.+J.+Winkle&author=E.+Peeva&title=The+Safety%2C+Tolerability%2C+Pharmacokinetics%2C+and+Pharmacodynamics+of+a+TYK2%2FJAK1+Inhibitor+%28PF-06700841%29+in+Healthy+Subjects+and+Patients+With+Plaque+Psoriasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBanfield%26aufirst%3DC.%26atitle%3DThe%2520Safety%252C%2520Tolerability%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520of%2520a%2520TYK2%252FJAK1%2520Inhibitor%2520%2528PF-06700841%2529%2520in%2520Healthy%2520Subjects%2520and%2520Patients%2520With%2520Plaque%2520Psoriasis%26jtitle%3DJournal%2520of%2520Clinical%2520Pharmacology%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korniski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmons, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gormley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommers, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenbrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasselli, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, T. E.</span></span> <span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>400</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2010.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+Patnyauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.+C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6&doi=10.1016%2Fj.jmb.2010.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0liIathRjLLjiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.%2BC.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433%26doi%3D10.1016%2Fj.jmb.2010.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajamohan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoth, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoghegan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subashi, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaila, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurumbail, R. G.</span></span> <span> </span><span class="NLM_article-title">Development of a high-throughput crystal structure-determination platform for JAK1 using a novel metal-chelator soaking system</span>. <i>Acta Crystallogr., Sect. F: Struct. Biol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">840</span>– <span class="NLM_lpage">845</span>, <span class="refDoi"> DOI: 10.1107/S2053230X16016356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1107%2FS2053230X16016356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=27827355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVWmt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2016&pages=840-845&author=N.+L.+Caspersauthor=S.+Hanauthor=F.+Rajamohanauthor=L.+R.+Hothauthor=K.+F.+Geogheganauthor=T.+A.+Subashiauthor=M.+L.+Vazquezauthor=N.+Kailaauthor=N.+Croninauthor=E.+Johnsonauthor=R.+G.+Kurumbail&title=Development+of+a+high-throughput+crystal+structure-determination+platform+for+JAK1+using+a+novel+metal-chelator+soaking+system&doi=10.1107%2FS2053230X16016356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a high-throughput crystal structure-determination platform for JAK1 using a novel metal-chelator soaking system</span></div><div class="casAuthors">Caspers, Nicole L.; Han, Seungil; Rajamohan, Francis; Hoth, Lise R.; Geoghegan, Kieran F.; Subashi, Timothy A.; Vazquez, Michael L.; Kaila, Neelu; Cronin, Ciaran N.; Johnson, Eric; Kurumbail, Ravi G.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">840-845</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Crystals of phosphorylated JAK1 kinase domain were initially generated in complex with nucleotide (ADP) and magnesium.  The tightly bound Mg2+-ADP at the ATP-binding site proved recalcitrant to ligand displacement.  Addn. of a molar excess of EDTA helped to dislodge the divalent metal ion, promoting the release of ADP and allowing facile exchange with ATP-competitive small-mol. ligands.  Many kinases require the presence of a stabilizing ligand in the ATP site for crystn.  This procedure could be useful for developing co-crystn. systems with an exchangeable ligand to enable structure-based drug design of other protein kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1j6dvXhIlZbVg90H21EOLACvtfcHk0liIathRjLLjiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVWmt7zI&md5=b4c15c4bc3deb1e54710882a70607ec8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1107%2FS2053230X16016356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X16016356%26sid%3Dliteratum%253Aachs%26aulast%3DCaspers%26aufirst%3DN.%2BL.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DRajamohan%26aufirst%3DF.%26aulast%3DHoth%26aufirst%3DL.%2BR.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DSubashi%26aufirst%3DT.%2BA.%26aulast%3DVazquez%26aufirst%3DM.%2BL.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DCronin%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DE.%26aulast%3DKurumbail%26aufirst%3DR.%2BG.%26atitle%3DDevelopment%2520of%2520a%2520high-throughput%2520crystal%2520structure-determination%2520platform%2520for%2520JAK1%2520using%2520a%2520novel%2520metal-chelator%2520soaking%2520system%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2016%26volume%3D72%26spage%3D840%26epage%3D845%26doi%3D10.1107%2FS2053230X16016356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vonrhein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flensburg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paciorek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Womack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span></span> <span> </span><span class="NLM_article-title">Data processing and analysis with the autoPROC toolbox</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1107/S0907444911007773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1107%2FS0907444911007773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=21460447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=293-302&author=C.+Vonrheinauthor=C.+Flensburgauthor=P.+Kellerauthor=A.+Sharffauthor=O.+Smartauthor=W.+Paciorekauthor=T.+Womackauthor=G.+Bricogne&title=Data+processing+and+analysis+with+the+autoPROC+toolbox&doi=10.1107%2FS0907444911007773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Data processing and analysis with the autoPROC toolbox</span></div><div class="casAuthors">Vonrhein, Clemens; Flensburg, Claus; Keller, Peter; Sharff, Andrew; Smart, Oliver; Paciorek, Wlodek; Womack, Thomas; Bricogne, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">293-302</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A typical diffraction expt. will generate many images and data sets from different crystals in a very short time.  This creates a challenge for the high-throughput operation of modern synchrotron beamlines as well as for the subsequent data processing.  Novice users in particular may feel overwhelmed by the tables, plots and nos. that the different data-processing programs and software packages present to them.  Here, some of the more common problems that a user has to deal with when processing a set of images that will finally make up a processed data set are shown, concg. on difficulties that may often show up during the first steps along the path of turning the expt. (i.e. data collection) into a model (i.e. interpreted electron d.).  Difficulties such as unexpected crystal forms, issues in crystal handling and suboptimal choices of data-collection strategies can often be dealt with, or at least diagnosed, by analyzing specific data characteristics during processing.  In the end, one wants to distinguish problems over which one has no immediate control once the expt. is finished from problems that can be remedied a posteriori.  A new software package, autoPROC, is also presented that combines third-party processing programs with new tools and an automated workflow script that is intended to provide users with both guidance and insight into the offline processing of data affected by the difficulties mentioned above, with particular emphasis on the automated treatment of multi-sweep data sets collected on multi-axis goniostats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmah7iUrMLXLVg90H21EOLACvtfcHk0li10L86TXz62g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D&md5=a0a3579f6b371b6312819883864aa80d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1107%2FS0907444911007773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444911007773%26sid%3Dliteratum%253Aachs%26aulast%3DVonrhein%26aufirst%3DC.%26aulast%3DFlensburg%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DP.%26aulast%3DSharff%26aufirst%3DA.%26aulast%3DSmart%26aufirst%3DO.%26aulast%3DPaciorek%26aufirst%3DW.%26aulast%3DWomack%26aufirst%3DT.%26aulast%3DBricogne%26aufirst%3DG.%26atitle%3DData%2520processing%2520and%2520analysis%2520with%2520the%2520autoPROC%2520toolbox%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D293%26epage%3D302%26doi%3D10.1107%2FS0907444911007773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span> <span> </span><span class="NLM_article-title">XDS</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1107/S0907444909047337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=20124692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=125-132&author=W.+Kabsch&title=XDS&doi=10.1107%2FS0907444909047337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0li10L86TXz62g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DXDS%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D125%26epage%3D132%26doi%3D10.1107%2FS0907444909047337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krissinel, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. S.</span></span> <span> </span><span class="NLM_article-title">Overview of the CCP4 suite and current developments</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1107/S0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=21460441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=235-242&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+W.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+suite+and+current+developments&doi=10.1107%2FS0907444910045749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the CCP4 suite and current developments</span></div><div class="casAuthors">Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.; Dodson, Eleanor J.; Emsley, Paul; Evans, Phil R.; Keegan, Ronan M.; Krissinel, Eugene B.; Leslie, Andrew G. W.; McCoy, Airlie; McNicholas, Stuart J.; Murshudov, Garib N.; Pannu, Navraj S.; Potterton, Elizabeth A.; Powell, Harold R.; Read, Randy J.; Vagin, Alexei; Wilson, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  The CCP4 (Collaborative Computational Project, No. 4) software suite is a collection of programs and assocd. data and software libraries which can be used for macromol. structure detn. by X-ray crystallog.  The suite is designed to be flexible, allowing users a no. of methods of achieving their aims.  The programs are from a wide variety of sources but are connected by a common infrastructure provided by std. file formats, data objects and graphical interfaces.  Structure soln. by macromol. crystallog. is becoming increasingly automated and the CCP4 suite includes several automation pipelines.  After giving a brief description of the evolution of CCP4 over the last 30 years, an overview of the current suite is given.  While detailed descriptions are given in the accompanying articles, here it is shown how the individual programs contribute to a complete software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wWMMIol6UrVg90H21EOLACvtfcHk0liVDo3NTfx65w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D&md5=c407e4d47bef46864be336d60147c17d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520suite%2520and%2520current%2520developments%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D235%26epage%3D242%26doi%3D10.1107%2FS0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span> <span> </span><span class="NLM_article-title">Refinement of Macromolecular Structures by the Maximum-Likelihood Method</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1107/S0907444996012255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+Macromolecular+Structures+by+the+Maximum-Likelihood+Method&doi=10.1107%2FS0907444996012255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0liVDo3NTfx65w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520Macromolecular%2520Structures%2520by%2520the%2520Maximum-Likelihood%2520Method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255%26doi%3D10.1107%2FS0907444996012255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span> <i>RHOFIT</i>, v. 1.2.4; <span class="NLM_publisher-name">Global Phasing Ltd.</span>: <span class="NLM_publisher-loc">Cambridge, UK</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+RHOFIT%2C+v.+1.2.4%3B+Global+Phasing+Ltd.%3A+Cambridge%2C+UK%2C+2014."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DRHOFIT%26pub%3DGlobal%2520Phasing%2520Ltd%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span> <i>BUSTER</i>, v. 2.8.0; <span class="NLM_publisher-name">Global Phasing Ltd.</span>: <span class="NLM_publisher-loc">Cambridge, UK</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+BUSTER%2C+v.+2.8.0%3B+Global+Phasing+Ltd.%3A+Cambridge%2C+UK%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DBUSTER%26pub%3DGlobal%2520Phasing%2520Ltd%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and development of Coot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0liVDo3NTfx65w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+pan+assay+interference+compounds+%28PAINS%29+from+screening+libraries+and+for+their+exclusion+in+bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0liGYjIC94ESAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520pan%2520assay%2520interference%2520compounds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520for%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J-.B.</span></span> <span> </span><span class="NLM_article-title">An Updated Analysis of In vitro Cytokine Inhibition Profiles of a Number of Janus Kinase Inhibitors at Clinically Maningful Concentrations</span>. <i>United European Gastroenterology Journal</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">abstract 1770</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=abstract+1770&author=M.+E.+Dowtyauthor=T.+H.+Linauthor=L.+Wangauthor=J.+M.+Jussifauthor=L.+Liauthor=E.+Moyauthor=J-.B.+Telliez&title=An+Updated+Analysis+of+In+vitro+Cytokine+Inhibition+Profiles+of+a+Number+of+Janus+Kinase+Inhibitors+at+Clinically+Maningful+Concentrations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DJussif%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DMoy%26aufirst%3DE.%26aulast%3DTelliez%26aufirst%3DJ-.B.%26atitle%3DAn%2520Updated%2520Analysis%2520of%2520In%2520vitro%2520Cytokine%2520Inhibition%2520Profiles%2520of%2520a%2520Number%2520of%2520Janus%2520Kinase%2520Inhibitors%2520at%2520Clinically%2520Maningful%2520Concentrations%26jtitle%3DUnited%2520European%2520Gastroenterology%2520Journal%26date%3D2017%26volume%3D5%26spage%3Dabstract%25201770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span> <span> </span><span class="NLM_article-title">Predicting clearance in humans from in vitro data</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.2174/156802611794480873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.2174%2F156802611794480873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=21320062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=334-339&author=R.+S.+Obach&title=Predicting+clearance+in+humans+from+in+vitro+data&doi=10.2174%2F156802611794480873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting clearance in humans from in vitro data</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">334-339</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The use of in vitro metab. in scaling to predict human clearance of new chem. entities has become a commonplace activity in the research and development of new drugs.  The measurement of in vitro lability in human liver microsomes, a rich source of drug metabolizing cytochrome P 450 enzymes, has become a high throughput screen in many research organizations which is a testament to its usefulness in drug design.  In this chapter, the methods used to scale in vitro intrinsic clearance data to predict in vivo clearance are described.  Importantly, the numerous assumptions that are required in order to use in vitro data in this manner are laid out.  These include assumptions regarding the scaling process as well as tech. aspects of the generation of the in vitro data.  Finally, some other drug clearance processes that have been emerging as important are described with regard to ongoing research efforts to develop clearance prediction methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHL7BnSTNtWbVg90H21EOLACvtfcHk0liGYjIC94ESAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSntbk%253D&md5=38df8707bb77fdc8b6bb6ef2144a79da</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.2174%2F156802611794480873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611794480873%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPredicting%2520clearance%2520in%2520humans%2520from%2520in%2520vitro%2520data%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D334%26epage%3D339%26doi%3D10.2174%2F156802611794480873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hosea, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collard, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, R. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakar, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span> <span> </span><span class="NLM_article-title">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1177/0091270009333209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=10.1177%2F0091270009333209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=19299532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=513-533&author=N.+A.+Hoseaauthor=W.+T.+Collardauthor=S.+Coleauthor=T.+S.+Maurerauthor=R.+X.+Fangauthor=H.+Jonesauthor=S.+M.+Kakarauthor=Y.+Nakaiauthor=B.+J.+Smithauthor=R.+Websterauthor=K.+Beaumont&title=Prediction+of+human+pharmacokinetics+from+preclinical+information%3A+comparative+accuracy+of+quantitative+prediction+approaches&doi=10.1177%2F0091270009333209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span></div><div class="casAuthors">Hosea, Natilie A.; Collard, Wendy T.; Cole, Susan; Maurer, Tristan S.; Fang, Rick X.; Jones, Hannah; Kakar, Shefali M.; Nakai, Yasuhiro; Smith, Bill J.; Webster, Rob; Beaumont, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">513-533</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Quant. prediction of human pharmacokinetics is crit. in assessing the viability of drug candidates and in detg. first-in-human dosing.  Numerous prediction methodologies, incorporating both in vitro and preclin. in vivo data, have been developed in recent years, each with advantages and disadvantages.  However, the lack of a comprehensive data set, both preclin. and clin., has limited efforts to evaluate the optimal strategy (or strategies) that results in quant. predictions of human pharmacokinetics.  To address this issue, the authors conducted a retrospective anal. using 50 proprietary compds. for which in vitro, preclin. pharmacokinetic data and oral single-dose human pharmacokinetic data were available.  Five predictive strategies, involving either allometry or use of unbound intrinsic clearance from microsomes or hepatocytes, were then compared for their ability to predict human oral clearance, half-life through predictions of systemic clearance, vol. of distribution, and bioavailability.  Use of a single-species scaling approach with rat, dog, or monkey was as accurate as or more accurate than using multiple-species allometry.  For those compds. cleared almost exclusively by P 450-mediated pathways, scaling from human liver microsomes was as predictive as single-species scaling of clearance based on data from rat, dog, or monkey.  These data suggest that use of predictive methods involving either single-species in vivo data or in vitro human liver microsomes can quant. predict human in vivo pharmacokinetics and suggest the possibility of streamlining the predictive methodol. through use of a single species or use only of human in vitro microsomal prepns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg67HcwS4O4LVg90H21EOLACvtfcHk0lj4aZo7TT3tBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D&md5=a0941d53fe43392f8fb1562ee546705e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1177%2F0091270009333209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009333209%26sid%3Dliteratum%253Aachs%26aulast%3DHosea%26aufirst%3DN.%2BA.%26aulast%3DCollard%26aufirst%3DW.%2BT.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DFang%26aufirst%3DR.%2BX.%26aulast%3DJones%26aufirst%3DH.%26aulast%3DKakar%26aufirst%3DS.%2BM.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DBeaumont%26aufirst%3DK.%26atitle%3DPrediction%2520of%2520human%2520pharmacokinetics%2520from%2520preclinical%2520information%253A%2520comparative%2520accuracy%2520of%2520quantitative%2520prediction%2520approaches%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D513%26epage%3D533%26doi%3D10.1177%2F0091270009333209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBK','PDB','6DBK'); return false;">PDB: 6DBK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBM','PDB','6DBM'); return false;">PDB: 6DBM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBN','PDB','6DBN'); return false;">PDB: 6DBN</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i30"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00917">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_83831"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00917">10.1021/acs.jmedchem.8b00917</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">(1) Human whole blood assay experimental conditions; (2) Physicochemical properties for compounds <b>14</b>–<b>25</b>; (3) Exposure and activity data for compound <b>23</b> from the rat AIA model; (4) Syntheses for compounds <b>8</b>–<b>22</b>, <b>24</b>, and <b>25</b>; (5) Thermodynamic solubility determination for compound <b>23</b>; (6) Crystallographic data and refinement statistics for compounds <b>8</b> and <b>23</b> in TYK2 and compound <b>23</b> in JAK1 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00917/suppl_file/jm8b00917_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00917/suppl_file/jm8b00917_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00917/suppl_file/jm8b00917_si_001.pdf">jm8b00917_si_001.pdf (387.62 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00917/suppl_file/jm8b00917_si_002.csv">jm8b00917_si_002.csv (1.12 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the X-ray structure of compound <b>8</b> in TYK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBK">6DBK</a>) and compound <b>23</b> in TYK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBM">6DBM</a>) and JAK1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DBN">6DBN</a>) are available from the RCSB Protein Data Bank (<a href="http://www.rcsb.org" class="extLink">www.rcsb.org</a>). Authors will release the atomic coordinates upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-19%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00917%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00917" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797ad2fec032cd","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
